var title_f24_47_25328="SLE Proliferative IF";
var content_f24_47_25328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing diffuse proliferative lupus nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kidney biopsy from a patient with diffuse proliferative lupus nephritis showing, on immunofluorescence microscopy, massive, lumpy deposits of IgG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H. Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25328=[""].join("\n");
var outline_f24_47_25328=null;
var title_f24_47_25329="Patient information: Aortic coarctation in children (The Basics)";
var content_f24_47_25329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83037\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/19/35124\">",
"         Aortic coarctation in a child",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aortic coarctation in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aortic-coarctation-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12130658\">",
"      <span class=\"h1\">",
"       What is aortic coarctation in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aortic coarctation",
"      <strong>",
"      </strong>",
"      is a problem that causes the heart&rsquo;s largest vessel, called the &ldquo;aorta,&rdquo; to narrow (",
"      <a class=\"graphic graphic_figure graphicRef82985 \" href=\"UTD.htm?34/19/35124\">",
"       figure 1",
"      </a>",
"      ). Children with aortic coarctation are born with the problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130673\">",
"      <span class=\"h1\">",
"       What are the symptoms of aortic coarctation in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most babies and children have no symptoms. In some cases, a routine imaging test (called an &ldquo;ultrasound&rdquo;) that women have during pregnancy might show the baby has narrowing of the aorta.",
"     </p>",
"     <p>",
"      Newborn infants with severe narrowing of the aorta might have symptoms that include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pale skin",
"       </li>",
"       <li>",
"        Crying and fussing more than normal",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Older babies and children can have symptoms, especially when they are physically active, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain or leg cramps",
"       </li>",
"       <li>",
"        Cold hands and feet",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130688\">",
"      <span class=\"h1\">",
"       Are there tests for aortic coarctation in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor will do an exam and measure your child&rsquo;s pulse and blood pressure in his or her arms and legs. Children with this condition have a weaker pulse and lower blood pressure in their legs than in their arms. &nbsp;",
"     </p>",
"     <p>",
"      Other tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram &ndash; This test measures the electrical activity of the heart. It is also called an &ldquo;ECG&rdquo; or &ldquo;EKG.&rdquo;",
"       </li>",
"       <li>",
"        An echocardiogram &ndash; This test uses sound waves to take pictures of the heart and aorta.",
"       </li>",
"       <li>",
"        An MRI or CT scan &ndash; These tests take pictures of the heart and aorta.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130703\">",
"      <span class=\"h1\">",
"       How is aortic coarctation in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment will depend on your child&rsquo;s age, size, and symptoms. Newborns with serious symptoms might need medicines given through a vein (called an &ldquo;IV&rdquo;).",
"     </p>",
"     <p>",
"      Other treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Angioplasty&nbsp;&ndash; A doctor puts a thin tube into a blood vessel in the leg or arm and advances the tube to the aorta. Then the doctor inflates a balloon inside the aorta to widen it. In older children, the doctor may prop open the aorta using a mesh tube called a &ldquo;stent.&rdquo;",
"       </li>",
"       <li>",
"        Surgery&nbsp;&ndash; Different types of surgery can fix the narrowed aorta. The doctor might remove the narrowed part of the aorta. In other cases, he or she uses a plastic tube called a &ldquo;graft&rdquo; or a piece of another one of your child&rsquo;s blood vessels to fix the aorta.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130719\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many children with aortic coarctatation are able to live normal lives. But aortic coarctation can return after treatment. This means your child will need to see his or her doctor on a regular basis. How often will depend on your child&rsquo;s condition. Also, you should check with your doctor about whether your child should not do certain activities or sports.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/47/25329?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83037 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25329=[""].join("\n");
var outline_f24_47_25329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130658\">",
"      What is aortic coarctation in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130673\">",
"      What are the symptoms of aortic coarctation in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130688\">",
"      Are there tests for aortic coarctation in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130703\">",
"      How is aortic coarctation in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130719\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/19/35124\">",
"      Aortic coarctation in a child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_47_25330="Contact dermatitis neomycin";
var content_f24_47_25330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis induced by neomycin ointment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A red, rectangular, scaly, and excoriated 2 cm plaque with surrounding scattered red papules and intac wound with sutures in place. An 8-year-old girl developed an acute allergic contact dermatitis following the application of neomycin to prevent infection after excision of a congenital pigmented nevus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25330=[""].join("\n");
var outline_f24_47_25330=null;
var title_f24_47_25331="Shave biopsy technique";
var content_f24_47_25331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shave biopsy technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 597px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shave biopsy can be facilitated by raising the lesion with a wheal of injected anesthetic. When performing a superficial shave biopsy, a number 15 blade on a scalpel is held tangential to the skin surface. The lesion is then removed with a smooth sweeping stroke of the blade going just under and across the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25331=[""].join("\n");
var outline_f24_47_25331=null;
var title_f24_47_25332="Anal fissure anatomy";
var content_f24_47_25332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Anal fissure anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 610px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25332=[""].join("\n");
var outline_f24_47_25332=null;
var title_f24_47_25333="African tick bite fever lesion";
var content_f24_47_25333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash of African tick bite fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A solitary lesion is visible with a central eschar. Multiple lesions can be present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel J Sexton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25333=[""].join("\n");
var outline_f24_47_25333=null;
var title_f24_47_25334="EUS-guided cholangiography";
var content_f24_47_25334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    EUS-guided cholangiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 599px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) EUS-guided cholangiography for antegrade access to the bile duct following unsuccessful retrograde access with ERCP. Two large filling defects consistent with choledocholithiasis are seen on the cholangiogram.",
"    <br>",
"     (B) A guidewire is passed through the FNA needle into the bile duct and across the major duodenal papilla into the second portion of the duodenum in preparation for a \"rendezvous\" procedure.",
"     <br>",
"      (C) The guidewire is then snared and withdrawn through a side-viewing duodenoscope, allowing access to the bile duct for completion of the \"rendezvous\" procedure. Stone extraction is then performed using conventional ERCP techniques.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25334=[""].join("\n");
var outline_f24_47_25334=null;
var title_f24_47_25335="Cutaneous innervation of the arm";
var content_f24_47_25335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Cutaneous innervation of the arm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 580px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJEAgwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poqDULuDT7C5vbyRYra3iaaWRuiooJYn6AGvE/gr8ZNY8aeLpdK8SaZaadb31o99pDRI6tNEsrIQ2XYE/KeQB9xvUUAe50UV5p8afipF8NLfS9ulNq15fNIRbpP5RSKNdzyZ2t0yOMDuc8UAel0Vyl/8QfDennQlu76VZdcg+0afFFayzPOm0NwI1bnDDjvnjNcxr/xn0OyTwtcaLDNrNhrl6bMz28U2YMEBvkEZZnGf9XgMewoA9SorjtZ+JfhPRbt7bU9Ua3ljSKSfNrMRbCT7nnMEIhJyOJCpqK++KHhC28Sv4bbWol17zY7dLZoJTmSRcoNwXBByMkHAzyRQB21Fea+Dfifp9x4L0XU/Emq6dPf6nLNFAui2l3ILgxsQfLhZDMdoA3HbgfTFaOo/FnwPp2l6XqV5r8Edjqfm/ZZhFIwcx43g4U7SMgYbBycUAdzRWDf+KtMtvBE3iqKUzaSlidQRwpUyR7N64BAIJGOCM81zOg/EH+zvAug658Q5rTTbnW5EFrBaW0zhfMG6KM43ksV5J4GTjAxyAeiUVyth4+8P6hp91eWE1/dJaXP2S4hg0y5kuIZcZ2vAI/MXp1Kge9cp47+K0Fl4YsdU8IS2t6765DpF1HeQSxtAW3b1aNtjo4wPvD8DQB6rRXE3/wAVPB2n3V/Beau0TWF0tldubSfy4JWztV5Nm1QcH5iccHmr1n498PXx1ZLK5u7i40pkS7torC4eePf90iIR72BzncqkY5zigDqKK45viX4TTR9Y1ObU5ILXR2jS/WeznjltjIQE3xMgkGSePlrm/FnxXgj8IHxZ4Lns9Z0LTb9LbVwYZFcRnZkxMSoyu9T0YHPbBoA9VorK17xDpeg+Hp9c1S58rSoEWWSdY2kwrEAHCAkjkdBXKeNviPpemaXqEWj6tp661Dpq6rH9sguJLdLdmUCSQxKSAc8AfNyOMUAegUVw9x8TPDekWVj/AG7qsS3kljFez/ZLWeWOJHCgSNtQmNCzDBk29RU978TPCFl/bJudYRBo8UM94fIlISOXb5bKQuHDblwUz1FAHY0VgaT4v0LV9bOk6bfrcX4s49QKJG+3yJMbH34287gQM59q36ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOK+MXh7W/FfgHUNC8NXFnbXd9tiklu3ZVWLOXA2qxyQMYx0Jri9Z+DMuman4I1TwLd+TfeH5VSUajfXDpNb4AdUB3iPPzDaoVfnPoK9pooA5bwZZeLLTU/ET+K9Ts72ynvWk0qO3UBre23NtR8IuWAK926da5HxN8MdS8V/E6+1zV9XNnoy6YdNsorExvMVcETeYssTIA25xlcnGOR0r1eigDwfwt8JvFWn6j8OpNUv8ASJofCst2jNHLKXlgkx5eAUA3DkEZAAAwTUWmfB3xJpnh7QI4LrR5dS0jxG+srE00iwyxNj5N4jJVvl/ukc177RQB4drXwi1G68SeJr5rfT9U0/xCIpp7G51m8s0t51HORCu24QNyNwUjAxjk10/w/wDAOoeG/Hni7WbmWxNlq0FpFbRwO5ePyotjbgw4GenzMcda9KooA8E8F/B/xJ4Tt/BOoW1zpF3rWgC8imtpJ5Et5452cgrIIyysN/8AcIP85dA+DOsaTqHga6/tCwmfSdTvdS1H5nUFp/LwsI2nIAT+IrXu1FAHO/EXQX8T+BNe0WFgs97ZyRRE9A5Hy59s4rxfxfD4h8Q/Dn4X+T4c1RNW0vWrOO8tZbWVPKMKlTIxCHERwDvAIAPcivoqigDwHU/g74n1CPW7+TUdNS+1nW4dQvtMS5mW1ntY94+ztMEDHIc5OzHTjgVXi+CevrpGp2sT6DZ/avE8OtRW9vLIIYIE35iX90ORuAAAAwO1fQ1FAHgfiv4N+INX0f4h2lteaUsniLVYb61MksgCIjEkSYQ4bntke9T+MfhH4m1fXfHl/pWr2VkuurYi3AmlRmEKqrpKVX5VbB5Xd2yK91ooA+d5/glrsmjfEK0sovDulJ4hjsUsrS1nlaG28h1ZgzeUp5AJyFOSecV2fxisNVn+Flp4R0iwuL3VNVW308ywxM0NuqlPMlkfGFUBcDOCc8dDXqtFAGTfaDZ33hWbQLoGSxmszZPnqUKbM/XFeK+G/gt4hsvh94v07V9U0688QavaQafazh5PJhtoVVY1JKZHTkBT0HJr6AooA8Iu/g1qSazd3yrY6tbajpVrY3ljPq13YIJYYkjzuhU+bGQudrgdeMU7xF8ErrU/Fvhu7t5NOg0OHT7Sx1iy8yU+ctuysqx7gxK/Iq/M2cDnJr3WigDyr4GfDXUvAX9tza7e2t7eXbQW8EkBZtlrBHsiUllGDjqBxwOTXqtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcLZ/ECKCXW/+EitI9PgsNVXSLdrV5r2S6lMSyjEaQhgSrrgDdzuHYFgDuqK81uviZa3PifSrXSbpItHeznv728uNNuXCpFJsaMkbRAV2ybmkyFIAK5Iztp8R/DDIpN7dRu00dukMun3KSu8iO8YWNowzBlik2kAhiuASeKAOvorjR8RNDhhd764dG8+eNYre1uZ5AkJAd5EEQZAu4biRtUnG41q2HizRtQ1f+zbC7e5uwqOwhgkdEV4xIjNIF2KGU5BJAJ4HPFAG7RXGQ+NBbaz4og1SC4Nppl9DawGxsLi6kIe1imJdYlcjl2G7AGMDr1qWHxS0K71nULfdMumW1hb6gmpC3maGSOVZG5by9qYEYxlsszFQNykUAd9RXJL8Q/DbbVN1eLcNI0ItX065W4LiPzNvkmPzMlDkfLz2zWd43+I1lo2ieIP7O85dc0+xuLuCC/sLiGObysBirOqCRQSuSjHgg5xzQB31FFFABRWN4u8RWnhfQ5dTvoridFdIo4LZA8s0jsFREUkZYkjuKbaeKtDudNt77+1LKGCayXUV86dEK27YxIwJ4XkDPTPGaANuiuD8VfEWHREumt7AXgt7bUJ2IuowCbWFZdvyb8bt4HzYYddpyK6C08WaDPfJp51nTE1YxiR7A3cZnQFA/KZ3cKc9OnNAG5RWTZeJdCv2ZbHWtMuWWIzEQ3UbkRhVYvwfu7ZEOemHU9xU15relWWmR6leanY2+nShSl1LcIkThhlSHJwcjpzzQBoUVV0zUbLVbGK80u8tr2zlyY57eVZI3wcHDKSDyDVqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnzwlrmq6Xqseta1fahDpT3erRi6k1C4vI7p45pVitzbsQkLAISmw/Ps25BOK9gXxVbDWNchuDb2ulaMsa3WoXFwI0WZ1DmPBGAFRoyWLDlwMdTVyz8T6Be2zXFnrel3FusL3Jliu43URIcPJkHG0EEFugI5oA8c0X4yatfx6gjTaIsMU9ii6q8Srb20U/m7pJkjupRhTEBgyocuNwXFU/CfjOXQ7S+umvLeaErrd8byGKV4Xf+04kVxB56psPmk5ZsqP8AloBuz7dF4o0CbVV0yHXNKk1JuFtFu4zKflDcJnP3SD06HNNt/Fnh25W6a21/SZltXWK4Md5Gwhdm2Kr4PyksQoB6njrQB5R4L8Z3njTxV4am1BbQy2OrX1ostqECSp9iDhsJLKufnI+WRhx17DpPGXjLxBpWv69Hpo0r+zdGtrC5ljuIJGln+0SyIyq4kATAjyCVbnse1u1+KOk3/i6bSdKudIvrSBoInuItWh8x5JXCjy4zw6qWUMQ+7JCqrHiuim8Y6CLtrS11XT7y9juIraa2gvYPMhZ5BGN6s4xhmHH3j0AJIBANHS9XsdUl1COwn817C5NpcjYy+XKFVyvIGfldTkZHPXrV+uQ13x/odlousXmk6jpur3emJvms7a9RnX5gpDbdxXk9x1rr6ACiiigAornrHW7mfx9q+hukItLPT7W7jcA7y8sk6sCc4xiJccdz17cPrfxktVg1a20PTpZ9YsBFIYWuLSdGRrhIWOYrg7SN4+Vip5BxjOAD1mivO5/i3oNp4ot/D99BdWmpPNBbSxSzW263lmClEZRMXb7y5aNXUZ5IwcMuvi3pdt4UsvEc+k6nDpd7GJLd7ieyt2kXbuO1ZbhSSOmBknsCCCQD0eiuO8D+I5fEOt6+8c7SaYgs5rJWQKUjltlk5wMnJbPJOKht/iLZzWdnfjR9XTSr28hsrS+YQeXcPLMIlZV83zAuTnLKOOQDwCAdvRXns3xCnl8e6bommaPd3NnI97BdS/ulZJIGgG9S0o/dgSktwWOV2g4IqvF8Y9BkXU1WzvnubDyN9vBNaXLP5s6wKFMU7qCHYZVmUgHOKAPSqK811X4xaDpNuP7StL60vvtE9s9jcS2sUiNEqM+XeYRHiWPADkndwDg4v23xO0i7kt3s7LU7jTZHtIn1FI0EEElyqNCj5cPkiWLJVSAXAJFAHd0Vww+JujnSLDUVtNTaG902fVI0WJS4ihaNWUgN94mRcdsA5IrU0rxhZaj4QvPEaW8yWVtHLKyLPbzsyxruJVoZXQ5HQbvrigDpaK5nwl4wt/El3c2q6dqOnXMNvBd+VerGC8M27y3Xy3cYOxuDhhjkCumoAK4608A2cGoXF3LqmqXLzasms7JTCFSdY/LwNsYO3ZtGCSfkBzksT2NeP3OteLl07XphdeIV1+3uHaPTU0YNZrbLcrzDL5B81zACQPMJJZsKCBgA623+HGiRC/SR7yeG+t7y1njlkXayXU7TSYwoIO5iAc8D1PNUvDvwq0PQp7KW0mmLWl3HeRlLSztyWSKWMK5hgQuMTMfmJOQMEc55HUL3XNc8Z6fq058T2GjWWszRWrw6OfNWB7KPDGN4GfYZfMXcV43nJGBtop4p+Ik97rYtLXX4oDp88lul3p4ke3uFmjCqpFpEjZRnwA0wIGd3BoA9FuvhxYSXU91Zarq+n3k8l00s9rJFudLhlaSL542AXKqQQAwxw1bXhrwvp/hyW7bTfOVLhII/LdgVjWGJYkC8Z+6ozknmvN/E+pfEDSP7RsrCbUr+1g1SFBqJs1E/2drYO2wRW0isBL8u5YXI6H+8K8GvePsWv2yXVPtvl2v2SGz0hmtb0mVhKbmSSBWhIQDOfJx1AbIFAHY+Jfhho/iG+vLu7ur1Xurxb2SPbBNEXWBIADHLE6EbUB+YEhskEVWtvhHolvpbaZHfaqdOl02PTLm3Z4itzHH5hjZyY8h1MjEbSoPGQRxWJJ4l8ZC9GmmPVYrqK91XzrptGkkt1t1jmNmwZY8SDPlYCEsSNp5OD1Xwp1DWb/R7w6//AGq9xFcbFnv4REJRsU5jU29u4XJI+ePrnDMMGgBvhj4aaP4dvbK6s5pWltJXmTba2lsGLRmMhhBDGGwCSCec98cViv8ABLw69zqEz3upl723uraRgLdX2TkF8yCEPIRj5TIz4HFVfB2ueMdLsrDUPFCa/rEU2gG/urRdMjWWK7WSMeTGqIh3FWY7GJPy5GBkV2fxFu9Ws9HtX0ZryJWvIkvJ7K2FzcQW5zueOPa+5s7R91sAk4OKANy/1bTtPubO3v7+0tbi8fy7aKeZUad+PlQE5Y8jgZ61dryDwVZeJNU8f6brGtXGsxQQaddQxyT2UUH2iP7UPLEqmPMbugVio2H5AcLyK9foA5rxf4Ui8U3ej/bry4isLCdrloLeWSF5ZdhWNhLG6sm3cxwOpI6Y55K5+E7yWemWcOuKlno1zJdaUktkJmhZpQ6pK7uTLGoG3b8pPBJyqkepUUAebax8MDqY1YtrAjbUBqIJFrkJ9rgji/v87fLz75xxjNU7j4bXmq+I7XVJPFrXVnZXZlitykriIrE0LRACfyhgljnyt45BY816rXH6H/xJfH2saSfltdVjGrWg7eYNsdyo/HyX+srUAc74g+HUsnhXwV4d09nI05VsLy+hCwg2hgKXAKk5/e7VGFyQxBJwDntfEvh2LW7TS7dZEt4rG+t7wIIgysImyEAyMZxjPb0rdooA5Xw74YvNDvWa21cGxlvr29uLUWqjzTPIHQbskrs+bp97dyBiuqoooAKKKKACiiigAoorL1jXbDSSqXUuZ3GUhQZZvw7fU0m0ldjSbdkalFYWm659rbLoIwei5zW2jh1yDSjNS2HKDjuOoooqiQooooAKKKKACiiigAooooAKKKKACiiigDgL3wpfXdz4u0sxW/8AZ2rzwalb3dwhkSOVViV42RJY5NwMCurKwwW65XBzLz4Y6xPYvGPFm+8uNNutKuZ7myefMEz7gI9028FPugu8hI6nPNepV5f8WtVOi+L/AAheDV9J0fbFfj7Vqil4R8kfy7Q6Ek4wAG/A9KAKmkfDjVJ9T1OHVLyG20VdZiv4Ujt/9IufKtYY1cSiQiNNyt8hTd8p5w1R6Z8GBa6W2n3GsR3USpbQQySRXMjrDDcxT+WyyXLx4bygvyIgGcgY+Uv074ia7daNqWq38FlpVtp2k2t/PE9nJcTB5onONvmphQwVuSPlyDj7y5nhf4n+JPEd7a6ZZNoaXU2rNY/bDb+bEYhZNcbgkN06lsqRxMRj0OQADu9W8Df2hqeoXn9o+X9r1TT9S2eRnb9laM7M7ud3l9e2ehxVCy+H+oW2iafoba3aPo+nX9ve2qjT2Wf91crPtkk83a5OCu4Ip5ycnIOL4c+JGpatqWk22paj4e0ATW0Uh+2xOx1GRppI3S2zKgXHljg+YQZF4Pen8Lbu9udG0Hwvr0emXmhato93OkawOskaxyohWRi5D7hLnIVcY79aALTfCDUbq9vrnVPFs17LcWE1gJJYJnYK8scgYh52QEeXjEaxqc5xxXr9ct8LLy41D4d+H7m8ne4me0T9+4O6YDhXPqWABz3zmupoAKKKKAOe1bwdo+qay2q3K6hHfPEkDyWmpXNsJI0LFVZYpFVgC7dQeprMtfhh4StreWCLT7kwyWxswkmoXLiOHer7I90h8sBkUjZjBHGK7SigDm7bwXo1tqMd/b/2nHdKYy7rql0PPKABTMPMxMQABmQMSAAcjisnxN4U8G6X4b09tWguLTTdHg+x2zW11cpIschRPKBibzJNxCLtO7Jxwa7LUUuZNPuksZEiu2iYQu4yqvg7SR6A4rxA+DPFWrWdhbXtr4ghtop9LkvEvddMryzx3CtPPEyTEogj3EAFTnaVQMoNAHpFtJ4Y8FaVbXtvBdWcOoLb28MS29zNPLsh2xIIcNJuEacjbkbSW5BqT/hX3hz7Jc2gtbwWc7iT7Ouo3IiicSCQNEgk2wsHGQYwpFU/GvhabWNe8EvALw2emXcz3Ekd/JEyIbWRVYsHV3O/YM5JwzA8M2eGtdA+IA0q8iT+3INROmSRXU8+sLKl3emaMrLbL5h8lQol4xHwyjbxmgD0SD4eeGoPsvk2Vwr200s6SfbrjezS7fM3tvzIr7F3KxKtjkGorL4a+FbNNkVhcMgjhiVZr+4lEccMqyxIm+Q7FV0UhVwOMYwSK43xR4Y8ZxeMojot/rLaKvkNBLFctO0LCQtL5qyXkQYNnoUlAU4ULgCsbUdE+JtxqOvS2VvqVkt1YX8aRpqjNGJ2ZTA0TSXb4PBwVjhC5xgjGAD1e98D6BdzyXD2txDcyXEl0bi1vZ7eXzHVFch43VgGEaAqCFO0cZpJPAvh+XVYNRls55LuJoZMveTssjxACOSRC+2SRQBh3DNwOeK4vxh4N8Qzajq8mh6h4g8tNLgNgy61Kga9+0StKSpkA+4U4YbMHAHGB1/gjSdS0W/8RWt1NfTaUbyN9Ne9vGupPKNvFv8AndmfHmiThj9ODQAyx+HfhqwupLiytb23maGS3Vo9SuV8mORw7pFiT90Cyg/Jtx2xk1p6d4V0jT9EvtJt7eU2V+ZDdCa5lmkmMi7XLSOxckjAzuyABjpW3RQBz934N0G7Wdbiw3iaC2tpP30g3R27mSFeG/hYk56nvkV0FFFABXMX3jrQNPu7221C4vLSS0gnuXNxp9xEjxwjMrRs0YWUKOfkLZBGM109eZSfBjw/JqOpXsl7qTS30N5BIcW4cLcqyyfvPK8x8Bvl8xm24AHHFAG1f/E7wrp/N3e3ka+T9pLf2ZdFRDu2+aSI8CPP8Z+U+tbfhzxJpniJbo6VNMzWriOaOe2lt5EJUMuUkVWwVYEHGCDxWZr3gXTNbh1CO6nvEW90oaRJ5TqMQ7idwyp+f5jycj2rY07Rbew1jVtSheVp9SeN5lYjapRAg28ZHA5yTzQBw+p/EW70zw4muzW2m/Yb7WDp1kLu6NmkUQZ086aUhxgtGzDCjCsuec1qaX8RLCTwpBrmsWl5ZwSNOGe0tp76ALE5UyiWOPiIgbldgoI57UumeCitnBp+pTbrHTNXbU9NeGT52Us7iOUMuMKZGUYJyoXkHNZeu/BzQdYiEE17qcdihm8mzAt5YbdZcFliWWJ9nIJVhhl3EKwGAAC/4g+Idhb6lpmn6LL9sup9RtLWdhazPDEk2DzMo8tX2sCFLZ5HBzVyDx/o6aXpt7qMk0MV6qstxBZ3M1qu6TYoafylVctgfPtPI45BNO2+GenWt3bPbarq8VpDdW98bIPF5Mk8KIiyNmPfkrGuQGAJ5wDWVqHwU8PXwslmvdTKWkMcKBhbyEBHLgqzxM0ZJbkxlNwAzmgDp/DHidr3QNa1TWPJgg07UL+3ZokbAht5pEDEZJJ2pk46noO1XPDXizR/ErzppFxNJJAkcrpNay27eXJnY4EiqWRtpwwyDjrTLbwpY2/h/WNHSW5Ntqkt3NMxZd6m5d2facYABc4yD2zmqr+CLMXMlxb6jqtrO9vZWpe3nCN5drIzoMhc/NvZX7FTgYoAtaFrNzc+JNf0a/SETWDQzwvEpUPbzBthYEn5g0cinBwdoOBnA6Cuf0LRrm28Sa/rN+8Jmv2hghSJiwS3hDbAxIHzFpJGOBgbgMnGT0FABRRRQAVyHxKRrLTbPxHCpM2gXAvX2jJa2IKXC+/7pmYD+8i119R3Iha3kW52GBlKuHxtKnqDntQA5HWRFeNgyMMqynII9RTq8l8L+Nk0bQpfD1rG+paho8z2KSbv3bQrzA5bv+7KA4zkq3NR3Oo65qoYahfskTf8sbceWuPTI5P4muepioU9N2dFPDTqa7I9G1PxNo2mOUvNQgWQdY1O9h+C5Ncnr3xX0jSoY5Y7K/uUeVYt4QIo3HrknP6VgWekwxD5I1H4c1R8baH9v8JanBGuZRCZEx13J8wA/LH40sFi41MTThVVoNpP0b/Q1rYVQpSlF3aWh2g+IikcaPd5/wB9aVPiJHuHm6PeqvcqVb9M1y/hcx6v4e0+/XBM8Ks2OzYww/AgitNrAelctatXo1JU57xbT+RtDD0ZxUo7M6GD4haM5AnW8ts/89ITgflmtRPFugPHvGrWgHoz7T+R5rhzpynqKZ/Y8JbJjTP0pLHTW6B4OHRm7rvjTzla38P4ckYa7YHan+6COT79PrXKwQsZmmnkeadzlpHOWNaR0/auEAA9KjWFkPzCuarXnUd2dFKjCmvdNDT5ShFdTpl9wAxrj4mC1o2dwQRzVUaziyK1JSR3SOHAIp1Y+nXe4AE1rqdwr16c1NXPKnBxdhaKKK0ICiiszxTqEuk+GdX1G2VGntLOa4jWQEqWRCwBwQcZHrQBp0V4ponxivb/AFLwnaXNpZwecsq6++1yLZ1hlkQRfN0YQs+DuIRk7nNb2kfGjw3q8cosIL6e6/c+RawvbzSXJlYqgXZKyocjlZChA5IFAHptFeVeGfiJdm81NNbjnQwnUbgWkqW8ckccFxFGqGbzhECPNxzkHrvGMNf0n4taTrFvbto+l6pf3M95LYrbWz2sjeZHEJWPmCbyiu1gQQ59OtAHo1FcxJ410xfAK+L0iu5NMa2W6EaxjztpwNu0kDdk46496teGPEkWvS6lb/Yb7T73T5lhuLa8Ee9SyK6kGN3UgqwPBz6gUAbtFFFABRRRQAVl+ItYTRLS1uJoWkjmvLezJU42GaVYlY+251/OtSuY+JttJc+ANeFuCbmG1e6gA7yxfvEH/fSCgDp6ralZQalp9xZXYc29xGYpAkjRsVIwQGUgj6gin2dzHeWcFzA26GaNZEPqpGQfyNTUAR2sENrbRW9tGkUESCOONBhUUDAAHYAVJRRQAVzOpahey+O9K0e0na3tUtZdQu2VVYzAMsaRfMDgEszEjB+QDPJrpqxdS0NrjxLpetWtytvc2kclvMrR7xPA+0lOo2kMiMG5xgjHzUAeQaZ8adYvNM0SJtPsBrVxqsMN2oR/KWxkmSNZkG7IYmVVGSRuRzjAxXoR+JWkf2VY34tNTeK8tr26jRIVd9tqwEgKhjyc/KBnPfFakfgjw5Hp1rYppUSwWzxPEQzbwYpTNGC+dxCyEsFJI5PHJqtbfD3w3a3r3dra3cNwVmRWj1G5XyRM26QRASYiyefk24PIxQBnab8TLTVVtF0nRNT1C7uhLJHbWlxZTERR7A0hkW4MQXdIq437s5+XHNWpvHthJbqsEF7HPNqN1pMZZE+WeCOV2Y/Mfk/dNg8npxUo+HXhtQjJb38dwsjy/a49UuluWZ1RW3TiTzGBEcYwWI+ReOBUn/CAeG/7aGqmynN4JnuBm9nMayvGY3cRb9gZlJBIXJ6nnmgDnPCnxLifw1oT6pa6jeTmx05tT1GGKIQQT3MSFd43K3JcE7EIUMM4rWt/iLZzWdnfjR9XTSr28hsrS+YQeXcPLMIlZV83zAuTnLKOOQDwDbT4eeGI5LFk051Wzjt4oohdTCJhAAIfMj37ZSmBhnDEYHNL/wAK+8OfZLm0FreCzncSfZ11G5EUTiQSBokEm2Fg4yDGFIoAyJviFPL4903RNM0e7ubOR72C6l/dKySQNAN6lpR+7AlJbgscrtBwRVeL4x6DIupqtnfPc2Hkb7eCa0uWfzZ1gUKYp3UEOwyrMpAOcVpReD/B9rrFjpkdvcJqEQn1GL/TLne6u0azF335kViI9yMSDxkc1PZfDXwrZpsisLhkEcMSrNf3EojjhlWWJE3yHYquikKuBxjGCRQBjar8YtB0m3H9pWl9aX32ie2exuJbWKRGiVGfLvMIjxLHgByTu4BwcX7b4naRdyW72dlqdxpsj2kT6ikaCCCS5VGhR8uHyRLFkqpALgEita98D6BdzyXD2txDcyXEl0bi1vZ7eXzHVFch43VgGEaAqCFO0cZpJPAvh+XVYNRls55LuJoZMveTssjxACOSRC+2SRQBh3DNwOeKAMwfE3RzpFhqK2mptDe6bPqkaLEpcRQtGrKQG+8TIuO2AckVqaV4wstR8IXniNLeZLK2jllZFnt52ZY13Eq0MrocjoN31xVax+HfhqwupLiytb23maGS3Vo9SuV8mORw7pFiT90Cyg/Jtx2xk1p6d4V0jT9EvtJt7eU2V+ZDdCa5lmkmMi7XLSOxckjAzuyABjpQBU8JeMLfxJd3Nqunajp1zDbwXflXqxgvDNu8t18t3GDsbg4YY5Ao0fU71fHGu6JezGeBLe31C0cqoMcchkRojgDOGiJBPOHwScVNd+DdBu1nW4sN4mgtraT99IN0du5khXhv4WJOep75FTaVof2PxDrGs3FwLi7v/KiTEe0QwRg7Ixyc/M8jE8ZLdBigDaooooAKKKKACiiigDl9WvrnS/HejebO50rVYZLHyyfljuUBljI9NyCYH3RBXUVzvj/TLnVPC12unAHU7YreWX/XeJhIg+hK7T7Ma1NB1S31vRLDVLJiba8gSePPUKwBwfcZwaAL1FFFABRRTJpooY2eaRI0XqzsAB+NAD6a7KiM7sFVRkknAArifEfxM0LR54La3dtQup38uNbfBTd2BfoPwzXMavq2peIGK6hKILInItITx/wJurfy9qyr1VRipSW+3n0/M2o0JVXZdDq9a8d2sRaDQ4/t9z0Mg4iQ+7fxfh+dcfeLf61OJdZumuMcrCvyxr9F/wAeasWdtEihY0wo6ACtOKDHavKq4idT0PSp0IUvU5yDQZbfxQmoWvlrbT2vkXSZwSyNmJgMc4DSA/UeldJHbqO1WFjx2qZI/Wsty27EKRCpRHxyKsJGKeE/CrUSOY4H4aL/AGdda94bk4/s27LwKf8AnhJ8y4/X867oxCuK8VD/AIR/x5oevD5bO9H9l3h7AnmNj+PU+gruWFermy9rOGLW1RXf+JaS/FX9Gjkwr5U6X8r/AA3X4afIrsmOlR4qwwqJhXjs7UMxTWQMOafijFSUVXtx2pqo6HgVcxSbaVh3LVhMwYZrp7KYOgrlYODW9pz8gV6GFnZ2OHERvqa9FA6CivSOAKr6hZwajYXNleR+ZbXMTQypkjcjAgjI5HBPSrFFAGC3hDQGexY6Xb7rNg8RGQSwhMAL8/vP3R2fPnjHoKpJ8PvDy6c9h5OotZkxskT6rdOIDG25DDmQ+UVIGCm3jjpXV0UAcePht4U+zSwNpsjpKksbtJeTu7CSSOVyXL7txeKNt2dwK8EZNXNH8EaDpF4l3ZWs/wBqS4e6E095NO5leIRMzNI7FiUUDnPT15rpKKAOc0vRfD2o+BrXStPhWbw3PbqIY1lfDRHDD5id35nNWJ/CujT6m2oS2e68a7jvzJ5rj9/HF5SPjOOEJGMYPUjPNZvw3H2XTtW0g9dL1S5twPSN28+IfhHMg/CutoAwPEvimy0GWGCaK4ubqZS6wwKC20HG45IAFZX/AAsG0xzpOrZ/65J/8XWJ8RElsPFtrqMq5s7i3WBX7K6sx2n0yGqS1vLaZRyAfSvOr4qdObij0KOGhOCkap+Itip+fStXUevkqf8A2apY/iLoZP78XtuO5ltmwPyzWPdSQRRluCAM1DaRxXcQZkGD2rNY2fUt4OnY7rRvEOka3EsmlajbXSsMjy5BnH061pyIksTxyKGRwVYHoQa+fvh9pcIttV0WdB9o0q8eNcjkxsSyN+PNdnBca3pXFjfO8Y/5ZXP7xT+J+YfnXpY2rHC4mdF7J6Punqn800zkpYd1aanF69V59fxOm+FkjHwDpFvIWMtjG2nOW6lrd2gbPvmM11VeTfD/AMZW+m3niLT9agltXGpNcq8amSMLMiSE8cj5zJ2r1GwvrXUIBNZXEVxEf4o2DCiNSM9mZSpyjuixRRRVkBRRRQAUUUUAFFFFABRRRQByXiwmy8XeENSGArXM+myt6JNEXH5yQRD8RXW1ynxSVl8D397EpaXTGi1Ncdf9HkWYgfUIRjvnHeuqRldVZGDKwyCDkEUALRRRQAUUUdOtABRVeS9tY22yXMCt6NIBSC/tCMi6t8evmD/GldDsyzRUCXls/CXMLfRwamV1b7rA/Q0xC0UUEgDkgUAFFUNQ1nTdOjL319bQADOHkAJ+g6mucuviBpeMabHc3rdikRVfzbFRKpGO7LjTlLZHZVxvgqRdG1LxF4fnZY4bK4+3WhY4H2a4LPjnssonX2CrWFd+K/EF5IfINvYRdgq+Y/4k8fpXDeJrF4dd0fW76Wa6zN9huZJ23YSUgIfbEoQdsBzXPLGQ2jqdCwc7Xloew6h440O0cxx3DXco/htk3/8Aj33f1rCu/HGp3OV03TorZf8AnpctvP8A3yMfzrOh08KBhQB7CrkdmAOlcksZUltodMcLTjvqUX1TxBdAi41eVFP8MEax4/HGf1qlJpMdzL5l2ZbmT+9PIzn9TXQi2x2pRAR2rCU5y3ZtFQj8KOF8c6D53hiaSwQLd2TLdw4H8Sc/yzW/4fuLXVtJtL+2UGO4jDgDse4/A5H4VuiHPGK8+0O9tfBnjC48PXNxCNLv3M9kd4/cSH70TD+EE9M/1OPWw1J47Byw8VedO8l5xduZfKykv+3jlq1FRrKo9paP16f5fcegQwqBwuKnVABUgAAo61451XGgCpUFNAqVKqJLJUUGlZcU6Oqes6vpujWv2jVr2C0i7GVwC3sB1J9hXRTpyqNQgrt9EYyko6vYo+L9CTxF4avtNfAaaP8AdMf4JByp/MD8KofD7WZNc8MQS3YK6jbMbW8RvvLMnDZ9zwfxrNHjfUtcOzwToU15EeP7QvswW49wD8zD2GDV7wX4X1DRtQ1TU9X1KO5vNSKvNDbxeXCjDuO5Pvxnvk817VTDPD4GdHFtRkmpRV7yvtJNK/KmrPWzvFdzjjV56ynSV1s308vX5dzpWFRMOKsOKiavnWj0kyAjBpPwp560mKzLuJSU7FGKAFjPNbFg+GFZCda0bRuRW9CVmY1VdHRxnKCnVFbHMYqWvZi7o8t7hRRRTEFFFFABRWVe+ItJspTHPex+YDgomXI+oUHFVZPGGiRrlruTHqLeU/8AstQ6kFuy1Tm9kUdO/wBA+J2r2/SLU9PgvEHrJEzRSn/vlreutrzDxX4t06HxR4W1a2iu5kinmspWEJXMc8eRjdjrLFD/AJ69J/wnOnqCZrPUYkHJdoQQPyY1Ptqf8yK9jU7HQ6lYW2p2clpfQrNBIMMrfzHofeuGvPh/cQbm0nUFdf4YrpTx7bx/hWq3j7StwCQag4PcW5H88Uk3xA0iCIvJDqAwMkC2Of8ACs6jo1NJNGlNVqfwpnMSeFPEhVoza2rA8bhdf4rVG01CWxvntLyF7e4j+/C/Ue4Pce4rppfiE0uDYaRKVPRrmURn8lDVha9rV3rSAXmmaf8AKPkcbzIn0cEfl0riqwoJe5LU7aU67fvx0Of8SztoXiKDxXYxtJaPGLfVIYxlvL/hlA7len0A9zXe2FxbalZxXVnKk9tMu5JEOQwritEe5Ept72RJeCCduM/UVGmi6v4VupLzwftu9OkbfPpEr7QD3aFv4T7fz4A7qcqWYUo0aklGrBWi3opLom+jXRvS2jtZMyqQlhpOcVeL1a6p913T6r5m83h508VX+oJsFrdWkMTLn5vMjaTnGOhVwOv8IpraXLZymfT5pbSbu8Dbc/UdD+NP0Px1oerv9mmmbTdRHD2d8PKkU+gzwfw59q6OSLj2rhxOFr4SfLWi4v8Arbv6o0pVoVY+67oo6b40vtPxHrUBu4h/y8QqFcD3Xofwx9K7nTdQtNTtVubGdJoW/iU9PYjsfauFurFJQcjmsJYr7Q7xrvSZDFKfvp1SQehH9etVRxko6T1RFTCxnrDRnsNFcXafETSFtw+sl9MccMZhmPPsw/rituPxTochAXVbPn1kA/nXpKacVLozgdOSdmjZorKPiPRQf+QrY88/69f8agl8W6DEpZ9VtSB/dfcfyHNHPHuLkl2NyiuTk+IGgqP3U1xOfSO3f+oFZtz8RCxI0/R7iQf3riRYh+Qyah16cd5FqhUltE76ivLZ/F3iK4JCNZWinp5cRdh+LHH6VRmvtZuxi51W8cHtGwiH/jgFYSxtNbam8cFUe+h6pq5sm0+4h1KWKO1mjaOTzHCgqRgjn2NcB4G8eaVb+BtGhu7mS5v7a2W1nWCMuWki/dsc9OShPXvWGNKE8nmTKZX/AL8pLn8zWf4U0eS1vddtHgdIUvjNCxXCusiK5wfZ2kFZSxzafKjVYJJrmZ203xEmdiLLRJCnZricR/oAf51n3Hi/xFcAiL7Fag/3Iy5H4k4/SnR6Yo6irSWCD+GuaWKqy6m6w9GPQxJb3Xbk5n1e7+kREY/8dqvPbXFwMXNxcz5/56Ss39a6hbVB2p32dPQVk6k5bs0Sgtkcauiw5/490P1Gaf8A2HAettH/AN812AgQdhThEvoKm7K5kcZ/YFuf+XZB9BTv+EfgIYKjoWGNyOVP5iuvKIOwqGR1XoBTUnHVMV0+h5RLZ6t4UkIvxfanoufluIJW82AejqDyB6//AKq6HSItE1yDztPululxlh5rFh/vKTkfjXXPN6VzGseDtG1Sf7QbU2t3nIuLVvKfPrxwT7kV68sZhsbrik4T/mirp+bjda93Fr/C2cioVaP8Kzj2fT0f+f3lyLR7SBsrbx59SMmrsduDgAYrmk8NeJLQ/wDEu8TyyR9o723WU/i/WqOuat4o8NWwm1DUvDPI+SORJhI/+6q8n+Qp0so+szUMPXjNvZe8n9zj+VwnjPZR5qkGvut+Z38NmD2q39hiliMc0aSIcZV1BBxyODXA+HLr4h65bG5eLSdKhfGzz4X3keoXJI/GtoeHfGNzn7T4wjt1PVLbT0/9CJyKqpk8aE3CtiIJrfWUv/SYszWNdRXhCT+5fm0dgsNVtQ1DTtMTdqN9a2q9czSqn8zXNf8ACvvtPOq+JfEF4D1j+1eXGf8AgIFXdO+HXhWxbemkQTSZyWuS0xJ+jkihYfL6fx1ZS/wx/WTX5EupiJbRS9X/AJL9SjcfEXQPOMGlm81e5H/LKwtmkP58D9ai/tTxpqvGl+H7TSoT0m1Ofc2P9xOQfrXd21tDbRLFbQxwxDokahQPwFSkUfW8JS/g0LvvNuX4LlX3pi9nVl8c/uVvzuzz4+CtV1IZ8SeKL+dT1t7EC2j+hxyw+uKvJ8PfC8enTWaaRBslXa0jZaX1yHOSDnniuuemEgAk9Kznm+MdlGo4pdI+6vujZFxwtJbxv66/mecxahq3gN1t9cabU/DudsOoKN0tsOyyjuP9of4Ad5YXltqFpHdWU8c9vIMpJG2QRXP65458O6ezW0t4l5cNlfstqvnu3quBx+BIrgYdG8Q3GqNe+CdLuvDNvIS0n2ucLHKf+uGDtP5j6V6n1D+0KftsTH2M/wCZ2jCXydmn5wTT7Lc5/b+wlyU3zrstWvn29bep7NuABJIAHUmuW1Xx/odhcfZbWWXVL88La6ennOT6ZHA/PNcl4T0d/GltcSeLNX1G5ubaZobnTAwgijYHgFV+97HjvXpOjaTp2jweRpdlBax9xEgBb6nqfxrirYXB5dUdLEN1JrpH3Y/+BPVr0irrZm0KtXERUqaUU++r+7Zff8jmRJ448RcRrbeGLBv4mxcXRH0+6v6EVp6N8PtDsbgXl8k2r6ieTdai/nNn2B4Htxn3rpkapA1ZyzatyunQSpxfSOl/V6yfzbD6pC/NP3n5/wCWy+4l4AAHAphNG6mk5rzm7m9rDG71E1StUL1lJmkSM0lKaSsywooooAcvWrlqcMKpDrVy2+8K0p7kT2Oks/8AVCp6qWB+Srde1T+FHlT3CiiirJCsrxQt0/h++WxDm4MfyhPvEZ5x74zWrVbUL+006AzX1xHBH03OcZ9h61MkmmmOOjTR5XpuoWsMYiMeGXggDkfUdRUurXUU1ptgzkkZBGOMit7VvE3h68f95pM2o/8ATQWy/oWINYYvdBupWS18KXZZTj5phGOn+yxryJUIraaPWjWk9XBmT4sRtQ8NzQWkYN7E0dxbgkDMsTrIoyemSoGfetLVLmOa3CRjgsAfzqwbaB8FPDflj/sJv/hVKVYUvEtjpUquw3f8hEkdf9ys3BWtzL8f8i1LW/K/w/zNS3mg8hMuuQORWHq1yLi9WBOUA3kfy/z7Vek0tyzMLWVV7Kt8OPzjNYtnBIdXunYnywURVZgxXHJyQBnr6VDjZblxd3sdBpunAoGkHWrrWqCVVA421YRlijUE4zxSzHBR/Q1IOTbOU1WJrS+WdRhc4NaVjfA45rR1OzW6gIxzXIyJLp83lyZ2fwmlsaJqSOn1HTNJ12ERavYW92oGAZE+Zfo3UfgaxV+H8FmM+Htf1nSlH3YUuPNhX/gDf41LaXzADnIrSh1OvRw2a4rDx9nCb5ez1X3O6/A5K2CpzfM1r36/eYz6J40tuIfFlrdKOn2jT1U4+qmsbxPN4r0PSJr7Ute0oRJ8qqtmS0jHoqjPJP8Aia7tL8PXFeNpooPGXhq/1ld2iRF0DH7kVwfus/twMemCa9XLMbLF4lQqU4NWbsqcE3ZN2Wlru1v89jjxND2NPmjJrb7Tsr6X36GXofhTU9VW11Xxo/nSAboLEqFSLPd1HBb27d/QdmdNyAQoIrduVEsXBBB5BFJbj5ADXkY7H1cbU5p2UVtFK0Yrsl0/N9TtoUo0YWWr6t7v1MA6bj+AflTPsTA/drqCg9KTyl9K4bG/Oc9HYseoqzHp3qK2hGB2qRY6aiJ1DMj09R2qzHZKO1aCR1MIxirUDN1CiluB0FSCKrmwUoUVfsyHMp+UaTyzV3aKNgo9mLnKPlmjYaulBUbKKTgUpFUqaYelJe31pZjN3dQQD1lkC/zrnr/xz4Ys8+drdkcdon83/wBBzWtLB4ivpRpuXom/yJlWhD45JerNyQE1WeFmNcyfiLpc5xpVhrGqE/dNpZsQf++scVDc+IfFl3HnTfDMdjGTgTajcD9Y15FdX9i4tfxYqH+JqP4Np/ciFjaX2Hzeib/I6xbU55rH1zxLoegkpqF7H9o6C3i+eVj2G0cj8cVnf8IprurqD4j8SzrC3W101BAmPQv1I+ore0Hwromg86Xp8MUuOZiN8h/4EcmmsPgMPrVqOo+0FZf+BSX5RfqJ1a9T4I8q7v8AyX+Zzi3vivxH8ukWK6Dp7f8AL3fLunYeqx9vx/Otjw74K0zSLn7bOZdR1UnLXt42+TP+znhfw5966XNKppVM0qODpYeKpwe6ju/8Unq/S9vII4ZX56j5n5/otl+ZOi1Mq1FGwqXeBXCjV3HBcUvArN1fWtP0i2M+p3kFrF/elcLn2A7n2Fcg/ju+1glPB2h3N+h4+23P7i3HuCeW+nBruw+Ar4mPPCPu/wAzso/e7L9TnqVoU3aT17bv7j0AkVzOv+N9A0RzFd6hG91nAtoP3spPptXofrisA+Fdc1s7vFniGYwnrY6Z+5i+hb7zD6/nXQ6H4c0bQUC6Tp9vbtjBkC5c/VjyfzrZ08Dh/wCLUdR9oaL/AMCkvyi/UlOvU+GPKvPV/cv8zBbxD4r1skaBoC6dbHpdauxU49ol5/mKaPAs+qHf4t12+1TPJtom+z2/02r1+uRXbZpC+Kn+1p0tMJBU/NK8v/Andr5W9C/qql/Fbl67fctPvuUdH0TS9Gi8vS7C3tRjBMaAM31PU/jV9mA4NRGXFQzSEg4615lSrOrJzqNtvq9WdUYKKtFWRxnidf8AhF/Ftn4lg+XTrwrZ6mB0GeI5T9OhPoMd69A68iuc1SCDWdIvNNu/9XcRmM+x7Ee4OD+FVPhlqst/4Yjtr0/6fp0jWNwO+5OAfyxz65r06z+t4KNb7dK0X5xfwv5WcfTlOWMfY1nDpLVevX79/vOwB/Onbqi560oNeWmdNiXdShveot1JuouKxIxqNjmkJppNS2NIDSUUVJQUUUUAOXrVy1HIqmvWr1p2rWluZ1NjcsPu1cqpYj5at17NP4TzJ7hRRRVkBXleozrceIr1tWLPJDK8cat0Rc8AD3GD716pWXq2g6bqxDXtsrSAYEiko4Hpkc1z4ik6sbRdjfD1VSleSOLF3Zqn7sD8BWXYXAiuZnI48wn8MCuk1Dw34a00j7bfXEJIyENydx+g6mse4tPCSECK41d3boE3jd7DcAK86WFlHeSPQjiIy2TLn9owbck1jXc6tqwnGSoTH61K+n2zj/R9P1YD1kvEU/ltNVZLaOOaO3NjdiRxkNJfAj9ErJ0/7yNFNdmbo1G3eM4cZx0rnNNYG/uh1PmA/oKuHRZz0ijUe88h/liqGnQtba1cRvgHap+Ukjv6kmpcbLcqL7I654hLFg9ccVGmZIWRvvLxUhmjiiDSyIi+rMBWTNr+j2t2xn1bT4lYcl7lF/mauFGpU+CLfojNzjHd2NW3k3xjPUcGob6yiukKyKDXPz+NvDNpMSdas2Ruvlvvx+Wart8TPCwYrDfy3DD+GK2kP/stdsMnx9TWNCb/AO3X/kYvGUIvWa+9E9zos0LZtnOPQ0yKC7U4dPxFRH4gWMn/AB66N4guvTybAnP5kU0+MLyXH2bwfr7Z6edCsXH4mq/sTG/ahb1aX5tFLMKPe/pdmrbQyk8gir9zptvqFhLZ38KzW8q7XRhwR/nvXODxH4lcj7N4JuGz082+ij4/EcH2pw1jxrIP3fhW0gz083UVbb9doqoZTiaclLnhFr/p5Tv/AOlXInjKc1azf/bsv8jKluNS+HflRXckmpeF3cRRSHm4tCfuqf7y9v8ADgG/F8Q9JDc22q/+Ab1z3i2719tQ0m68WaWI9DtJfOlWwbzvnH3Wk77R9PX2r0HQNXstWtVutPuY54T/ABIeh9COoPsa9XMIUo0qeJxNL2kpX5pQklG99LtJrm6u1unW5y4dzcpU6cuVLZNa/LVO3Yxh8RNNY4h0zXJsdfLsWOKX/hYNn/0BfEP/AIAH/GuwWQHvTg49a8r6zgP+fD/8D/8AtTo9lX/n/D/gnIL8QID/AKnw34onPfy9OJx9ctTx4/x/zKXi7/wW/wD2VdesgpwkFNYvBL/mH/8AJ3/kJ0q3/Pz8DkR46vB/zJ3iP/wHX/Gl/wCE11c8p4L1naem4oDj3GeK60yj1pPMFV9ewi2w6/8AApf5i9hV/wCfj+5f5HI/8JZ4pfAg8D3BY/8APTUIkGPrij+3vHE3+r8KWVvn/ntqKvj67RXXb6TfS/tKgvhw0PvqP/2+34B9Wn1qP/yX/I5E3PxEn/1dv4atQf8Anq8zkflxkUfYPHlx/rfEOl2mf+fey8zH/ff511pf3pN1H9ryXwUoL/t1P/0q4/qie8pP5/5WORbwt4hn/wCP/wAb6i/r9mto7f8AlmmH4e2Uw/4mOteIL89xcXxIP4ADjr+ddhuozS/tvGL4JKP+GMY/+kpD+pUeqv6tv82cpbfDrwpbNuXSI5HzktNI8mT6ncSK27LQ9JscfY9MsbcjvFAqn9BWhkUZrlrZji6/8WrKXrJv9TWGHpU/hil8gqpqilrNyvVfm/KreRSEBlIPIPFcZqRW0omtkkU8EUpY0sMKQx7IxhaZO6xqzOQqgZJJwBRvsNCEkUCTFcbqXjywW4a00OGfWr4f8s7QZRf96ToB7jNUm0rxL4gyde1IaXZN/wAuWnH5yPRpP8Mg16cMqqQSqYqSpR/vfE/SK975tJeZg8VGT5aS5n5bfN7fr5HR65410fRJPJuLkzXhOFtbZfMlY+m0dD9cVk/bvGXiLizgh8OWDf8ALW4AluWHsnRfoefetPQdA0jQo8aZZRQuRhpcbpG+rHmtkSelX9cwmG0wtPmf809fuh8K/wC3uYh0KtT+LKy7R/z3+6xz2leBtHtbkXmo+drGod7nUH80/gp4Htxx611gcAADAA4AFUzJnvTlf3rjxOMr4qXNXm5evT0WyXkjanQhSVoKxb3+9BcVU3+9IZeK5rmli0ZKjZ6reZQXouPlJGeo2PrTDIB3qCWfmk2UkMu0wd6HmuR0K5OlfEXUbY/LDqlutyo7eanysPqRkmuqaZSOTXF+OD9l1HQNTj4aC8ELMOySDB/lXqZQ+epPDvapFr5r3o/+TJHPi1aEan8rT+Wz/Bs9QguAwGTVjcCPeuWtb0rw9a1vdhgOc15dzZwNMEUGq6yZ5FTK2RTuS1YXNJR3opAFFFFABS54pKKAHL1q/a9qoxjJrRtl6VtSWplUZtWP3KtVBZjEdT17EPhPMnuFFFFWSFVNWkuYtLvJLFBJdrC7QoTjc4U7R+eKt0UID500/VvFhZ5f7L0ozyMWeW6nZ2J9DjvUuoz+NLhoJJZvD0Ww4XyUmYjPru+navbNR8L6PqEzTXNkvmtyXjZoyT6naRk1U/4QnQ+QbeZl9DcyY/8AQqJVZJ+5Rpr5N/m2dKnC3vSl96/Sx5GJPGMvEniK0t+37qwVvx+Y9aqXWleILm5ha68V3UjcjdHaRxY+mK9ln8JeHLePfcQ+Un957uRR+rVjT2/gy2Yi3tnvpf7sEkkv6ltv61DxeJh/z7j/ANw4f/I3KiqMtlJ/9vP/ADPPE8P3MgH2zxT4iJ6/uboRDP4A1RbwdpjagqT32pXKuuP3t2STjscYruNQNl58cNr4fghZwSrXFw7kdvug4/Wq+o6TcfYt+YEaJhIoht0TBHuBux+NYPN8ZHatb/CkvySN44SjLen97v8A5lDTvh34UdN76WJJO7STyMT/AOPYrSHgzw3bSxGPQ9PKk874Q/8APNTaPfLJEsq8A8MPQ+la8kySCMg/xCueebY6ppOvN/8Abz/zLWDoRfuwX3IgTQtKhTFvptlD6eXAq4x06CrFtgRBVULt4wBgVY3e9RrxI57GuOdWdR3m2/U0jFRVkh4NLVK21G2uL28tYJN01m6pMuD8pZQwGeh4IP41aaRQOtQMfTHcKKrTXiIOWFZV5qe4ER/nSuXGDZNqd0CpXIya4u88MBJW1Lw3cjTNVHJC/wCpn9nXp+IrasorzV7p4dMt3u5V++2dqJ9WPFbsXgvxCACZdMX/AGd7nH47a7cFWxWHl7Shs91umuzT0a9TPEKhJclR6/ivTsY/hHxH/bVjJ9pi+zajauYbqDP3HHcex7VufaPesH/hXXiaDxSdVtm04JLD5VyglYeZj7rD5eo4H0rUk0HxJFnOmK4HeO4Q/wAzW2YYaPtFUw692STt/K+sfk9vK3Uyw9dcvLUeq0v37P8Az8y2LnHeni696xXstcjz5mjXwx/dUN/I1BJcXcH+v0/UYv8AetX/AMK890prdHSpwezOhN170fafeuVOu2inEk2w/wC0pFTJrNm4+W6iP41FmVZHS/aai/tCH7UbbzU+0BBIY9w3bc43Y9MjGaxV1KFvuzxn/gQrB0S7W58VeIL3cpEZgsEbPUIhkOPxmI/D2ppN3E0tEd79poFz71ifawf41/Oj7QP74/Op1K5Ubn2kU37UKw2uRj76/nUEl4i9ZkH1YUahyo6L7YvrThdA965ZtQgX71zEP+BCnRarCTiORpD6RqWP6U0mxNRR1Qn96hv9YsNLtjcaldw20I/ikYDPsPU/SuI1GbxnqN1JbaFo1xa2q4H22WBmZhjqqkAfnmksfCEen3H23X9O1S/vV5NzfRGRV+gGVA/PFevTy+lSgquKqb68sfel838MfvbX8pwyxDnJwpL5vRf5v8vM0H8a3+sEx+D9Gmu06fbrwGG3HuM8t9Bg1Xbwhd6swl8YaxNfjOfsduTDbr7YHLfXg1tLr1gIwBeQKBxjcBj8KfZ/2hrLldHtXnXvM+UiH/Aj1/DNNZlKn7uBpqn57z/8Ce3/AG6og8NF64iXN5bL7uvzuS2VpaadbiCwt4beEfwRKFH6VM0gHU1uWngaRowdQ1WcuR8y2yqij6Egk1YTwDpYP7y41GXj+K4I/kBXI8JWqNym9X3L+t0o6R2OYMq+tNEw9a6iT4f6S2Nk+oR/7txnP5g1Wm+HsBTFtq19G3YuEf8AoKn6jUQ1jKbMHzRnr+tSLIP71T3HgDWI8/ZdYtpfTzYCn8iapy+DPFUZ/dy6XIP+urr/AOy1DwlVdC1iaT6kxlUdTWXoetDVLSa4MflItzNAnzZ3rHIybvbJU1HrmheJNI0e/wBSvI7EW9lbyXErC4PCopY/w+gqr4Y8C+KrPw5pts1rah0gQyF7jBLkZYkY4OSaPq1S2we3p33Nt7xB3qF75PWnx+BfEsrfvZdOgX1Du5/kK29N+HCAhtV1S4n/AOmcCiJfxPJ/UVUcJUfQUsVSj1OWuNTjiGXkVR6scVXgnutQP/EutLq794YyV/766V6jp/g3QNPk8yDTYmk/vzFpW/Nia31UKAFAAHQCt4YH+ZmEsd/Kjyuz8IeILtA0sdrZg9ppSzfkox+tY/jn4d+IbjQZFs5bS7dHSXYm5H+Vgflz1PX0r22iu7DU44arGtTXvRaa+Ry1cROrFwlszwm1uVnQMM89QRyD6GrsUrwkEHIq3450tdK8UySxALb36+coA4Djh/z4P41nIcrXh1Yezk4ns0pqpFSOgsbkSKKvo3IrlbWYxSA54roLeXeoOagJIv7s08VAp4qVDTM2h1FFFAgpcUCloAlgXJFatrHlhWfaqS1bdlHyK7MPC5y1pWReiGEFPoHSivUR57CiiimAUUUUAFc1431K4sbW2itZDCbhyrSjqoA6D0J9a6Wqmp6dbanam3vY/Mjzkc4Kn1B7VFSLlFqLsy6clGScloedJa2WDI8vmTEcu7bj+Z5qjpF0tnLIjg7ckcfWu3XwTpgbJlvCP7vm4H6DNWV8I6IMbrLeR3aVz/WvMWBqPdo9H65TWlmcBrF3HNLDMjbGjyPm4yD/APqqRNbMke0R+bnj5FLZ/KvSYNE0u3YNFp9qrDo3lAn8+taAAAwABWiwD6yM3jl0iePppup+c1xY6Xdsr/fTyyoPuN2Oaiur37G2y6Se2b0miZP5ivZaRlV1IZQwPYireAjbRiWPlfVHjia9Hj/j4jI/3qG1pD0uIsf7wr1l9MsH+/ZWrH3iU/0rF8XxaVo3hbV9VfTLFjY2ktwoMCHJRCwA46kgCo/s/wDvFfX1/KeN+ENbiNtqN7JcIHv7+eb3Kq3lIfxSNK2X1pZjtheSVv7saMx/lXqXg3w/BoPhfR9OMEPnWdpFA7hRlmVAGJPckgnNbwAHQAVTwCbu5ErHWVlE8Vt7HWtQx9k0m9fPRpV8pfzbFdLo3gCWbbL4guQV6/ZbckKfZm6n6D869ForWng6cHfczqYypNWWhFbW8NrAkFtEkUKDCogwAKloorrOQKKKKACiiigAIB4IBFQtaW7Z3W8Jz6oKmooAz5NF0uQkyabZMT1JgU/0rjPht4c0a/8ACFvqVzpVm7anNPqCloV/1c0rPEB7CMoB7Cug+I19Lp/gXXZ7U4ujaPFb84zM42Rj/vtlrY0mxi0vSrOwtxiC1hSCMf7KqFH6ClyrsPmfczT4Q8PEYOkWf4RgUg8H+HgcjSLT/vit6ilyR7D55dzGHhXQQcjR7H8YVqaLw/o8X+q0qxX6W6f4Vp0Ucq7BzS7leOytYv8AV20Cf7sYFWAABgAAe1FFUSFFFFAEZgiMnmGJC/8AeKjP51JRRQAUUUUAFFFFABRRRQByXxQxceGE0sE7tWvbbTyAOsbyr5v/AJCEh/CutrkvEH+nfEDwrYdUtEutVcdgVQQJn6/aHI/3fautoAKKKKACiiigAooooA5j4h6WNQ8PyTIubizPnofYfeH5Z/IV5nbNuRSOQRkV7lIiyIyOAysMEHuK8Qubb+zdUu7DJIt5Si5/u9V/QivNx1PaZ6WBqbwY5hg1paZN8u0npVEDctS2h2yGvOR6EkdDE2RU6tVGB8qDVrd3FMyaCa+hik8tmJkxnaKj/tKENhgwqjqdpK7ma3G5iOVzzWH5WrymGI28m2Ns7thBI9M9KaTYrI7SKVJRmNgasRIWPSsjRdOuUuTcXBCFk2iNTn866mztvUVrTpuTMqk1EksrfpxWxDHtAqOCLaBVkV6tKnyo82pPmYUUUVuZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXJfEofadJ03Sep1TVLW2I9UWQTSj8Y4pBXW1y2sW8t78QfDqmCQ2lhbXV40u07BMQkSLnpnZJMfw96AOpooooAKKKKACiiigAoqK6uI7S1muLhtkMKGR2wThQMk4HtXO2vjzwzdweH5rbVY5I9fZk00iN83BUZbjblcd92MHjrQB09FFY2k+I7PVL28tYIrtZLa7ls3LQEoXjVGY71yqjDjG4gnnA4oA2aKy9a1u20i60iC5SZn1O8FlCYwCFfypJMtkjAxE3TJyRx3GpQByXj7F3deGNI5P23VopXA/uW6tcZPtuijH1YV1tUdc1Ox0TSbvVdVlENlZxtNNLsL7EA5OFBJ49BV6gAooooAKKKKACiiigAooooAKKK4h/Hiafq3iGHxBaw2On6XcW9tHcwSy3Mk7zgGMeUsWVJ3KOC3J9OaAO3orhP+Fm6PL4i0bTbOG+nh1BbkPOLK4VraSF40KSRmLcvMh3FtoQAFuGBq4nxI8KvaTXTalJFbRLG/mzWc8aukkixI8ZZB5iF2Ub0yvIJOOaAOvormY/HOhSXj2olvhLGoefdptyq2wK7h5zGPbD8vzYkK8EHoRVWP4keGJLdpVvbvIaJVhOnXIml83PlmOIx75Fba2GUEHB5oA7CiuEi+JmkDxBq1hewX9laWFlBem8uLG5jXa4kJDhoh5eBGMbjlyxUDcpFQat8TLCHUdCXT/tEttcX8lnfRPptyLqHFtJMm2DYJMkqn8BBUnHqADpbPSrlfGup6xcmIwSWVvaWqqcsu15XkJ9Ml0H/ABW7XLQ+PvDlzJDHZ3lxdyzWq3qR2tjPM/kszqGKohI+aN1IPIIAOCRmP/hYfhvyJHN1eLKlwtqbVtOuVujKyb1UW5j805QFuFxgE9KAOtorgdP8AiPYHxXqWl6mZrWBZbSKzd7C4Q5njUqszFcRMXbaA+w9sE1dPxB0a00ZNS1SSaK1MtxG1xbWd1cQRiKZoiZJRCAnK87sAHOCwG4gHY0VznhfXpdT/AOEhe9EMcWm6jLao0anmNERstycn5j09uKXwv400LxRL5ei3c0rm3S6UTWk0HmQscLInmIu9cjGVyAetAHRUUUUAFeW/FC0Nn4gs79FxHdx+U5/216fmD+lepVgeOtKOr+GrqFM+dGPOix/eXkD8eR+NZV4c8GjahP2c0zzOFgyAipEOHqjpkwliUjowzV7ac14LVme7ujVtXyoq9GeMVm2ascDFbVtbM3arjFvYxnJIiVTnirlvGxxkVbhsuBxWjbWR44xXTTw7ZzTrJEFrb5I4rXgg2jpUkMIjHSpa9GnSUTgnVchAAKWiitjIKKKKACiiigAooooAKKKKACiiigAooooAivJvs1pPPt3eUjPtzjOBnFed6/8AEiez8C6Vrdnp0QudU0K41aJJZS6QPHaeeEbABcZIUkFelejyIskbI4DIwIIPQiuBi+FmljTG0651bWruxTTp9Ls4ZpYsWUEqbGEZEYJIXCgyF8AUAalj4+0G41KHS5LuVdRaVLVwLOcQrO0YkEfm7PLDFTkDdz2yaWX4g+HIHvUvLu6sns41mmW80+4tz5ZkEYdfMjG5d7AblyBnnikh8CaZFv2z3vz6rHq5+df9ckSRBeF+7tjBx1znntXN6T8FfD2myXLx3upyPPAtu7sLdXKiaOYFmSFWkbdGPmcs2Cee4AO2v/FGlaf4cOu38txb6aGRC8tpMsmWkEajyiu/lmAHy85B6c1N4e17T/EFpLc6XLK6QytBKs0EkEkci4JVo5FVlOCDyBwQaPEuiW3iHSjp968yQmeC43REBt0UySqOQeCyAH2z061QsvCdtZau9/a6hqcbSahLqMsCzARTO8IhKOoX5kAUMAeQwBz2oA6OiiigAooooAp61avfaPf2kRVZJ4JIlLcAFlIGfbmvI9J+Dd1ph8NzwanF9o0+e2ldOQlqFtZI5/IOMsZJnWT5gOnbofaKKAPBNF+Duu2GlXlvLPYTTSJAsqtdqsGpCOdJGW4SO0RxvVWBZnmPzEHcCa17L4aa7aW87WEHhvTnZ9Skis41aW1iFxDEiJtMahlBjbd8oGD0OSK9krm/F3iK50e80jT9MsIL3UdTlkSJbm6NtEojjLsWcI5zgcAKc+wFAHnvgz4Ya5o2oWk1xJpkNtFrUOp/ZreRdqItpNAwUR28Kbi0iHhF4BySeT1Xijwldaj44ttabS9E1yyW1jgW31WVkNk6yMxmhHlSAswYA/dP7tfmx0wvAviHUfGnxFk1ExPBpFppVrNFAuqSBUklNwrsYkXy5smMgFjhQisvLELWtfE+tWfjjxDPJZreyz62ug6bFJrE0VvH/o0c/wA8fllFyoZvMAZyzbAMckAoap8KfEOqaEmh3T6ILCzstStraczSSPI9xIskTuhjATaVXOGbBGR6B3iL4YeINV1TTLmw07wpo0Vk1s8EdiUU23lz+ZIqyfZPMYMMkbXiALMCGBJPT6d8SrnUDCtvokZZbW5urs/bcrEtvcGGURkIfM+6xU8BuAducjM074uXl5pn2uTw29p56QvYtP8AbRHcmTd+6DC03NKFG7bGsikZw3FAFV/hHepp/wDxL7iw07V5/wC1lu9QttwlkW5kdoQW2gsFBTIOMEHbnrVTSfhPq1lp8aS2mj3USXsdzLo9zdobG6CwyR5KxWUSowLq3Mcm4oM4IzXU+D/iPd+KptLhsNCSKW6gmnn8+7aMQCG58hwAYtzHgsAVU9AdvJGJB8Wtcl0NNV/4RKxFu2ivrwH9sNuFsn3wf9H/ANZ0wvQ55YdKAKV58L/FEWi3ljp9xo0zalpCabO1xcTItqUuJpVEQEbF0Cy+WMlSNgPPSup0DwTfad8TL/xALXSorK5aZ3kZ1uLpy2MbWNujxDjlTLIvYAda9CtpluLeKZAQsiBwD1wRmpKAPM/EHw5k1LxPqeuRx6cNRl1HTbqzun3ebBFAY/OUNtypdVcYBw2QCR273Rv7T+zS/wBtfYvtHny+X9k3bfJ3ny87ud+zbu7Zzjir9FABRRRQAVx0/gG0udWv7+51XVJWvL+01FoWMIRJLZ1aMLiMNt+RVOSSR3zzXY0UAcbL8PtPbVo9Rhv9RguBc3Nw+wxMsq3Hl+bEwaM/IfKTphhzhqyNH+Dnh3SbSa1tJZ1hdoCu22tI5EEM8cyr5qQLI43RKDvZiR3zzXpNY3jG8urDwtql1p9ve3F3FAxijslVpi3bYGVgSOvKt06HpQBnXvgq1udU1W5TUtRgtNWGNR0+PyjBdfuhES26MupKBQdjLnaO9Ymo/DzSYNJvG1nxDfyRNBDbvdaitnKsVvEW2RbZIDFty+SzKWJx81cr4X1X4g6xe2un3t1rNlaPqzRtqH9nL5n2X7E0g5ltIlx5wC7jCvJ2/NxnL8T3vjXWPC0thra+IEkk06IQw2Oj71vpvPcSee3lN5WFSNgAY87iQTwAAeiL8LdJS2lto9S1dbWewj0+4i82MidYzIYnLFNyujSMw2FV4AIIGKkk+G8D3kOoHxFrv9sxXX2oakTbGXPktCF2mHytoR24CA5JOc1e8cf27Nqnhmy0O9vbC2uryRL+6tbeOVo4lt5XXJkR1TLqgyR1IHfFefQan8S7PQknWXUNR1C50Wa4aK40+OIW1ylxCgC7Is7jE8jbG3klMgY+WgDt7T4aaNaafe2dvc6lHHd6YulyOs4D7BJLIZAwXPmM87knp0465x/DXws8O21pHqHh3WbxJZp0vbbUbAWaBSImjzGscIhKsjkHKHPXrzWFpuueNntbMapea1Fpr3kyy3tjpEk17GoiQxoyS2UYKly/7xYMDgEjk1j+F5PFHh3wfDHDpGsW0y6Ro9ustrYBZo3/ANJ83extpnZVwgK+W5TfwF3E0AeoTeD9JuLq6tL3V7u41K8ms9Rm3ywrM5tWj2PtVAApZFDYXHJxt4rD1/4K+HtbtFtrq91MRBbhcYt5P9dPJMxXzIm2MGlYBk2tjAJOKq/C2XxJqfiDS9U8U2d5HdjSbu2lmmtmh3EXo8vOUQBjGob7q5HO0dK9aoAxtJ8O2ml22qwW8k7JqNw9zKXYEqzoqELgDAwo65rHh+H9hb2NpbWeo6tata6TDo8U8E6pKsMbKQ24L987QCRxgngV2NFABRRRQAUUUUAeT3uh/wBn65eW8YIh3mSLjorc4/A5FX4NMLY4ru7/AE6K7ljkcfOoxn2pYtPijH3a4ZYROVzuji2o2ZzVnpmAOP0rctrDGMitJIUTooqQDFbwoRiYTrykQR26p2qYADoKWitkktjFtsKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKo6zo+ma5aC01rTrPUbUMH8m7gWZNw6HawIzyefer1FAFSy02xsZGeysra3do0hLQxKhMaZ2JwPurubA6DJx1qC90DR761u7a90nT7m2u5RPcRTWyOk0gAAdwRhmwqjJ5+UelaVFAFKy0nTbAwmx0+ztjBD9niMMKp5cWc7FwOFyAcDjNZQ8C+EhFcxDwtoIiuSGnT+z4cSkHILDb82CSea6KigDO0zQ9J0ry/7L0uxsvLRo0+zW6R7VZtzKNoGAW+YjueaRdA0dbYWy6Tp4txbGyEQtk2fZz1ixjGw/wB3p7VpUUAIiqiKiKFRRgADAApaKKACiiigAooooAK5bUfH3h3T31P7VdXQi0wP9suI7C4kghKgFlMqoU3AEfLuzzjGa6muMvfh9Y3cOuWb6nqi6RrBme601TD5PmSj53VjGZFOfmwH27u3UUAJ4s+IWm+HtXsNOMN3eXEt6lpcJbW00rW4eGSVWASNt5PlgbV5wSf4TV288d6BY3V5b39xeWclrBPcubnT7mJXjhGZWjZowJNo5+Qtx0zWU3w1tnme7l8Q67Jqhu4b1b9mtzKkkcTxLhfJ8vGyRgQUPr15rOk+DHh+TUdSvZL3UmlvobyCQ4tw4W5Vlk/eeV5j4DfL5jNtwAOOKAOih+IPhua0uLhLy5AgkijaF7C4WZmlBMeyIx733AEgqpBwcdDUU3xK8KQwxSvqMux0aR8WU5MCrIYy0wCZhAdWXMm3lT6Gq/iH4ZaFr32s37XLNcfZCCyxSLG1uHCMEdGU5ErghwwOegql/wAKm0hLFrS31LUrSCe1NlepZx2tst7Bvd9kiRwqq/6xxmMIxDHJNAHTS+MdBiRmkv1VVvm01mMb4FwqFymcdlBO77vvVnw54h0/xFatc6X9sa3AVlkuLKe3WRWGQyGRF3qR3XI6Vz03w4sH1n7fFqmrQRC/OprZRtCYFuTF5ZfDRljlTnBYjPbk5v8AgjwXY+EDqDWNzczvfOrymSOCJQVB+7HDHGgJySTtye5OBQA/Q/HHh/XdSWw028lkuXWVo/MtJoklEbBZNjugV9pIBCk4rW1zV7HQtNkv9Un8m2RlXIRnZmZgqqqqCzMSQAoBJJ4rno/AGnRWtjDb32pwNZQXtvBNFMqyL9qYM7BgvDKQNpGMd81q654cttZ0GHTLq5vFMDwyw3aOPPjliYMkgJBBbKgnIIPOQQaAOV1H4iR3nibw5pPhyU4v5J/tMtxpV1I0XlGNWiKDYYnJkGWfhBgsMMM9Tr/irStAuYYdWe8gWXYBOLGeSBS7bFDzKhjQlsDDMOo9RWfongWw0rWbbVvtuoXeoxG6aSe4dCZ3uPJ3s4VFAIEEYUKFAA6VneNfhdo3i/W11PU7q+SYJEmxFgdV8tiylDJGzxkk8+Wy7sDOaANC5+Ivhq383feXbiO8bT2MOn3MoNyrshhBWM7nyh+UZJGCOCCZfD3j3w74hv4bPSry4knmWRohLZTwLJ5ZAkCtIiqWUkBlByO4FLD4K06GG3jWa7KwaxLrS5dcmaR5HZT8v3MytgdeBz6mkeC9O0q40ua3mu2bTpL2WIO6kMbqUySbsKMgE/LjGB1z1oA6eiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKxPG3iWz8H+Fr/XtTiuJbOyQPIluoaQgsF4DEDqR3FctonxY0nUtc0DS7rStY0ubXrUXmmyXiQmO4jK7hgxSuVJHOGAoA9EoorkNf+I3hjQdZutJ1K9uhqFrbfbJ4oNPuLjyof8AnoxjjYBR3JPHegDr6KqaVqNnq+nW+oaZcxXVlcIJIpom3K6nuDVugAorHXxLpLeLG8NC7/4na2n2423lv/qd2zfuxt+8cYzn2rYoAKKyPFeuf8I7oc+pf2Zqmq+UVH2XTLfz53ywGVTIzjOTz0BrVjffGr7WXcAdrDBHsfegB1FFc/458Wad4M0B9W1YTyReYkMcNugeWaRzhUQEgEn3I6GgDoKKztS1WPTfD11q97BPHFa2r3csGFMihULMvB2luCOuM9+9QeD/ABDaeK/DOn65p0c8dpfR+bGk6hXAyRyASM8diaANiiiigAoorzpvi5og8Lar4gGn6w2m6XqjaXeMsMZaJlKgykb+Y8uvIy3+zQB6LRTIJY54Y5oXWSKRQ6OpyGB5BB9Kg1W8/s/TLy9+z3N19mhebyLZN8su1SdqL/ExxgDuSKALVFUNA1L+2NGtNQ+xXth9oQP9mvovKni9nXJwfbNX6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDz/4+2F5qnwg8SWWmWlxeXksKCOC3jMkjnzUOAoBJ4BryPw34d1JPE3wouvC+leIYtS0+zjg12bV7e6EFvFsjEkcZuRhT/rQBDgc8cV9OUUAct4M8S6lr2p+IrbUvDt5o8WmXrWttPcbtt9GGYCVMovynAPBYc9a801vwt4j1b4++I5NMZtM0+98OCzbUp9OeeI7nQMkbB0USdxktjB+U9vdKKAPm/wAQfD8eGvEOnabqWkan4g8GWfhye0sI4rR7zy75mLF2jRTsdsnDkADI5GOMbWfCnimHwn4Pu9Y+1av4k0zTnU6HqGh3Gp2kwaSQoGkVTGkuzYh3EEAA5GAT9U0UAfPVh4buIfjJoetav4Pis1u/DUEMbWumG4trHUldAmSiMIiiqAHONqgDOBXOeBvB+vwaho1zro1Wy8VWeoT/AG2SDQZ5JL9JDlvOv/M8qSIqABxlegUnk/VFFAHyPY/DO4tv2Y9RuY/DmrDxjdKttJbtHOZzEL5HCiA9BhQ3Cjue5re8e+GtYuNd8cNrGg6pqt5eWFmnhi4t7SSdbV1A3BXUEQMHwSWK5weTnn6aooA+evC/w9utY+MU9x470y9u/smi6e/2wtNHBLexrHuIdSFkIYMcEkdeK6z4+MLK48BaxeHGk6d4ht5Ltj92IEFVkb2U/wA69ZqvqNjaanZS2eo2sF3aTDbJBPGJEcehUjBoA8J+LGjX978StWuNX0XUdX0eTw1PDoxt7KS7igvT3KopCSHnDnHbnjjm9G8NalBbeAW8Y+HdV1HwvbaBNbvp40+W4a3vi0nzPAqlgxQqAxXg9x1r6et4Yra3igt4kigiUJHHGoVUUDAAA4AA7VJQB8qeFfhvrms+Ifh/p/xD0rU7uxj0e5ju2ZpVWIGSRoopZUIwQCvylvQdq3G8O6lo3xeS90PSx4mt7zVE806xoFwj6XGrY3QXcihdiADaVJzxgHANfR9FAHyha6T4mm8feGtYfw7e6XqyeJdt7Dp2g/Z4IrQuMu1ykeZQwLZJkIwCSBnJ6bRI38MfA74rN4lsriyS61TUvIjuoTGZvNjRIioYDILEYI9PavomqWp6Vp2rJCmqWFpepDIJoluYVkCOOjLuBww7Ec0Acz4Q8PNc/CDSPD2vxtul0aKyuo2+8uYQrD6jp+FeGeCPCXiq/g1lPE2kX0Z8KeHbzRdMLwOPtksnmqJIsj5x5eEG3PVfWvqaigD5Ni8HeI5rLwfb+ItOuh4d/wCEdazCT6LPqP2G6Zm3M1tEyukm3G2Qg44HuJfFfg3xRYx+F5tDh1zU5ta0aXw7qF1LZSRzRxGYbZJ0y3ljYwHzN0TnHSvq2igD59+B3hPXbX4hXL+I7K8itPC1g+jabcTxsqXKtcSMJYyQAw8vauR2Ir6CoooAKKKKACiiigAooooAKKK5j4i+Kv8AhDvDf9q/Z7ef/SYLbFzc/Z4k82RU3vJtbaq7sk4PAoA6eiuI0P4hWl34ck1fU7O4ihS5ltxJpkM+pQShBkyxyRRZMZ5+cqoyDVXxX8S9NstNt20CcX95PJYFStpNLAkNzNGoaSRRtjJjZiodgSccHoQD0GiuOPxB0a00ZNS1SSaK1MtxG1xbWd1cQRiKZoiZJRCAnK87sAHOCwG43vC+vS6n/wAJC96IY4tN1GW1Ro1PMaIjZbk5PzHp7cUAdHRXO+F/GmheKJfL0W7mlc26XSia0mg8yFjhZE8xF3rkYyuQD1roqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorE1vxXoOhzLBq2r2VtcsMrbtKDK30jHzH8BWePHmlSc2tl4guR/ei0O82/gxiAP4E0AdXWT4l0G18RWNva3sk6Rw3cF4phIBLwyLIoOQeCVGfbuKy/+EzjbmLQPEki+v9nOn6Ng/pSHxoikGXw/4lRD1b+zmfH4KSf0oAx9f+E2h6yzJJd38Fn58lylkiwS28byACTbHLE6jcRu9VYkrtycpB8J9JtrO3s7XVtZgsY1shLbpJCVuWtCnlO5MROf3aA7SoOOlbX/AAmsDHEOh+JZG6kf2VKmPxcAUx/Fmpz/ACaX4P1ydzwHuTBbRr/vF5N2PorUAcr4i+EHhXV2t9LvtUvo5ZYrto4C1s7usk7TSOgkiYqVefG9NrAFQSa77SfDtppdtqsFvJOyajcPcyl2BKs6KhC4AwMKOua5S98G65rN0niDUdTt7PxRa/8AINS2DSWtmv8AHG2dplEg4diF4C7QpXJ14/E2uW6iPVPBmqmYcNLp9xbTwMf9ktIj4+qCgCOH4f2FvY2ltZ6jq1q1rpMOjxTwTqkqwxspDbgv3ztAJHGCeBXY1yv/AAlt5/0KHiT/AL4t/wD49R/wlt5/0KHiT/vi3/8Aj1AHVUVyv/CW3n/QoeJP++Lf/wCPUDxlkf8AIt+JB/24/wD2VAHVUVyT+PtKtedWtNZ0uPvNeabMsK+7ShSij3ZhXUWtxBd28dxazRz28qh0ljYMrg9CCOCKAJaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW8Yyare32naBo8s1iL5JZrrUo1y1vBGUDLGSMCVzIApPQB2xkCupooAytA8PaT4etmh0exhtg53SOozJK3dnc5Z292JNacsiQxPJK6pGgLM7HAUDqSewp1NlYpE7rG0jKCQi4y3sMkDP1IoAp6Pq+m63Z/a9G1Cz1C03FPOtJ1lTcOo3KSM1Cmvae/iCTRY5JZNRiiWaRUt5GSJWzt3yBdik4OFLAnsK8t0nwr4mutI0GzurbWdJgtbfVjcQ2+qC3LTySo9sSYJfm4MnfAIOeDzRPgvxommatqFvJqEWvXa6b5+NRcm4VYYxcqqrOih96kBt8ZxkK4B5APdKgsbu2v7SG7sbiG5tZlDxTQuHR1PQqw4I9xXl3g3w14pfVNJHiG910aXDbXbSJJeGFhKZ4WhRtlzM7gKJMMZGO35WOCQcew0D4gR2WkpfjW5tUSysEhuY9YVYLSVG/0g3KeZ++J652yZGACvWgD3CqWjarZazY/bNNm86282WHftZfnjkaNxggHhkYe+OOKwPAmkalZNq13rk9/JeT6jeGBJ7xpY0tTcO0IVAxVfkK443AHbwAAPKvEHhj4gweG4rDw/p97BdI+oXEU9pqJQrLJezSRh1F1FHgoyEMyy9SCooA97tru3ujMLa4imMMhilEbhvLcAEq2OhwRwfUVNXh+oeE/FloviNdDtdWhubzWBetOupForm1YLujjT7VGUkDDk5j+VdofGBWn4a8OeMEBk1a51m4S302RrW3uL822+6E8jRpJ5VxKxAUoNxkbK43ZIwAD1DVNUs9LW2a+m8oXNxHaxfKW3SOcKvAOMnueKu14T4Z8NeOpb7/ic2l8tguo6ZeRQ3d753k+XJIZype6nbAGz+Mbuyg5r3agArm9A0F9C8Q6n/ZyRQ6FeIk4t04ENzlhIUUcBXXYSP7wJ6sa6SigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDl/F+q3un6/4OtrOby4dQ1N7e5Xap8yMWs8gGSOPmRTkYPHpmsPxL8SG0fxlb6Jb6dBexSXcFjJPHNOGgmmAKCTFuYl6qcebuwc7e1dpreh6Tr1slvrml2OpW6P5iRXlukyq2CNwDAgHBIz71nW3gjwpa3UF1beGNDhubcqYZY9PiV4ypyu1guRg8jHSgDzjSPij4gsvCvhttT0WPVNX1aKeaE2sk8gkSIruLrDasVbLgABSvGSw6VvRfEq7ltNYu20OKwttN+zJJ/aV3JDKZZ4IZUi8pIHfeGm2EYJyBgHJA6uXwX4Wmt5bebw1okkE0xuJI3sIirynq5G3Bb361Zl8P6GNNurOTSNN+wTqguIDap5Uioqqu5cYIVUUDPQKAOgoA8+8M+OLvxX4u8P7re40zyZ9Ss7q0EkuyR444WViskcbdJMgOgIyeK6e78V6i3iPWdP0vSbW4ttHjje8muL1oZCXjMgEUaxPv4A5LKM5A6GqfhvUfC1l4Jk8VWXhuPRNHtIZb6BvscEbvCY1YzRrGSQHVVGDtY7RkDit200vS9dew13VPDMNtq0YzEdQt4HurfDHHzqXC+ow3GecHIoA898UfE/UpvDOlT+H7S3t76+sdM1RmlugREtxdQxtCf3bZyHKlsDAJIGQAdm4+JM9n4v0/RLrS7WRZ7uLT57izubiZba4eLeUZmtliOD28wPghto5A6qDwb4Yt4bqGDw5osUN0pS4RLGJVmUkHDgL8wyAee4p0Pg/w1BfW97B4d0aO9t1RIbhLGISRqgAQKwXICgADHQAYoA88h+MdzFoEGqap4cWFLzTI9Ss47a9a4Zw88UIWQCEFTumQ/KH4zxnAOja/ErVroW1snhf7NqszXTCPULmaygaGBImaRHlt1c585QAY15V8kBcnu/8AhH9G+zJb/wBkad9nS3Nosf2ZNqwEgmIDGAmQPl6cDiqX/CFeFf7NXTv+Ea0T+z1lM62v2CLyhIRguE243YAGcZoA5Ow+K0F7pkl7FpbIn2nSoIkluArSC9ERDY28FBKeBnOw8jtt+FPF93rPiK+0rUdKTS5YFeSKKWWbz5EWTZv2tCsZU5BykjgbgDz02brwt4fu7+C+utC0qe9gVFiuJLONpIwhygViMgKeRjoelSaT4d0TRrq4udI0fTbC4ueZ5bW1SJ5ec/MVALcknmgDlLDx9e3HiaCwn0WGLTbjVrnR4rtb0vKZYUd9xi8sAIRGRneSD2xzXcWN5bX9pFdWFxDc2so3RzQuHRx6hhwahXSdOWSORbC0DxztdIwhXKzMCGkBxw5DMC3Ugn1qaxs7awtIrWwt4ba1iG2OGFAiIPQKOBQBPRRRQBxmp/EC1sV124XR9XudM0VZvtl/CIRErxR72RQ8qux6LkLjJ64yRneKfiLJp+rWOnaNpF5f3LXVolwgEQzHcRysojLSqN/7o9eBXQz+CtCn1C/u5La43agrrdwLeTLb3G+Py2LwBxGxK8ZK56HqM1Rh+GvheGGeNLO93TPDK051O6MwaEMIispk3rtDsBhhwcdKAM+8+K2i2PiG50W8tbqO9ggnnKrcWkpIhjMjqUjmZ0O0HG9VBx1qG6+Lui2NlNPqun6np0qi2eKC8NvG063G/wApg5l8tQRE+d7KRt5ArWX4a+FlupJ/sNyzOZ2KPqFy0YadWWZljMm1S4dskAHnPXmr174J0C9ZnnsnEpit4BLHcyxyIsBcxbHVgUZfMf5lIJ3HJNAHOW3xc0S900XmmWGqahGlvJd3a2ogc2kUcjRs7nzdrDKNjyy5IBIyK14PH+kzpG8MN66SasdHRljU7pREZNwG7OwqPrntUl/8P/DuoQQxX1vfXAjiaAvLqVyzyxM24xyuZN0qZ/gcsvbGKe/gLw42srqn2GVLtbj7Uoju5kiWbZ5fmCIOEDbeMhcnA9KADwH40svGlrc3GnWtxBFAVU+fNbsxJycFIpXaNhjlZAjDPTg4q+H/AIgWWtaxb2Mel6rbJdSXUNtdXCReVO9u5SULtkZhyCQWUA4654rY0Dwxpmg3N1cWCXTXV0qJNPd3s11Iypu2rvldmCjc2ADjk1Avg7QPs8NutiPKgN0UXzpPlNyWab+L+Iux56Z4xxQBd8Ta5beHdGl1G9SaSNHjiWKBQ0kskjqiIoJAyzMo5IHPJA5rgNT8c6jq/irQtE0mx1zTJDeTRalGEszNF5ccbhSXdk2FZkcsm4leF54rvrvw9pd34cXQbi0D6UsSQrDvYbVTGzDZ3AqVUhs5BAOc1T0fwboWkXMFzY2kguoZJZVnluZZpGeUKrs7uxLkhFGWJwFGMUAZvj74iaT4Hntk1mKUxzqG8yO4tlKjdt/1byrI+M5+RG4qK9+I1pb/AGkxaJrd1HDqB0sPCkIElz5mwRpulUnJOd3CgdSDxWj4l8CeHvEt7JdaxaTyTSwLay+VezwLNErFlR1jdQ4BYkbgcZq9/wAIxo/leX9k+T7f/amPNf8A4+d27f19ecdPagDB8OfEW01vV7aw/sbWbBria5tY5btIdhntyRLF8krHI2tzjacHBNdvWLaeF9HtLq3uLez2TW91cXsbea52zTljK2CedxduDwM8AVtUAFFFFABRRRQAUUUUAFFUrzVtOspTFeX9pbygIxSWZUIDvsQ4J6M5Cj1PA5q7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcr8R7q5h0S0tbS4e1fUr+2sHuI3KPHHJIA5RhyGK7gCOhIPagDqqK8T8UeOPEuieN/Euj2LNcWbw29hpWYg5tLx4Q4d2Iyy7fNkO8n/U4HWr/hX4pXJ8ER3mq2q3V/a2ekPLKZlj+1PebQWChMLtJY4Gc4PSgD12vJtV+G2oX/AIqvbyS30WWK5vnujqcrubwwNB5f2Mpsx5WePv42/wAGeauX/wATrvTbrVYdS0FLSS3fy7WCa5lSW5JuI4EfLQCIREyoxdJJNoYZGTgWta+IF/4fXXE1zRrKK60zRm1fbbai0kcuHdBEGaFCCdg52n7wGD3AIpfh2V+Br+CrW30uG/k0pLaR1TbA90I1BlJC5JLru3Fd3Q9azr34ZXCeLvtek2WhW9iL6zura7G6K50+GHZvtoI1Tbscq2fmUfvXyrHBpdK8ZanbeIde060tl1K+u9anFrHe3zQQwQxWNrIyh9jkcyEhQuMljxya0vDvxGvPEyTXGh6JbtZWlpBc3bXV+Y5QZIzIFiRYnEgA43FlBPToaAOd1b4R3k/hrSre1/sxtRgvJp71H2eXeIzSmMM8sEwOzzMgNEwBLYweao6n8J/ElxJoQtpdJVdLSzWG4mmR7qERS73QzfZPMdccLsaEDOCpGc6vij4n6lN4Z0qfw/aW9vfX1jpmqM0t0CIluLqGNoT+7bOQ5UtgYBJAyADs3HxJns/F+n6JdaXayLPdxafPcWdzcTLbXDxbyjM1ssRwe3mB8ENtHIABnxfCeCXT9Ei1Ky0i6mg1241G/aVDIJ7Z2u2ji+ZecfaEOw4XO8855teA/hq3hXWNDvraLTYHt7W+t797bcHuBJNG1uCdo3BEQr833eAMis6H4x3MWgQapqnhxYUvNMj1Kzjtr1rhnDzxQhZAIQVO6ZD8ofjPGcA6Nr8StWuhbWyeF/s2qzNdMI9QuZrKBoYEiZpEeW3VznzlABjXlXyQFyQD06ivM7D4rQXumSXsWlsifadKgiSW4CtIL0RENjbwUEp4Gc7DyO234U8X3es+Ir7StR0pNLlgV5IopZZvPkRZNm/a0KxlTkHKSOBuAPPQA7GiuAsPH17ceJoLCfRYYtNuNWudHiu1vS8plhR33GLywAhEZGd5IPbHNW9e1YJ4g8G6npGorc2GpXUmnyJFPvhmRoZJVkUAlSytCPmHOGYZoA7SsTxf4ig8L6Qt/c2t1dh7iG1jgtQnmPJLIEQDeyqPmYckituud8eeGE8W6JFpsl3JaIt5b3TSR7gxEUqyFQysrKTtwGByM5HSgCtp3j/w/cW5bUb6DRbpbp7JrTU7iKGUTJjKDDlWOGU/KWBDCjxZ8QfDPhe01KTUdXsWu7CEzy2EVzEbkgDosZYHJyMZx1FYOsfC2BjdL4cvotMhv7GXT74XVu188qSOXaQO8gYSks3zPvB+XI+UVBrPwtuNSl1eGLXvsOlahbS28lrbQS5kZ4vLEku6do2YYBysaM2Bk4FAHZx+MPDUj2CR+ItGd7//AI9FW9iJufmK/u/m+f5gRxnkEUN4r0Zr+0srTUbK7ubifyPLgvISyHEmSVLgn5oXXChmyp4wrEcZq/wwvNX106rqOtW001ysC30CwXcUExhclCkcd2oHGPv+Z8wyMZxWh/wrWBtB0zS31AhLXVrvVJZY4AjTeeLkFPvcFRcAbuf9WOBngA6W08W+HLyKWWz8QaRcRQypBI8V7GwSRztVCQ3DE8AHkmtSwvLXULOG7sLmG6tJl3xzQSB0dfVWHBH0rzWL4V3EyWC6trVrcixWwghWHTRCjQWs6y7JAZG3M20LnhRk4XkivUaACuP03Oi/EbUbE8WeuQDUYPQXEQWOZfxQwMB7OfWuwrkviVC8OiQa5aozXeg3C6igUZZ41BWdB67oWkAHrt9KAOtoqOCaO4gjmgdZIZFDo6nIZSMgj2xUlAHk3jv4i6poPjS/0qzn0bFtbWc1vp88Ttd6i80ro0cLCQYICg/cbrzgc1tp8UdKNrJdvpmsR2TWs15aXBhjZb2OJgHMQVyw+8CA4TIOema6s6fpmn6lqGuuqQXM1ukd1cySkL5UW9lzk7VC73OeOvPSsfT/AAL4ahaS60+C4T7RC8cckOoTgRRyMHYQYkxCGIBPl7c4FAHOWXxRe+8TadDa6PO2iT6dcXk9ylxaTGHypYlMm6K4ZTGquSwXc/K4B5o0r41eGtTjdrWG+dw9sqRxNbzu4nlESHEUrbcMRlG2uAR8tdFa/D3w3bTwTw2dyLiJ5JDM1/cNJMZChcSsXJlVvLTKyFlIUDGKls/Amg2kEUEcN+9tFNBPFBPqVzNHE8Lh49iPIVQKyjhQBgYII4oAx4/iGE1W90+TSNUn1NbtLaHTIYYFnT/RUnfdIZzEwAflty9QoDY3G/4e8fWPiHU0stK07VJm+zw3MshjjRLdJDKo37nByGiZSoBOSMAgEi5qfgnQdSuri6ubSZbue4W6e4t7uaCUSiIQ5V43Vl/dqFIUgHHINW9B8M6P4fkd9HsltWe3htW2uxBji3+WuCSOPMfnqc8k0AbNFFFAHlnxj0TXfF9/p2haLaKba3glv5bi4nktohPgx2+2RY33OjM0mzA+6pJHGYIfEfjC91zQ3FrrVnpN0tt/aqnSwWsp8NmOIlcvG7Ab32vsGCCNx2etUUAfPt1pGu3dqsk2jXaymKyUrFYmIDZrfmH5VUAERgOeOnzHrmptR8VfET+0NeOl2evrB9gv3t4rnT/MaCdGXyQhFpGpyN20CSfcOpBHPvlZ/wDa1r/b50di63n2YXagj5Xj37TtPcqdufTevrQBwfiW98V6T4k0vRLLVJbz+3E2RXTwQg2Lxy753ChQCphfaobdgouSS2T0HjNdcuNa8PWWi317p9pcyzi9urW3jlMarEWTJkR1XLADJHPSulaztWvkvWtoTeJG0KTmMeYqMQSobqASqkjpwPSp6AOR+H2uarqGjaVbeIdP1CHV206O5uriW18mIuWZSntJ8u4rgYDA98V11FFABRRRQAUUUUAFFB4HNcxrPjPTbBmiti19dDjy4T8oPu3QfhmplOMFeTKjCU3aKOmJCgliABySe1c8PEkF1fmGxcSRIcNIOhPt7e9cVrGu6prcbRTstvaN1hh/i/3m6n9Kl0SP7NtCjAFcM8am7QO2GDaV5np8Lh0BFPrM0iffGATWnXbCXMrnFOPK7BRRRVkhRRRQBVudRsrW7tLW6vLeG6uyy28Mkqq8xUZYIpOWwOTjoKLLUbK/e5WxvLa5a2lME4hlVzFIMEo2D8rDI4PPNcD8VvCWr+Jdb8M3OieVFPpn2m4iupWwkNxhGh3AHcVZk2ttB+UmuIj8BeNNC06/tdIa5eGbWjd3LW8+ya9VrSJTKClxARmYSEr5qHkHDDggHuWsapZ6Np8l9qU3k2sbIrPtLYLMFXgAnksBU9nd219B59lcQ3EO5k8yJw67lYqwyO4YEEdiCK8O1bwr40vtPhs9Tg13V3EFiLab+0I7aKFo5t032mFbgiRyACDmUHjkGmeLNE+JU2hRW+l2+pnUEN7JFdxaowdXa7laFHH2uJNvlGLBZZcD5SoxigD3qivMbbw/4oj8Rxaq1xqhc6+TJE2pFoBpxtyP9Tv2f6zH8O4duKt/ETw/r2s6pdyaXc6pDBFolwLQWeotbKb/AHAxbgrrnv8Ae+X1oA9DorI0C51WXzoNWsPs4gSFY7jzlf7STGpkO1fubXLLz1xkcVr0AFZviLR7fXtIm0+7aWNHKuksRAkikRgySISCAysqsCQeRWlRQBVg0+1heeQQRNPcKq3ExjUPPtXaC5AG7jj+VZsvhDw1NJayTeHtHkktI0ht2ayiJhRTlVQ7flUHkAcCtyigDEg8JeHIHvng8P6RG9+rLdsllGpuAxyRJhfnBPJzmq7+BfCT20Fu/hbQWt4N/lRHT4Sse7720bcDPfHWujooAyL/AMM6DqNvLBqGiaXdQSzfaJI57SORXl2hd5BGC21QMnnAApZvDWhT39pfT6Lpkl7Zqq21w9rGZIAv3QjEZUDtjGK1qKAMGDwb4Yt4bqGDw5osUN0pS4RLGJVmUkHDgL8wyAee4p0Pg/w1BfW97B4d0aO9t1RIbhLGISRqgAQKwXICgADHQAYrcooAzP8AhH9G+zJb/wBkad9nS3Nosf2ZNqwEgmIDGAmQPl6cDiqX/CFeFf7NXTv+Ea0T+z1lM62v2CLyhIRguE243YAGcZroKKAMe68LeH7u/gvrrQtKnvYFRYriSzjaSMIcoFYjICnkY6HpVDwTa+HXW+1DQNEstLunuZra78q1jhlMkcjKRIUHOSNwyTkMD3rp6462P9h/Em4t+Vs/ENv9pj9BdwBUkH1eLyyP+uLUAdIuk6cskci2FoHjna6RhCuVmYENIDjhyGYFupBPrVJfDOnR6npd3BF5EWlxyR2lpCqxwQlxhnCgD5tuVHOAGbjnNbVFAGH441i40Dwlquq2VsLm4tIGkSMgleP4mxztH3jjnANcDP8AExtLewkvfEXhfVNMuba9Y6hYoY4VuYlhaK3H7+TLkO5253MMYAwc+tVlXniPRLHVE0291nTbfUXXelrNdIkrLzyEJyRwecdjQB4zpXxG1SyGvatrOv6ZbtNYafewac9o8jKZoIstErXKARB3IYkgZ5LLg1o+F/iR4n8TJZW2ntocNzJd30D3UlsZomSCOKRGVIrlly3m4OJWHcHtXY+GPiHZaz4O1XxPI2nxaVZGVgYL9Z32Jk/vRtAjcjBCZbhhzVnwx490nU9H0q61TU9AsbvUxutraHVUn8wZxtViE3MD8pCg4IIyaAPO7P4v69e6toMKafpltHfW+nzGG4mhia5FwqmQwvLcRt8u4qAsUmSuCRmpJPixrq2F7cwJo13cR2c93NYQwS+dpRimRdlyfMOSVZj0jOVJAI5r1a58WeHLb7T9p1/SIfs2fP8AMvI18rDlDuy3y4cFee4I602bxh4ag+w+d4i0aP7coe033sQ+0KTgGP5vmBPHGaAPOPEHxWnUazPoWoeHX0yz1CG1iu5poyJI2thIxTfPEkrBzjiRflyQGIwer8QeKNRt/AmharpBtXvdTuNPt1kurWRI/wDSJI0LmLfuX7+QpY46ZNbt54t8N2Lype+INIt3hz5izXsaFMNtO7LcYbg578UuleLPDusXi2mk6/pN9dMnmiG1vI5XKf3tqknHvQBjeD/Fz3craZ4gntRrH9o3VhCbWCRI7jyQGLBSX2fKRwWPTg9q7JlDKVYAqRgg9CKWigDj/hsxsbC/8Nyk+ZoNybSLJyTakB7c++I2VM+sbVT8dWGr3PiXTpks9c1HQktpFe20fUxZSpcblIdz50RdduQBvODnjnNXNdzo3j7RtWHFrqkZ0i7PYSDdJbufx81PrKtdhQB4tq+geN9TS40Oe31NrI3Ors982pIsU8M0c32WPAk8zCl0BUqAuBjI5GVr+hePP7F0q08L6Nr2nyWtnHiSbWmlf7QH+ZW/04IEwBglZeGxtXGK9+rj5vHtmmsS2Mel6rNDHeHTvtyJEIGutm7yRmQPk/d3FQm7jdQBy114a8ZJqEuoabfalHfTarfgefqLSW0do0E32c+SXKYEvlHhd4+nAw9E8PeP4dMlF/Jr8sZmtDd2YvBHLOi7/N+zzm+lZWJKEjMIIXgAk123wu8QalqXw4TxJrzX0s1xE14I5/ssahNu4LCUIAj7AysG4O4gVBpfxd0TVIlNhZahc3D36aatvbvbTkyvC8y4kjmaMqVjYZ38H72ACQAc22m/EKy026MFrrF39r0q+s7W3/tWMy2MjTFrd5ZHkAZ1Q43qXYEYyfvVtaHpXii3+IdrdXUOr3GmGNRPLd3xWGEi3Cny0juSsmXHR4Acszb+Fq9/ws+BtRjsofDHiKaaW8m0+LYtriS4iUs6AmcdFVjuOF4POeK6/wAM61beItAsdXsVlS2u4hKiTLtdc9QwBIyDkcEigDhfGfh7xNf6/r1/plzqsYitrD+yo7fUmhiaZZZDPujDhT8mwHeMEHjJHHf6Xc3tyb37fYfYhFcvFAfOWTz4gBtl4+7nJ+U8jFXqKACiiigArj/iJ/xLBpPidOP7Guc3J9bSXEc2fZfkl/7ZV2FQ31rBfWVxaXcay21xG0UsbdGVhgg/UGgCaivP/CXim10fw4NK1q5eTV9IkbTpYwN0s3lgeXIQOm+Mxvk4HzGqGp+KNZ1XdHbY022P/PM7pSP97t+A/GsauIhT3eptTw86my0PQNV1jT9Kj36hdxQZHCscs30Ucn8K5S88fqxK6Xp0sq9pJ28sfgOT/KvKviJpq2vhO4vcMzwzxStIx3Mf3gGST1616BDpuQDjNZ16k1h4YiD+JyXpyqL/AB5jop0IKpKnPWyT++/+QsvivxBOTtktYAenlw5x/wB9E1ANc8Rnrqzfhbxf/E1opp2B92lNnt7V5zq1n9pnUoUV9lGcdd8RY41V8+9vF/8AE1NF4o8Qwg7praf/AK6Q4/8AQSKsm2HpTGth6Ue1qr7TH7Ok/soydRvtV1cbNSvXaH/njENiH6gcn8SaZb2iRgBUAA7CtX7Mc8CnC3YdRWU5Sk7yZrHlirRRVjhx2q1DGQRUyRY61MqVA3I19HkKkCumQ7lBrkbFtjiuntG3IK9bBzurHl4qOtyxRRRXacgUUUUAFFFFABXhl94k19f2iNb0jRdRctHpsEsOm3jn7LdFQGkjU8mOTbIGDjj5TuBBGPc6+efGgbTfi7e+KYsL/Zd6wlPcolpYyS++BbyXH4/qAe2eGPEdn4gt5jbrLb3ts3l3dlcLtmtnxna6/wAmGVYcgkVtVznibw0mrzw6npl02m69bptt9QiXdlCc+XKvSSInqp6dVKnmo/DfiZ7u/bRdethp3iGJN7QbsxXKDrLA5++nqPvLnDDoSAdPRRRQAUUUUAZHjG8n07wjrl7Zv5dzbWM80T4B2usbEHB4PIHWvK/CHj3WrOx1SfXbuad47Owkt7XWRFDPNNOSCYvscT7omyoQBHcsCpxXs9xDFc28sFxEksEqlJI5FDK6kYIIPBBHas7UPDeh6lFFFqOjaZdxxReRGk9rHIEjyDsAI4X5V46fKPSgDzQ/FO/1vR7m10vRY7fVRBqDT/ar2S2S3W2KqzozQiQtmRSFMaEc520aJ8Qruw0SGJwdQ1ARafFFDdTys07SWayuYxBbyys3UnIbudygYr0F/BfhZ7GCyfw1ojWcDmWKA2ERjjcgAsq7cAnA5HoKozab4W1HWbrw7feHtNkaK3guxHcWUTRSoN0alQQc7Am3kDaCoHBFAGB8O/Fk3i3xe2oKLi2srrw9Z3K2TylkikNzdK5A4GTsAzgEhRnpirlj4/vJ/EsNlc6LDDpk+q3OkRXYvi0hlhjkfc0XlgBCI253kg9sc12WnaPpmmMp03TrO0KxCAGCBY8RhmYJwB8oLscdMsT3NA0jTQ6MNPs9yTtcqfJXKysCGkHHDEMwLdSCfWgCexu7a/tIbuxuIbm1mUPFNC4dHU9CrDgj3FT1BY2ltYWkNpY28NtawqEihhQIiKOgVRwB7Cp6ACiiigArl/iNZzzeHv7R0+Myalo8y6laoOrtHnfGPd4zJH/wOuoooAr6deQajp9te2cgltrmJZonHRkYAg/iCKsVx3w9/wCJXNrPhh8AaVc+ZaL/ANOcxLxY9lPmRD/rlXY0AFcDq3gCa+8R3d5Hq0UWm3uoWmp3Ns1nvmMtuECBJt42IfKTI2k/ewQGIrvqKAOW03wl9i+HT+Fftu/dZS2f2rysffDDds3dt3TPbrWFrXw2mvzPHb6zFBa32n2unX6yWXmyOkBYqYX3jyidzZyHHQjBGa9GooA841T4YreaG1nBqr292uu3GuxXEaSRjzJXkOxvKlRzhZdu5XU/KOgyKxdX+D9/qOhQ6Tb+KTaacsLxyW0Ud00RlaZ5WlAN3lmJYAiUyjK5G3OK9hrkPA7f2dq/iPw63C2d19uthnrb3JaQY9hKJ1A7BR9KAK//AAgMX2eSL7YmZNfGuu32cfMRJvEZ+bnoBu/SjR/ASabqmn3qXysbTU9Q1HaLfbv+1Fzszu427wM99vQdu3ooAKKKKAMXxnoza/4Yv9OikEVzIge2l/55ToQ8T/8AAXVT+FSeEtZXxB4a07VVjMTXMIaSI9YpBw8Z91YMp9xWtXHeGf8AiTeM9e0NuLe8P9s2f0kO24UfSUBz/wBdxQB2Nc8fBmhHxB/bP2N/t3n/AGrH2mXyfO2bPN8nd5fmbeN+3d710NFAGKvhfRl8Jjwz9hU6GLb7ILVnZh5WMbdxO7p3zn3qlp3gPw/YXSXUNrcyXSXKXgnub64uJDKkbxKxaR2Jwkjrg8YPTgY6eigDkn0/w/YeLdKsjYSR30kt3q1rOZG2faCuyb+LlikzHaRjGSOnHQaNpdnoumW+nabD5NnAu2OPcW2jOepJJ69zWB8SoJY9Bi1qzRnvdDnXUo1X7zogImQe7QtIo9yPSuotZ4rq2iuLeRZIJUEkbr0ZSMgj8KAJKKKCQBknAFABRWPf+JtGsSRcajBvH8Ebb2/JcmuX1Xx3NOGi0WzZQePtFwMY9wg/r+VZTrQhuzWFGc9kdhrOr2Wj23n6hOsanhV6s59FHU1wuq+MNQ1IGPTUawgP8ZwZWH8l/U+9Yq2k13dG5vpZLi4brJIcn6D0HsK17WyXjivOq4yU9IaI9ClhYU9Z6s4pLJtN8b20z7jDrMZgd3JP+kxgupJPdk8z/v2K72208LjNR6tokGq2kMMrvE0M8VzHLHjcjxuGBGQRzjB9QSK3I0FYqPNqzRztojlfiFpYuvAmtxKMsLV5APdPm/8AZa2fCc41DwzpV4D/AK+1ikP1KjP61pzQxz28kMq5jkUow9QRg1x/wdmceEW02c5uNKuprGTPXKsSP0YD8K9inFVMulH+SafykrP8Yr7zhlJxxCfdfk/+CztREKjljAqznioHOTXnOxutSq6VAU5q4w4qFxzWTRaZEEGeaUoKU0CsmaIbtpjZFTCldMjNFrhexHC+HFdVpb7ohXJfdauj0V8oBXVg5WlY58SrxubFFFFeqecFFFFABRRRQAV5HqNtFceIdQuriMPbN4uS3lQ9Gjl0uK1Kn2LOD+X0r1yvKNZyPCHjnUBhfseurqIP90WrW7k/+QSfoaAOu+GlzNL4RtbO9cvfaW76ZcM3VmhYxhz/AL6qr/RxWn4k0Cw8RWAtdRR8xuJYJ4mKTW8g6SRuOVYeo9wcgkVjaZ/xKviVq9lgrb6zapqUXoZotsM3/jn2Y/nXX0AcTZ+I73w3dx6Z42lTypG2WetKoSG5PaOUDiKb2+6/8OD8o0YfFKTxLLFboI26eZNtb8QAcVsa1p0Gr6ReafeRRzW91E0TpKoZSCMcg9a8T8L2+o6DfyaXfslxp0SlU+0MWntnBH7skj50xyGPIHXPBrlxNWVKzR04alGpdM9Pk8SXsrFLSyt+OsjTkj8toqhfeJtatoZmS2sZGjQttAYZ9s5qvb3cJUKuFHoKn8yMtnIyeMetcSxdS97nX9XgtLEXhD4gtrOhWeoXmlyRrOm4tbuJADkg8HB7e9dTY+ItJvW2Q3sQkzjZLmNj+DYJryj4U/6JpuraOw50zUJYEB7xk7lP45Ndjcafa3a7ZolIPqK9LMKrw+LqU4L3bu3+F6r8GjkoUY1KUZPR219ev4neA5GR0rjviCDpcmleKYuDpExW7IHWylws2fZSI5f+2VZsGjS2XOl39zajqESQ7P8Avk8fpTrzVdZgs57bUrS21eylRo5YyPLZ0YYIJGQeD6VlHFxfxKwPDS+y7noIORkdKK86+E/iu1uNFTQtRuXi1bS3NkUufleWNf8AUvnozNGUJwfvbq9FrpUlLVHO4uOjCiiimIKKKKACiiigDj/F3/Em8UaD4iXiBn/sm+PbypmHlOf92YIvsJWrsKzfEukQa/4f1DSbolYryBoS6/eQkcMPcHBB9QKpeBdWn1nwxaXF8oTUot1reoOi3ETFJAPbcpI9iDQBv0UUUAFFI7KilnYKo7k4rLu/EWj2hxcanaK390Sgn8hzSbS3Gk3satch4mxpXjPw7rQwsVyz6PdHOBiT54WP0kTYP+uxqefx1oUefLuJZz6Rwt/MgCuV8c+K7fxB4X1LTbGwvluZY91tM+xRHMhDxP1P3XVT+FZuvTW8jRUKj2iepUV5lonxPn1XSbS9i0NQJ4lcg3eCpxyp+TqDkfhWivju8YH/AIkyA9v9Lz/7JUPFUlpctYWq9bHeUV58/jjUv4dMtx7mYn+lPTx3er/rdJib/duCP/ZaPrdLuH1Wr2O+rj/iL/xLE0rxOnH9jXO65I72kuEmz7KCsv8A2yFYV58XNOsLyG0vLGT7VK4RYYJRK/PcjAxWhf8AjjTr2yntLzSL6W3uI2iljIQhkYYIPzdwa3m/ZxjOeiltdWv6GapSk3Fatbne0V5P4A+IkMPhyHTdQtNSnvtLJsZpAqEybMbHPzDlkKMfdq2bn4gysCLHSXyejXEoUD8BnP5isniKcd2VHD1JbI7+oLy8trKLzLy4ht4/70rhR+Zry2517xBqDEy332dP+edquwD8Tk/rVFdMEshln3Synq8pLsfxNc88dFfCrnRDAyfxOx391440JFdYp5Ls9CsMTEH8ThT+defeC/G17p2m3Ph6zsF/4lMzQwPcvz9mY7oBtH91CE69UNXorADtWHq9oNK8WaTqWMQXw/sy4PYMcvCx/wCBb0+sorD65UnotDb6pThq9TfufEGv3ZO++MKn+GBAv68n9ayprR7p991JNcN6yuW/nXRJZD0qVbIelc0pznuzpiqcNkeceBbULfeI7fbjy9Sd8Y6BgDXcW9qq/wANc/4dhFr8RfFNoQAJo7e5jHtt2sfzrtVjA7V6OcK+J5/5owf3wi/zObBytS5eza/FkEEPIJFaES4FRpiplIrzUbSdyRetTpVdTUwbitYmbJCa4fRf+JH8VtVsG+W21u3W9g9PNT5ZAPcjLGu1DVxfxTtpodLsfENipa90ScXQA6vEeJF+hHJ9ga9bKZKdWWGltUXL894/+TJfK5x4qLUVUX2Xf5dfwO9amECq1jfQ39jb3ds++CeNZY29VYZH86kZ686acW090dEddUJIarvkmpGaoyaxk7miGkUhpSaQ9KzZSBetWI+RVYdaniNOO4SRFPHhq1tFbBxVGUBlzVrSeJa6KOkzGprA6MdKKRfuilr1jzQooooAKKKKACuB0XT/AO2fCXjWyKgjUL7UrfaeepaL9cZ/Guj1TxAtpIY7a0nunBKll+VFI6gnqfwBrh/Amu6kdI1CS1trRRLq2oNiR2YqRdSqR0HpWMq8Ibs1jRnLZFvUNR+0eD/A/jIMx+zfZLidh/FBcxrFJn2XzFkP/XOvSK8X8Ltqmp/Dy58P3EtklmpvNLkAhZmCLLJF1Lf3QCOOmKtTeJfEGh+BTqGt6m4vrS1XzVjjiIabAXGSDkFiOfeinWjVqKlDWTaSXmxuhKMXKWiWp69WNrvhvT9ZbzLiNo7kLtE8TbXA9+x/EGuL8N6h4nn0Oyn1PVyL2SMNKgtowFJ7fd6joffNapvdYYAHU5PciKMZ/wDHaiviKUJSpy1s7eWnYunQqWUo6FebwLexufsupROnbzUKn9M/yrM1fw3rel266jJPBNFbEs8cW4sFxgtyB0/lWu0V1N801/fPnridlH5KQKhGnWu/e0as/UswyT+JrhnKj9mJ1x9r1keeeENahg8ceJy7L5dyLaQYPGQhB/OvRbfUYJgPLYnPtViO3gXJEa5PU4FSgRjooFXjMR9ZqKpa1oxX/gMVG/ztcdKCpxcfNv723+oqSMKmJDj5hUQcUpcHpWCdgaucT4n0u2svF+m6i8a/Y9TH9m3XGMSjLQP+e9Pq6elbseqazoDL5Mn22yXgwTH5gP8AZfr+eRU/iXS11zQL3TmkMTzJ+7lHWKQEMjj3VgrD6VNo7XF7otlLqtr9mvnhU3EGQwSTHzAEcEZzj2q1Jr3ouzFZP3ZK6Ok0DxHp2uJi1lKXCjL28o2yL+Hce4yK2K811DRIZmDINrg5BHUH60QX3iDTRthuzPGOizjzP16/rXTDGraaMJ4S+sGelUV5zd+NdXsbOa4vILFIoULu5VuABkn71YWgeMfFWv6St9M0NhHOxaFYYRuMX8JO7PJ9u2K7FUToyrr4U0vm76Lvt8jD2E+dU+r1PY6ZNNFBGXnkSNB1Z2AH615JLHq13/x9anfSA/wiYqPyGKhTQIy254gzd2bkn8a45Y9fZidCwL+1I9GuvF+g2zFW1OCRh/DDmU/+O5rz6DxvbaL461OPT7K4ms9ajW8jV8RgXMYCS46/eQQnp1Vz3qxFoyL91Av0FOuPDttdTWks8ZMlrL50LBiCrbWXt2wxGOnNZPG1HsrGqwlNbu5auPGmt3GRb29paqfUGRvz4H6VQl1XxBdDE2qThfSJVj/VQD+tXLmTT7EH7Zd2tvjr5sqpj8zWRdeNPCllnzdas2x/zxYy/wDoANVToY7E/wAKMpeib/Ipyw1L4rL1Gvpkt2267kmnb1mkZ/5mp4dEjQDEaj6CqK/EDSZh/wASyw1nU/T7JYs2fzxUo8SeI7njTfBV4Qf4ry5SDH4HJrf+xMb/AMvI8v8Aiko/+lNE/wBoUV8Dv6Jv8jUj0pR/DVhdMT+7WKqfEC9PEegabGf7xkmkH5fLSr4Q8R3g/wCJr4yvNpHKWNukGPow5p/2VTh/FrwXpeT/APJU1+JLxs38MG/uX5sqeGbSPTda1/R7grHFDML+3LEAeTPkn8pVl/Aireo+JfDGmBvtWsWe5eqxv5jD8FyawvEXw90XTdY0LUdSa+1OCW6Fjcve3TOR5oxG2Rj/AJaBF/4Ga9B03wzo2lkHT9Ksrdx/GkKhv++sZq/Y5fDWUpz9Eor725P/AMlIVbEPRJL73/l+ZwzeKpNQ+Xw34d1TUc/dmlT7PCf+Bt/gKQeGfFGtc6zqcOlWrdbbThmQj0Mh6H6ZFemtHTClH1+nQ/3WjGL7v3pfj7q9VFMPZSn/ABZt+S0X4a/ieZy6RYeE9W0Sx0mxhM2pTtHLPKS0hVV3MdxPX26e1da+nr6U3VZ9LHifR7S8tzJqTLNJaSbciPCjfznjI9q2CK5swqyrRpzqp87Tbb15velr6JafJm2HtByjG1r6JdNF/wAOcUNGmtPGDXUEJexvrXbcEEDy5oz8jYzk7ldgcf3FrcFog/hrVZKZ5dea9TqTsVIrdR0FWY4B6VPGgFMuby1tJbeO5niikuH8uJXYAu2M4HqauFNydkrsic7EiQKK4n4g69ocmn3mgNeSPqsoAijtYjK8MykNG5A4yrBWx7VftNJ1278Qf2hrGrGG0t5WNtY2Xyoy8gGUnlsjt+VdMkNvFNLNHDEk0uDJIqAM+BgZPfgAV6ShhcNNe1ftNL+67WfZtp3t1st9L9Tlbq1Y+77vrrp95yUOv+ItU0fTLrw/pFk7XEO64e6n2rBMCVeMqOTtYEZz2ravrPXb3QbaKPVLfTNVyGnnt4POj6HKqr9unJ54rM0J/wCyfF2saUeIL3/iaWvpliFnUfR9r/8AbWuoMhqPrigoqEIpx1va7frzXT9LWGqLldyk9fO33Wszzm20+98O/EnSJdS1WbUm1S1mtTNJGqYKYcDA/wA9a9ENcb8U1kj0S01aBS0+k3cV2AOpUHDD6YOfwrrYLiOeCOaJg0cih1YdwRkGurM6ssXQo4qW9nF2SWsXdaKyXuyX3EYaCpTnSXk18/8AgpkmcU9W96gZ6VWrxTssWlapVeqatUivVJktFsMKZOkc0MkUqh43UqynoQeCKh30b6tTa2J5bnG/DuZ9GvNT8JXTszWDmezZjzJbOcj/AL5JwfrjtXblya4T4i2s9obHxRpqF73SWLSoP+WtufvqfoMn25rrtNvrfUbC3vLOQSW86CRGHcEV6uZf7RGOOj9vSXlNb/8AgXxfNrocuH/dt0H029On3bFzOaKbmjdXj3OuwuKQ0uaaaVxgOtSoahHWpVpLcZOOlWNPOJhVXtUtm2J1rppv3kYTWjOnj+4KdTYv9WKdXrLY81hRRRTEFFFUtU1K20yAS3TEbjhVVdzMfYf16Ck2lqxpN6I43VNRGl3n2S6JjkGdu4cSDJ+YHvnP4GuP8AaikehXEjkfv9RvpwPTfdStj9a72+8U/ad0UOmwyp2898/moBH61wngaR38LWzx6Xo372WeUtJYh2+aZ2xncOBnH0FeXWVN3tL8D06TmrJx/Eb4W1NLfUvE1rxhdR85P92SGNyf++y/5VmfFC7WXwdcg/dE0Rb0A8xetXra3MPj3VIzYaZi60+3mUCzTAKPKrEDkDho/wAqpeO45I7fTbO3js/tGpXccCo1pFsCg7mYjbyBgfnXXlKSzCjKLvZp/Jav8E2RiX/s801a6a+/Y7GDVFjTBXjJq1HqEUi8HH1rMi0BlABkjA/69of/AIirEehIHUmU5Bz8saLn/vkCvJsujOu/kakGolE2bVI7GpFPmHfnr2qsLAoMjOKeEcdGIou7WYrLdE9FRDf/AHqMyeopCJaUGowX9qeM96AHBjT1lIqKindoVkTCUE8inFoyORVeuf8AGviFdA0sGBPP1O6bybO2HJkkPA49BnJ/LvXRhqVTE1Y0aSvJ/wBfd3fQzqONOLnJ6I5H4l6/pd74gtPDd3ex2umxsLjUpSTlgOVhGOcngn8PQitVfiDoDKsekW2paiq4VVsrJz9AM4q94S8J22k6aj6jDBd6vMxnurqRAzNI3JwSOg/+v3rphwABwBXtYvG5fGMMNCEpqnfXmSTb3lblb16arRI5KNHENuo5JOXldpdFvbT03OOXxRr11/yDPBl8wPRrydLfH1BzT9/j68B2QaBpyH/no0krj8vlrsAafmuNZjSh/Cw8F680n+MmvwNnh5v4qjf3L8lf8TjP+Eb8U3ePt/jB41PWOzskjx9GzmnD4e2U/Op6zr2oHus96dv5ADFdhupA3vT/ALZxcf4bUf8ADGMf/SUhfU6T+JX9W3+bOatPh74UtCDHo1u59ZmaXP8A30TW7ZaRpljj7Fp1nb4/55QKn8hVgt70bq5a2YYqv/FqSl6tv8zSGHpw+GKXyLCtUm8YqkXpPN965lOxpyF0yClElURLThJT5w5CDxPpqa7oF9prSGE3EZVJQMmJxyjgeqsAR9K0YpHESCVg0mBuKjAJ74FVfMo3H1o9oL2ZaaQYqPzKgyT3qtLeW0QJkuYUA4JZwMUk5SfuorlS3KGsafZy+JNF1W5vVt57UyxRRswAnMi4289x1GK2mIriPHklpqdjYfY9U05L20vYruLzblVHynnnPoTWzJ4s8PR5367pnHpdIf5GvRrYWvWoUpRTk1dWtsk7r5Pmf49jnhUhCck7LZ3vvpb9DdxmlC1zT+OfDEbYbW7InGflfd/Kq0nxJ8JxrltYjI/2YpG/ktYxynHz+GhN/wDbsv8AIt4qgt5r70da5WNGd2CooyzE4AHrXMx6AL3xadfvLuO8gjhVNPiUfLDkfM3oSex/wFcp438d6RrPh+fT9F1F91yyxSzfZpcLET8+Pl5OO3oTWtY+OdFs7G3tLDTdYaKFFjjjjsmJCgYFenSyjMcNQdSFOSnO8WuWzUdLu72vtp0vfR680sXh6k+WUk0rPfr/AMA7fpSE1xzePY2BMPhvxPKv95bDjP8A31TD4x1BziHwlrZbvvRUH55rg/sbGdYW9ZRX5s6PrlHo/wAH/kdZLbwSXUNy8MbXEIZY5CuWQNjcAe2cDP0qQk+tcafFHiB+YfB14R28y6jQ/iO1NOueL5D8vhGOL3fUo2z+Qo/sjEdZQXrUp/8AyQ/rVPon/wCAy/yOsvraK9sri1uRuhnjaNx6qRg1yvw3vJY9LuNDvW/07R5TbN/tR9Y2+hHA+lRnUPGrj5dF0yLPTzLott+uOtc9qX/CSaLrqeKNRtLFbdEWC9SydmZ4ifvkHqV45+navRweXynRqYSdSF5WcbTi3zrZaP7SbXrbsc9WulONVRemj0ez/wAt/vPUtwoD471Tt7iO6t4ri2kWSGVQ6OvIYHoal5r5ppxdnuemrNXRaD4pweqoJpwelcOUtCSnBqrq2akBFVclokIDoVYBlIwQRkEVwvhmVvCfiabw1cMRpl2WuNLdjwuTl4c+x5H/ANeu3LgAknAHUmvN/GepR+L2XRvDNu17e28yyf2gjbIrRgeu/uevA/UivbyaEq7nh5r91Je8+kbbSu9NH96bS1Zw4xqHLUXxLZd+6+f4bnpm404GqmnJcJZQLeyJLdKgErou1WbHJA7c1brxZaNq9zsW1xwNOBplKKkY4DmplqJetSdqaEx5NT2A3XCiqucCr+jpunzXTQV5GNV2idGnCD6UtA6UV66PLCiiigArmvFTNDdRStgRtCyKx6BsgkfiB/47XS1FdW0N3A0N1EksTdUcZBqKkeeLRdOXJJSPPLrUoZY0jV1aQsuAvbnrWF8PLyEeCdJ3P80kPmHjoWJbH611mtWWj2M5gtNKuLucfeC3UiInsTk845wB/SuL8B2ar4M0KKbR0S5FjC0yzTzKysUBOVyMckjFeXUp8t1KS/E9ONRTs4xdvkbk0Vk+pw6j5j/aYbeS2AB+Uq7IxyPUGMY+prkfGd1GniDwlcM2I47p4WJ4wXTaP5V2P2AZISwtEPbdNO3/ALPXJeJoV/4Sfw/pc9pYtHeyTSMSJCEMSBgQC555rrypWxN07rlnf05JX+5XZnibOltbVffdWO1/tW2H8R/KkXVIWYeU/PoRWaLa2SINJe6coH8T28J/Vgarzy6QjJ9p1jS4xH8wC+RCe/dQDjr7VwLD1JfCm/kb+0gt7fedKuoPIu3aPrT1YYGW5rlm8T+GrcHfr+nHH9ydX/lmqM3xD8KRNtXVvNfssUMjZ/JcV1wyrH1dY0Jv/t1/5GMsTh4fbS+aO52j1FNO0elcN/wnthJ/x5aXr176eRYsc/mRSjxZq02Psfg/WHz/AM9ysP8APNX/AGLjV8UOX/E4x/Non63R6Sv6Jv8AI7cuBSCQHpXE/wBqeNJx+58L2lr/ANfGoK//AKCKesPj6f70vh2zU/3FlkYfnxR/ZUo/xKtNf9vp/wDpPMH1qL+GMn8mvzsdpvpwri/7A8Xz83Pi9IB3S309P/Qic0yXwHNeRNHqXirX50YYKxzrGp+owaawOFi/3mJj8ozf5xivxB16r+Gm/m1/mzQ8S+M9P0iT7HahtR1d/lisbb5nLf7WPuj6/lVbwr4buv7RfxB4ndJ9blGI415js0/uJ7+p+vuTm2Hwt0/THeTStb12zlYYLRXCLn64QZqxJpXjHRwX0zXIdXjXn7NqEIRj9JF5z9cCvUawUKToZfXSctJSmmnLyTs1GPe716u2hyr2znz14XS2Ss0vPu3/AFY7kkVGzD1rzPRfEPi/xJcXlvA+j6VPaPsmt5Y5GnT0OD8pHv8A/WrTbw34kuc/bvF9xtP8NraJFj8RzXn1snWGnyYmvCD7e83/AOSxa/E6YYv2i5qcG18l+bO3LgVXuL63thm4niiHrI4X+dccfAVrN/x/6xrl7nqJrw7fyAHHX86fB8P/AAzAc/2WkjdS0srvn8zWSo5fD4q0n6QX5uS/IvmxEtoJer/yTNi68YaBbf63WbDI7LOrH8gaypviR4ZR9iaiZX/uxQSN/JcVfg0DRLXHkaTp8ZHcW6Z/PFXoxFCu2JEjX0VQBR7TLY/YnL/t6Mf/AG2QcmJfWK+Tf6o57/hYNrJ/x6aPr11/1xsif5kUf8Jhq8ufsvhLU2/67OkX866LzRS+ZR9dwcfhw9/WUn+XKP6vWe9T7kv1uc5/bfjGb/V+GbW3/wCu1+r/APoIpPM8eT9F8O2y/wC0ZXYf0rpPM96PNNL+1IL4MPTXyk//AEqTH9UfWpJ/cvySOc/s7xpN/rPEGn2//XGy34/769KP+Ec8Ryf8fPjK6bPXybOOL+VdH51KJ6P7Yrr4IwXpTh+bi2L6lDq2/wDt6X+Zzf8AwhtzJ/x8eK/ETHr+6uhHz+A6e1A8A6c3E+pa3PgceZescflXTCcetOE4o/tvHfZqW9El+SQfUaPWN/W7/M5ofDfwu3+usZpsdPMupTj8mqzF8PvCkZXbo8J2/wB53b+bc1vfaAKPtFS86zGWjxE//Apf5gsDh1/y7X3Iy4/BPhmMHbotic/3ow386bqPgnw3e2jW8mj2USkcPBEInHvuXBrX+1Ad6a12KzWaYxSUvbSuv7z/AMyvqtK1uRfcjz9dPu/AwPm2EOteHgcmQW6fabYercfOPf8AlXeaJe6dqVnHe6S1vLAw+V41Ax7HuD7GlN6BXFapos+nahJq3hCVLW7fmeybiC5/D+Fvcfpya9B4unmnu4mXJV/m+zL/ABLo/wC8tO66mCoTw2tNXj26r07+n3dj0RpD2qMy+prk/D3i+31hntZY3s9Ti/1tpNwwPqP7w961pbggV5GJw1XC1HTrRs/61XddmtGdlKcaseaDujRaYetCzCsQ3JzT1uveuc15Ta8xT3pGdR3rJFx70jTE96A5TSaYetRStHLG0ciq6OCrKwyCD1BrPMp9aPONCdndD5TlbC5bwTqw067cnw9duTaTsci2c8mNj/d9D/8AXx3AlzWPqdtb6nYzWd7GJIJV2sp/mPQ+9cvpWq3Xhm9i0jW5TLYOdtlfN+kbnsff/I9upFZtB1Yfx0veX86X2l/e/mXX4l1OKP8Asj5ZfA9n28n5dn027HoPm0ecKzjP71Bd38NrA01zMkMK9XdgoH514sYuTUYq7Z2uyV2bCzgGqGv+JtP0K2WS+l/ePxFBGN0kp9FX/IrjZPEeo607Q+FrfEOdrahcLiNf9xT94/5xWt4d8OWmm3BvbiR7/VH+/dz8t9FH8I/zmvXWApYP3se7P+RfF/289oL1vL+71ON1pVtMOtP5nt8u/wCXmRpp2teMCJNeaTStGPK6fC2JZh/01bsPb+R5rttMsrXTbSO1sII4LeMYVEGAP/r+9RQtkVajNc2KzCpiYqmko01tFbLz7t+buy6eHjSfNvJ7t7/8D0RZB44pQ2RTFNOrhNB2aeKYKetMRItOzTe1MdsD3poQ8nJwK3tEiwucVh2ybmFdTp8flxCvQw0NTjxEtC3RRRXoHCFFFFABRRRQB5F4/wBA3668s2sa7YrKSUjsrvyo5QTknGPvDJU+wWuXHhbTpJmNxqeuvHjAWS/Jyfwr6EdVdSrqGU9QRkVW/s6y3Fvsdtk9/KX/AAq/rWMguWlVcUvI1i6NvfhdngEnhbw5uPnfbpj2Ml6/H61GvhDwizEvpu9jzua6lJP1+avdNTvNH0xhHcRwmZhlYY4d7n8AOB7nArnrnULS53G38L25bON12kS/jhd2fzFYzzLHw3xcl6Nr8mbQp0J7UE/u/wAjzNfDnhWOQlNGtTgnG52P6E1PFpfhaA86NpnXPzKrfzrtP9IcuRa6PbBOSILFc9M9WzVuN9R2rjU2RMcCKCJB+i5rjlmeLl8WIm/m/wDM6VQpLalFf16HN6fZaI+HsdK06LHeO2jHP4Cty3EaY2qiD0VQB+lP+zpHK8s8zySPjc7nJNWHFosed4zXFOtUq/HJv1Zsowj8Mbegv2iId6UTI33c1XVo9ueKUSxjuKyHYn30oJNQGdB3qnYazZ6hZRXdlKJbeUZRwCNwzjPNAWNQUFgOprPe+GDg1nz3+SctSuUoNm1LcIg5NZ1zqapnBrFub7dna1Q2VrearKyafby3JXglB8o+rHgfiaSvJ2ii+WMVeTMHxndGxv7XxNp6kXdn8lyq8efATyD7jqP/AKwrsoNdtpoEljcMjqGU+oPIqY/DzU9QsZYbuS1t0mQoVLF2AIwc4GP1pmnfDLU9O063tI7+zuBCgQO4ZCQOnY17FVTr4OEZr34Oy84vX/yV3t/i7I4o1KUK0mn7r1+f/BX5EbaujfcwaZ/aAY9KsS+BtdiPyR2Ug/2ZyP5qKrnwp4hXj+zN3+7cR/1IrzHh6q+ydSrUf5kRveUz7RuqU+GdeXltKmH0kjP8mqN9G1eL7+l3n/AY938s1Psai3TLVWn0aBZ/enrce9VZLS8j/wBZY3qf70Dj+lQOxj/1iun+8pH86nka3HzRexpef71HbX8N1F5tvKsse5k3KcjKsVI/Agj8KxtR1OGw066u5JFKW8TysM9lBJ/lVTwnC1j4b0y2kYGZLdPN95CMsf8Avomjl0uF9bHUebR5lZvmH1pfNalYZoGXHemmf3qgZDSb/cUWAv8A2g+tKLj3rP3+4pplUdXUfjRYDRM/vTGn96qRBpuIleT/AHFLfyq7DpOpTHEenXre5hZR+ZFUoSeyJc4rdldpWY0ICTya1U8K644yNPKj/alQf1qK68Oa1axF5dPlKjvEyyH8lJP6Vp7GoteVke2pt25kYet6BY61EjT74ruLmG5iO2SM+x/pWR/aeu+Hx5esWx1axXgXlqv71R/tp/UfrWy88kUmx1dX6bWUg/lWtpeg6xqm0wWrpEf+Ws3yKPz5P4Cu/DY2ooLD1oe0guj3X+FrWP5d0zCrSgn7SMuWXddfVbP8/MxNN1/SdWA+w3sTuf8AlmTtcf8AATzVxzjpXSXHwg0jUxv1lxLMerwRiNv++uprR0P4XaLo5lEN5q00bgARz3O5Uxn7owMZz+gretgMNKDnQlKMv5ZJP/yZNf8ApKMIY6UZcs0mu60/B/5nEhyKzvE2py6b4e1G7g/18UDmIYzmTGEH/fWK9TuPAVi/+pvLyM+5Vh/KuP8AG/gb99oGmxam7HUdTiQgwjhIladj16Yhx+OO9eesHUT1R0PGU2tGZkDukEazP5koUBnxjcccnFOMvpXbr8PU436pKf8AdhA/rUsfw8st2Zb+8Yei7V/pSWCqvoP65SXU4TzDVDVYbTUbSSzvVWWKQYKdTn1HvXrlp4K0O3ILWrTsO80jN+mcfpW7aWdrZpstLeGBfSNAo/St6ODqU5KalZrVNboxqY2Ek48t0+5866Pofji3xpunaU19bkf6Ne3ZMSxp6PnrjjGP16DqdI+Dd1fTpd+M9Y+2Sg5FvCv7pPoDx+le0UV7zxsleVOKhN/FKKs38+l+qjZPqeY03pJtpbJ6pf5/O5xdx8P7EWwSwurmCRRhdxVk/FcD9MVw3723uZ7W5AS5t3KSKD39R7HrXtteefE3TfIu7XWIVARsW9yR/wCOMf1H4ivDxWHjy88Vqd+FxEublk9GYdtPxzWjFICKwoztbNX4JeBXlnptGurZqQGqUb5xVqM5pohomFSrUaU4tgUyBzNgVCDvkxTXftVizhLMOOTVwjdkyfKjV0qDey+gro0UKuBVTTbfyYRkc1cr2KMOWJ5dWfMwooorYyCiiigAooooAKjuWdLaVoV3SKhKr6nHAqSigDza+n09VlZZMzSDeH3kuxI6+uaY+pRJFHvb5wASB64rsL/wro19dPcXFniZ+XaKV49x9SFIBPuagXwToCnP2ORj/tXMp/8AZq82eDnKV00ejDF01FJpnGDVIjIxyRnFRnWkRVRR0GOTXer4R0JeRp0R/wB5mP8AM1ah8P6PD/q9LsgfXyFJ/PFSsBPrIp42HSJ5fNq+88lQPdqgOppnh48/71ewJp1khylnbKfaJR/SiXT7KZSstpbuvo0Sn+lV/Z/94X19fynkP9qOR0BHsaZ/aT+n616rJ4b0WQ5bSbHPqIFB/QVVn8G6DMfnsAP9yV0/kwqHl8+ki1j4dYnkXiXXpNO8P6leID5kNu7pjuwU7R+JwKZo4/srRbCwVgEtbeOEEn+6oH9K7Tx54S0JYdC0yCxAk1PVbeE7pXYmOMmeQck8FIWB+tdta+G9FtSDBpVkrDoTCpP5mmsBK1mxPHwvdRPHormW7fZarLcv/dgQyH/x0Gtqz8J69eFSbRbaM/xXMgX/AMdGT+YFeuIiooVFCqOwGBS1rDAQXxO5lLMJv4VY4nTPh9ZxMH1W4kvSP+WSjy4/xAOT+Jx7V2VvBFbQpDbxJFEgwqIoUAfSpKK7IU401aKscc6k6jvJ3CiiirICiiigAooooAKCMjB6UUUAcZ8UbW3uPDKacbeNn1W9trDGwfcklUSH8IxIfwroJPD+jyZ36XZc+kKj+lYviL/TfH/hOwxuW1W61V/QFEECZ/8AAliP93PautpOKe6GpNbMw38J6G5ydNhH+7kfyNRt4N0EnJsB+Er/AONdBRU+zh2RXtZ92YI8I6EBj+z0/F2P9akXwtoa9NNg/EE1tUUezh2Qe0n3ZlR+HdHT7umWn4xA/wA6uRWFnCAIbS3QDptjA/pVmimopbITk3uwAwMDgUUUVRIUUUUAGKKKKACiiigArkbz/Tvinp0WQU0vS5rl1/255FSM/wDfMM4/GuurkfB3+meKPGGqZypvI9PiP+xBEuf/ACLJMPwoA66iiigAooooAKKKKACqOt6emq6Rd2MuNs8ZQH+6ex/A4P4VeopNXVmNOzujwuzaQw7J12zxMY5F9GU4I/MVoQnir/jmxGneKS8a7YL+PzR6eYvDfptP4msrzlhid3+6ozxXgVYezm4nvUp+0gpGpC2RitCGsCyupfNkWeEJsjEh2vuPOeOg54NaemXv2jYHheFmjEihiD8p9cdDUIcjVHSo5GwKoW2qxXDIgjlSVg5Ksv3drYOT07irC7pXA7VS1M9ia3QySV1Gk2WAHYVS0iwLEMRxXSxoEQKOlenhqNtWcGIrdEOAwMCiiiu44gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOS1E/bvifo1sOY9N064vXGOkkrJFGfb5Vnrra5bwzBNN4w8WanPG6KZbfT4C6kb4oot5Iz28yeUfVTXU0AFFFFABRRRQAUUVk+LdetvC/hvUNav4p5bWyiMsiW6hpGHooJAJ59RQBrUVxtl8RtBvfEGl6TbyTNLqGmHVUmwoijhGD87FvlbBzjBx3xxWqnjHwy+lSaoniLRm0yOQRPdi+iMKueil920H2zQBu0Vxnhv4haVquiR6pfTWmm2hha4aea9h8pYxO8KncWDYYqCGKhfmADE1di8YWN34h0PT9KkttRs9Utru4S9trlZI18holKjbkNnzeuRjb3zwAdNRWTqHiXQtN1FLDUda0y0v3XettPdxxyMuCchSckYB59qzvE/jvw74bs7S51HU7QRXMtuiFbiP7kz7UlOWH7vhmLf3VYjOKAIdEze/EbxNeEEx2Nva6Yh7B9rTyfmJofyFdbWJbeLfDdzqC2Ft4g0ia+aMSrbx3sbSFCm8MFDZxtIbPoc9KbaeMPDV5a3dzaeItGntrRBJcyxXsTJCp6M5DYUH1NAG7RWHL4v8NQ6dbX8viHR0sLpzHBctexCOVh1VG3YY+wq7/bOl7nX+0rLckyWzjz1ysrgFIzzwzBlIXqcjHWgC/RWXpfiLRdXu7i00nWNOvrq2/wBfDbXSSvFzj5lUkrzxzTbfxLoVzrD6Tb61pkuqpuDWcd1G0y7fvZQHdxg544oA1qKKKACiiigAoqvqAgawuReQ+fbGJhLF5Rl3pg5XYAS2RkbQDnpg14f4RtfEtp4T0XTvDq6toFvb6Lf3U8cWkLGz3qSx+UjCaE8sGY4AywBweMgA94orwMz+MtLuPF+oaeutjV9QaxuhAdO/ceWYLZJpEcW7/vY8Ogj+Y4XJjcjJ6Hwte+ONUvdDtr7UL2CzlF+1xcpYFJMIbcwLI09rEFY7phkRAMoOASMqAet0V41aa34rfw9bzXN94oj1Z54V1aFdDG3T4yzeYbT/AEc+dghVzum+UlsVCde8bq+jNJLr0kDyyJ5MOl+TcXEX2grHLMTayRITHglC0BA54yAAD2usbw1Z2OkRXGlWt4txdJNJe3Cs6mUG4lkk3Mo6AsXA46LgdK8h8OHxHoGjQ6cb7xXb266ve/2hLDoqzyW6NLcPE0AFuRIspKs7ASBSQBsBqtHd+NYNZutUEWuW+vXmmaYsUMWk77e8kWWfctw/lssOEcMwDoQXOM4xQB9AUV49rOqeM7bSbq7afxAZ5davLWCO0so1S3tUll8qRwLSeRgyhQGVCDlSccsU8Ja74vvbnQ/+Eum8QaUr2cDBbHR/NW5uPNdZBcHyHMIwsfaMYYnPoAeuWd3b31rHc2U8VxbyDKSwuHRh6gjg1JLIkMTySuqRoCzOxwFA6knsK8At7PxjpHw7/s+KLUb+G58PX0n2C50uOVLa5SRBFGF8vLFld/kk37tpIGOK1de13xlc+OrvTrWy1s6HK15azQzWm+LYLeQxyRutqoCs4XH79yd2CozwAe0W80VzbxT28qSwSqHjkjYMrqRkEEcEEd6krz26GvWXwv8ACtrov2yz1Nv7MtZ2jthJJBEzRJMSjqQNqliSRxgnjFX/AAfqusW8raZr0Oq30rajdW8GoSWiovkRgMjylAqjcCVVlUBiKAOzooooA5j4h6c194dkliTdPZsLhPXA+8P++Sf0rzNh58IMbDkq6k9MggjP5V7kwDKVYAgjBB714xqGntpOq3en8lIn3RE90PK/l0/CvNx9PaaPRwNTeDI4IZmju/MaMST/AHSMkKNuMfz/ADqxFa3SmSWzFtaykKNqcq2D1bgdvQfjRbKzEAVu2VoSATXBGDZ3Tkkihp9pKHDTIqsqCNQrFuM5JJIHJPt2rqtJ04sQzDipdN0veQzDiuighWJAAOlehh8N1Z59fEdELBEIkAAqSiivQSscDdwooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcNrHiK7sfGniGye8SGytPDseowo6oNsnmXCu+SMkALFkHIHHHPPc1l6z4e0XXHgfWtI07UWgOYjd2yTGM+q7gcfhQB5X4e8a67a3EbzRNquoajBo0CwXFybeKOaa3leR+EYKCychV/DgCrOtfGR9M0L7edEhmuLcXBvrOO5neSEQzvCzKUt2UoWjbDSGIcY4r1KTSdOkuvtMlhaNc70k81oVL7kBCNnGcqGYA9snHWs6/8ABvhjUdn9oeHNFuthdl8+xifaXYs5GV43MST6kkmgCv4Y8R3evapqsSabFBp9hdSWhuGuSZJHVUYER7MAEOcktwQMA5yMWx8f3k/iWGyudFhh0yfVbnSIrsXxaQywxyPuaLywAhEbc7yQe2Oa7m0s7az837Jbwwec5lk8pAu9yACxx1OAOT6CoBpGmh0YafZ7kna5U+SuVlYENIOOGIZgW6kE+tAE9jd21/aQ3djcQ3NrMoeKaFw6Op6FWHBHuKnqCxtLawtIbSxt4ba1hUJFDCgREUdAqjgD2FT0AFFFFABWH440D/hKPCep6J9p+y/bYvK87y9+zkHO3Iz09RW5RQB5fq3wc0i7uLg2l7c2sNzFqCTr99ybsRD5GyNqJ5XCYI+Y9Ocx6d8LL2wmtr+HW7RtatbpLiO5mtrq5jcLDJFtkSa7cnCynBR0xjoa9UooA8vg+F+oWmnCKx8US2159kFq1xFbNHvH2p52zslVgGEhQ7WVh1DCrngn4byeG9UsL6bWDey2738jjyXG9rpoWPzSSu/ymE8szE7uTxy34neNr7wxqUNtbXej6bCbCa8WfVIndbuVCoFtFtdMOQc/xHkYU81U+FEF1qXi7xn4g1OKyF216tooNoRcwR/ZraQQ+aXPyDcMoFGXBbuFABvz+D73+3NfuLTVLZNM13ab62msmkmyIRD+6mEi7RtVThkbBzjrXNp8LNUZLd7rxLbSXdnbafb2brphVEFnP5qGRfOJfceGwy+2Olcl4a1/UfDGn/bri+8M6fNrl/qkt1rN/YSKrPb3MiJA7CYF2bLeWMjaiFQHPNdOfiF4nm0XVtUt9Ls0/s3SbTUJLF4ZGmZ5oWZkzvAUIwBJI6KRxncAC5qHw01fVfE9pq2qeKmuFt7r7UsAt5giEwtGURDcGNVyxYHyy/YueaZqHwiiu9E0uwXV2hk0/SbTTo5YoWj3SW8qyCU7JFYAleVDAjOQwPNctL8Y9Xj0NpnuNDFy1w0dtNGttLFMqxBij7dQ2ROCeAZWZh0TINbVv8R/EWo+HdX1eyh0m3i07wxba60c0MkheWWG4cxjEi4XdEvPUDIwd2VANC1+Ft5ZKJ7DWrOLUpIrqC5mms57qOVLjy9zBZrl3En7pfmLlT3U0+D4WT2V7bpp+vLHpKXun38lvLZ+ZNJJaRxxgCXzAArLEpPyEg85xxWfP418Y6fdXjXsvh+e2sJtMEyw2U0bypeSpHtUmZgpTJO4ht3HC16/QBx3gfwhe+Gr+9kl1aOWxmXbDYW0U0cEJ3FiyrLNLtPOMJsX/ZzUEHgJYdQtLuPUFElvrl1rXFuMsZopI/Lzu7eYDu77cYHbuKKAKWiW15Z6RZ2+qX/9o30USrNd+SsPnOBy+xeFz6CrtFFABRRRQAUUUUAFZ2uaza6JarcXsd88bNs/0SymumBwTkrEjEDjqRj35rRrmPHXgvT/ABnBYxanNPGlpKZVVI4ZUcldpDxzRujdeMrkHkEUAVW+JfhMPbhdTkkSaCC5WWOzneNYpmKxO7hCqBiCPmIweuKhfx7aXfjXR9E0ZmuYp57mC7na0mEatFGxKxzECNmDLhgC2MEcVDpnwt0TTtDutKgutSa3uLK0sXZ5ELhLZ3dCCExuJkbPGOBgCrelfD+y0zXLTUINT1RoLKe5ubWwd4jBA8+7zNuIw5BLkgFzjtgcUAWPEPj/AMOeHdRmsdWvZ4biCOKWbZZTypEkjFULuiFVBYEDJHNNHxC8ONZidLq8Ym4e1+zrp1y1yJEUO6mAR+aMKykkrgBge4qXWPBWnatd6xcXM12r6pHaRTCN1AUW0jyJtypwSXOc54xjFY/iH4VaBrtxcXF485uJr59QEjxW84R3hiiZQk0TptKwoeVJBGQRQAzxX8TNMs9Ngbw/OL+8nlsCpW0mlgSK4njQNJIo2xkozFQ7Ak44PQ6J+IOjWmjJqWqSTRWpluI2uLazuriCMRTNETJKIQE5XndgA5wWA3Gg/wALdL2rFBqWp2tozWklxa2y20UVxJbMrRuyrD8p+RQRHsUgdBxWfr/wV8Pa3aLbXV7qYiC3C4xbyf66eSZivmRNsYNKwDJtbGAScUAdh4R1q41mXXluUhVbDU5LKIxgjciojAtknJ+Y9MD2roK53QIdE0PVtQ0m01OJ9UvZm1KSzluEMwDBULBBhtnyDkg855roqACiiigAooooAK4vx/pu64s9QUdvIk/mp/n+ddpVXUrRL2ykgccMMj2I5FZ1Ye0g4mlKfs5qRwGnWWcYXmuq03TTgFxVzT9OSFBkDNaYAAwKwpYZR1ZvVxDlohkUaxrhRT6KK60rHIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFLW5L2HRb+TSokm1BLeRraNzhXlCnYD7E4FeY6d4g16zXw7fS3nirUbQ3G3WobnQDG8W62kKiNEt1ZkEwXLKXxxlsHn1uigDwa2uvFEWqweIdTTxX9vn0GRFt7LTI8ySpNKRE+YGEZ2lGG7GT/e+6bPh7V/iDqjxWVxca1aW8mswxfbjp481bVrWZpOZbSJcCVEG4wjBYDLAjPuFFAHhGsa/8SotP0pYvtsDfZ7gPdf2fIzSTpcOiedHFaTkKY1jbCiINuOGHArXi1jx1Nrs0CNqgvGuL2N7VtMVbCC3WKQ20sVw0YLuzCLKl2+8wKrtr2CigDxWfxV4xvrLdaf23YeVpNkZnm0OZWe8MjfaFTFvIc7QBuEboOoBHNdXPqfiKT4QSahYxapF4iNuTGtzbpJc7/MwCY1jQHI5A8tTgjIBzXf0UAcN4f1LW9K1nVNN1pdX1i2/tGG2sr02SKQj24kZ3Maonlq4ZdwHBIByag+Jepa9ZajZJpk2r2mnNaXDmfStOF7K90NnlROpjfahBc7sDkAFl7+gUUAebfC3Ttcj8SeKdU8QPewz3b2ha3eKNYGf7HAXKMEDMEffGMMV4OQWya5TUvFHj867ry6XZ68lqtlqZgiubHzPKnjRjbmMi1RTuZflHmzbgQDg8H3SigDyDxa3j20h1CTSdZ1mWS10QX8SRabA6z3hc/uAPJJxgfcB38j5j37TwYNct9W8QWGt3t5qFtbTQmzvLm3jiaRWiUuAY0VWAfcOBkdCTXV0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25335=[""].join("\n");
var outline_f24_47_25335=null;
var title_f24_47_25336="Levonorgestrel: Drug information";
var content_f24_47_25336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levonorgestrel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/24/15750?source=see_link\">",
"    see \"Levonorgestrel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mirena&reg;;",
"     </li>",
"     <li>",
"      My Way&trade;;",
"     </li>",
"     <li>",
"      Next Choice&reg;;",
"     </li>",
"     <li>",
"      Next Choice&trade; One Dose;",
"     </li>",
"     <li>",
"      Plan B&reg; One Step;",
"     </li>",
"     <li>",
"      Skyla&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mirena&reg;;",
"     </li>",
"     <li>",
"      Next Choice&reg;;",
"     </li>",
"     <li>",
"      NorLevo&reg;;",
"     </li>",
"     <li>",
"      Plan B&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Progestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Long-term prevention of pregnancy:",
"     </b>",
"     Intrauterine device (Skyla&trade;): To be inserted into uterine cavity; should be inserted within 7 days of onset of menstruation or immediately after first trimester abortion; releases levonorgestrel ~6 mcg per day over 3 years. May be removed and replaced with a new unit at anytime during menstrual cycle; do not leave any one system in place for &gt;3 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Long-term prevention of pregnancy, treatment of heavy menstrual bleeding:",
"     </b>",
"     Intrauterine device (Mirena&reg;): To be inserted into uterine cavity; should be inserted within 7 days of onset of menstruation or immediately after first trimester abortion; initially releases levonorgestrel 20 mcg per day, then rate subsequently decreases; mean release rate over 5 years is levonorgestrel ~14 mcg per day.  May be removed and replaced with a new unit at anytime during menstrual cycle; do not leave any one system in place for &gt;5 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Continuation of therapy or switching to different contraceptive (Skyla&trade;, Mirena&reg;):",
"     </i>",
"     At the time of device removal, a new device may be inserted immediately if continuation of therapy is desired. If the patient wishes to change to a different method of birth control, remove the device during the first 7 days of menstrual cycle and begin the new therapy. If the device is not removed during menstruation (or if the patient has irregular menstrual cycles) and wants to start a different method of birth control, consider starting the new method 7 days prior to device removal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emergency contraception:",
"     </b>",
"     Oral: May be used at any time during menstrual cycle:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Two-dose regimen:",
"     </i>",
"     One 0.75 mg tablet as soon as possible within 72 hours of unprotected sexual intercourse; a second 0.75 mg tablet should be taken 12 hours after the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Single-dose regimen:",
"     </i>",
"     One 1.5 mg tablet as soon as possible within 72 hours of unprotected sexual intercourse",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5509119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5509120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use of the intrauterine device is contraindicated with active hepatic disease or hepatic tumor.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrauterine device, intrauterine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mirena&reg;: 52 mg/device",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skyla&trade;: 13.5 mg/device",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     My Way&trade;: 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Next Choice&reg;: 0.75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Next Choice&trade; One Dose: 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plan B&reg; One Step: 1.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral tablets for OTC use are limited to pharmacies or healthcare clinics with a valid license to distribute prescription products. Pharmacies are required to keep the product behind the counter.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrauterine device: Insert into the uterine cavity to the recommended depth with the provided insertion device; should not be forced into the uterus. Transvaginal ultrasound may be used to check proper placement. Remove if not positioned properly and insert a new IUD; do not reinsert removed IUD. Exclude perforation if exceptional pain or bleeding occurs after insertion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Consider repeating the dose if vomiting occurs within 2 hours. If severe vomiting occurs, may consider administering the oral tablets vaginally (ACOG, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrauterine device (IUD): Prevention of pregnancy; treatment of heavy menstrual bleeding in women who also choose to use an IUD for contraception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Emergency contraception following unprotected intercourse or possible contraceptive failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral products are approved for OTC use by women &ge;17 years of age and available by prescription only for women &lt;17 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Intrauterine device:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ovarian cysts (13%), enlarged follicles (12%), amenorrhea (&lt;1% to 12%, increases with duration of treatment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Uterine/vaginal bleeding alterations (52%), intermenstrual bleeding/spotting (23%), vulvovaginitis (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Ectopic pregnancy (&le;50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (4%), migraine (2%), nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (1%), eczema, hirsutism, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (9%), menorrhagia (6%), breast pain/tenderness (3% to 9%), libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6%), abdominal distension, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pelvic pain (6%), leukorrhea (5%), vaginal discharge (4%), pelvic infection (1%), cervicitis, dyspareunia, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: IUD expulsion (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, cervical wall perforation, device breakage, failed insertion, hypersensitivity reactions, jaundice, sepsis, uterine bleeding, uterine wall perforation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral tablets:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (13% to 17%), headache (10% to 17%), dizziness (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Heavier menstrual bleeding (14% to 31%), lighter menstrual bleeding (12%), breast tenderness (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (14% to 23%), abdominal pain (13% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menses delayed (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (6%), diarrhea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Dysmenorrhea, menstruation irregularities, oligomenorrhea, pelvic pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levonorgestrel or any component of the formulation; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Additional product-specific contraindications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intrauterine device: Congenital or acquired uterine anomaly, acute pelvic inflammatory disease, history of pelvic inflammatory disease (unless there has been a subsequent intrauterine pregnancy), postpartum endometritis or infected abortion within past 3 months, known or suspected uterine or cervical neoplasia, unresolved/abnormal Pap smear, untreated acute cervicitis or vaginitis, conditions which increase susceptibility to pelvic infections, unremoved IUD, undiagnosed abnormal uterine bleeding, active hepatic disease or hepatic tumors, current or history of known or suspected carcinoma of the breast or other progestin-sensitive cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Bacterial endocarditis, known immunodeficiency, hematologic malignancy, recent trophoblastic disease while human chorionic gonadotropin (hCG) hormone levels are elevated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: It is not known if the same contraindications associated with long-term progestin-only contraceptives apply to the levonorgestrel emergency contraception dose regimens. A history of ectopic pregnancy is not a contraindication to use in emergency contraception. Canadian labeling contraindicates use in patients with undiagnosed vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal pain: Patients taking progestin-only contraceptives and presenting with lower abdominal pain should be evaluated for follicular atresia and ectopic pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding irregularities: Menstrual bleeding patterns may be altered with use of the intrauterine device; the possibility of pregnancy should be considered if menstruation does not occur within 6 weeks of the previous menstrual period. If bleeding irregularities continue with prolonged use, appropriate diagnostic measures should be taken to rule out endometrial pathology. An increase in menstrual bleeding may indicate a partial or complete expulsion of the IUD. If expulsion occurs, device may be replaced within 7 days once pregnancy is ruled out. When using the oral tablet, spotting may occur following use; the possibility of pregnancy should be considered if menstruation is delayed for &gt;7 days of the expected menstrual period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia/syncope: Bradycardia or syncope may occur during insertion or removal of the intrauterine device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in the frequency of breast cancer, however, studies are not consistent. Data is insufficient to determine if progestin only contraceptives also increase this risk. Use of the intrauterine device is contraindicated in patients who have or who have had breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ectopic pregnancy: Use caution in patients with previous ectopic pregnancy. Women with history of ectopic pregnancy were excluded from clinical trials; women with previous ectopic pregnancy, tubal surgery or pelvic infection may be at increased risk ectopic pregnancy. The possibility of ectopic pregnancy should be considered in patients with abdominal pain or vaginal bleeding in  women with prior amenorrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression; may be more susceptible to recurrence of depressive episodes; consider removal of IUD for serious recurrence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Safety and efficacy of the intrauterine device have not been established for use in hepatic impairment. Use is contraindicated with active hepatic disease or hepatic tumors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established for use in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic enzyme-inducing medications: Patients receiving hepatic enzyme-inducing medications should be evaluated for an alternative method of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postmenopausal women: Not indicated for use in postmenopausal women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: The risk of cardiovascular side effects increases in women using estrogen containing combined hormonal contraceptives and who smoke cigarettes, especially those who are &gt;35 years of age. This risk relative to progestin-only contraceptives has not been established. Women who take contraceptives should be advised not to smoke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrauterine device: An increased incidence of group A streptococcal sepsis, pelvic inflammatory disease (may be asymptomatic), and actinomycosis have been reported with use. Using aseptic technique during insertion is essential to minimizing the risk of serious infections. The highest risk of pelvic inflammatory disease is within 20 days of insertion; risk is increased with multiple sexual partners. May perforate uterus or cervix; risk of perforation is increased in lactating women. Pregnancy may result if perforation occurs; delayed detection of perforation may result in migration of IUD outside of uterine cavity. Partial penetration or embedment in the myometrium may decrease effectiveness and lead to difficult removal. Use caution in patients with coagulopathy or receiving anticoagulants. Use caution in patients with congenital heart disease or other heart conditions which may increase the risk of infective endocarditis during insertion of the device (prophylactic antibiotics may be required at time of insertion).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Skyla&trade;: Only under specific conditions may this device be scanned safely by MRI. Image quality may also be impaired if area of interest is relatively close to the device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral tablet: Not intended to be used for routine contraception and will not terminate an existing pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Intrauterine device: Insertion should be done by a trained healthcare provider. Removal of the device may be necessary for the following reasons: Bleeding which causes anemia; coagulopathy or use of anticoagulants; marked increase in blood pressure; severe arterial disease (eg, stroke, MI); if the patient or her partner become HIV positive or acquire a sexually-transmitted disease; pelvic infection, endometritis, symptomatic genital actinomycosis; migraine or exceptionally severe headache; intractable pelvic pain, pain during intercourse; endometrial or cervical cancer; uterine or cervical perforation; jaundice; pregnancy. Embedded devices should also be removed.  Use is contraindicated in patients with vaginitis or cervicitis. Postpone insertion until after treatment for infection is complete and cause of the cervicitis is proven not to be due to gonorrhea or chlamydia. Not effective for emergency contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fertility: Oral tablet: Barrier contraception is recommended immediately following emergency contraception and throughout the same menstrual cycle; efficacy of hormonal contraception may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F188233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F188197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort (an enzyme inducer) may decrease serum levels of levonorgestrel.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during pregnancy is contraindicated. When pregnancies have continued following levonorgestrel exposure, congenital anomalies have been infrequent. Significant adverse effects on infant growth and development have not been observed (limited data). In doses larger than those used for oral contraception, progestins have been reported to increase the risk of masculinization of female genitalia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Intrauterine device: Pregnancy should be ruled out prior to insertion. Women who become pregnant with an IUD in place risk septic abortion (septic shock and death may occur). Removal of the device is recommended, however, removal or manipulation of IUD may result in pregnancy loss. In addition, miscarriage, premature labor, and premature delivery may occur if pregnancy is continued with IUD in place. Following pregnancy, insertion of the device should not take place until 6 weeks postpartum or until involution of the uterus is complete. Consider waiting until 12 weeks postpartum if involution is substantially delayed. The device may be inserted immediately following a first trimester abortion. Following removal of the device, ~80% of women who wished to conceive became pregnant within 12 months.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral tablet: A rapid return of fertility is expected following use for emergency contraception; routine contraceptive measures should be initiated or continued following use to ensure ongoing prevention of pregnancy. Barrier contraception is recommended immediately following emergency contraception. Short-term contraception (eg, oral hormonal contraceptive pills, patches, rings) may be started with barrier contraception or after the next menstrual period. Long term contraception (eg, IUD, depot medroxyprogesterone, progestin implant) should be started after the next menstrual period.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F188187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following maternal use of the oral tablets or intrauterine device, levonorgestrel is found in breast milk and can be detected in the serum of nursing infants (Shikary, 1987). In general, no adverse effects on the growth or development if the infant have been observed. Isolated cases of decreased milk production have been reported. Risk of perforation with IUD is increased in lactating women. Following pregnancy, insertion of the device should not take place until 6 weeks postpartum or until involution of the uterus is complete. Consider waiting until 12 weeks postpartum if involution is substantially delayed. Women who are breast-feeding may use levonorgestrel for emergency contraception.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intrauterine Device",
"     </b>",
"     (Mirena Intrauterine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mcg/24 hrs (1): $843.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intrauterine Device",
"     </b>",
"     (Skyla Intrauterine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13.5 mg (1): $780.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levonorgestrel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (2): $36.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (My Way Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $36.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Next Choice One Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $36.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Plan B One-Step Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $40.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Plan B Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (2): $40.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F188174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     IUD: Re-examine following insertion (4-12 weeks Mirena&reg;; 4-6 weeks Skyla&trade;) and then yearly or more frequently if necessary. Threads should be visible; if length of  thread has changed device may have become displaced, broken, perforated the uterus, or expelled. Transvaginal ultrasound may be used to check placement. Monitor for prolonged menstrual bleeding, amenorrhea, irregularity of menses, Pap smear, blood pressure, serum glucose in patients with diabetes, LDL levels in patients with hyperlipidemias; re-examine following first menses postinsertion of IUD. Patients presenting with lower abdominal pain should be evaluated for follicular atresia and ectopic pregnancy. Signs of infection following IUD insertion, especially in patients at increased risk (eg, patients on chronic corticosteroids, patients with type 1 diabetes mellitus).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral tablet: Evaluate for pregnancy, spontaneous abortion or ectopic pregnancy if menses is delayed for &ge;1 week following emergency contraception, or if lower abdominal pain or persistent irregular bleeding develops.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F188177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intrauterine device:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirena&reg;: Plasma concentrations range from 150-200 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Skyla&trade;: Plasma concentrations range from a peak of 192 pg/mL (2 days following insertion) to 61 pg/mL (after 3 years)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F188188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ange 28 (JP);",
"     </li>",
"     <li>",
"      duofem (DE);",
"     </li>",
"     <li>",
"      ECEEZ (IN);",
"     </li>",
"     <li>",
"      Escapelle (CL);",
"     </li>",
"     <li>",
"      Estinor (SG);",
"     </li>",
"     <li>",
"      Glanique (EC);",
"     </li>",
"     <li>",
"      Hyan (TH);",
"     </li>",
"     <li>",
"      Imediat N (UY);",
"     </li>",
"     <li>",
"      Jadelle (NZ, TH);",
"     </li>",
"     <li>",
"      Levonelle (GB, IE, NZ);",
"     </li>",
"     <li>",
"      Levonelle-2 (AU);",
"     </li>",
"     <li>",
"      Levonova (SE);",
"     </li>",
"     <li>",
"      Levostrel (TW);",
"     </li>",
"     <li>",
"      Madonna (MY);",
"     </li>",
"     <li>",
"      Microlut (CO, LU);",
"     </li>",
"     <li>",
"      Microval (LU);",
"     </li>",
"     <li>",
"      Mirena (AR, AT, AU, BB, BE, BG, BM, BS, BZ, CH, CO, CR, CZ, DE, DO, EC, ES, GB, GT, GY, HK, HN, HU, ID, IE, IL, IT, JM, LU, MY, NI, NL, NZ, PA, PE, PH, PR, RU, SR, SV, TT, UY, ZA);",
"     </li>",
"     <li>",
"      Norlevo (AU, DK, ES, FI, FR, GR, IL, IN, KP, NO, PT, SE, SG, TR, ZA);",
"     </li>",
"     <li>",
"      Norplant (CL, LU, PH, TH, TW);",
"     </li>",
"     <li>",
"      Pill 72 (HK);",
"     </li>",
"     <li>",
"      Plan B (DO, HN, NI, SV);",
"     </li>",
"     <li>",
"      Postinor (BE, CH, CL, EE, HU, PL, SE);",
"     </li>",
"     <li>",
"      Postinor-1 (AU, NZ);",
"     </li>",
"     <li>",
"      Postinor-2 (AU, BR, CN, HK, MX, PE, SG, TW, VE);",
"     </li>",
"     <li>",
"      Pronta (PY);",
"     </li>",
"     <li>",
"      Rigesoft (HU);",
"     </li>",
"     <li>",
"      Safe Plan (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F188163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy may be prevented through several mechanisms: Thickening of cervical mucus, which inhibits sperm passage through the uterus and sperm survival; inhibition of ovulation, from a negative feedback mechanism on the hypothalamus, leading to reduced secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH);  and inhibition of implantation. Levonorgestrel is not effective once the implantation process has begun.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Intrauterine device: Mirena&reg;: Up to 5 years; Skyla&trade;: Up to 3 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Highly bound to albumin (~50%) and sex hormone-binding globulin (~47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; forms inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (45%); feces (32%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins-Gynecology, &ldquo;ACOG Practice Bulletin. No. 73: Use of Hormonal Contraception in Women With Coexisting Medical Conditions,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2006, 107(6):1453-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/16738183/pubmed\" id=\"16738183\" target=\"_blank\">",
"        16738183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 112: Emergency Contraception,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 115(5):1100-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/20410799/pubmed\" id=\"20410799\" target=\"_blank\">",
"        20410799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fotherby K, &ldquo;Levonorgestrel. Clinical Pharmacokinetics,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(3):203-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/7758251/pubmed\" id=\"7758251\" target=\"_blank\">",
"        7758251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frank ML and DiMaria C, &ldquo;Levonorgestrel Subdermal Implants,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1997, 17(6):360-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/9429835/pubmed\" id=\"9429835\" target=\"_blank\">",
"        9429835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta J, Kai J, Middleton L, et al, \"Levonorgestrel Intrauterine System versus Medical Therapy for Menorrhagia,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2013, 368(2):128-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/23301731/pubmed\" id=\"23301731\" target=\"_blank\">",
"        23301731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shikary ZK, Betrabet SS, Patel ZM, et al, \"ICMR Task Force Study on Hormonal Contraception. Transfer of Levonorgestrel (LNG) Administered Through Different Drug Delivery Systems from the Maternal Circulation into the Newborn Infant's Circulation via Breast Milk,\"",
"      <i>",
"       Contraception",
"      </i>",
"      , 1987, 35(5):477-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/3113823/pubmed\" id=\"3113823\" target=\"_blank\">",
"        3113823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viegas OA, Koh SC, and Ratnam SS, &ldquo;The Effects of Reformulated 2-Rod Norplant&reg; Implant on Hemostasis After Three Years,&rdquo;",
"      <i>",
"       Contraception",
"      </i>",
"      , 1996, 54(4):219-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/8922875/pubmed\" id=\"8922875\" target=\"_blank\">",
"        8922875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK and Green L, &ldquo;Serious Adverse Events in Norplant&reg; Users Reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1995, 85(4):538-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/7898829/pubmed\" id=\"7898829\" target=\"_blank\">",
"        7898829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang L, Chen J, Wang Y, et al, \"Pregnancy Outcome After Levonorgestrel-Only Emergency Contraception Failure: A Prospective Cohort Study,\"",
"      <i>",
"       Hum Reprod",
"      </i>",
"      , 2009, 24(7):1605-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/47/25336/abstract-text/19336440/pubmed\" id=\"19336440\" target=\"_blank\">",
"        19336440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9555 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25336=[""].join("\n");
var outline_f24_47_25336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188202\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188203\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188237\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188206\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188207\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5509119\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5509120\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188176\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188160\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234040\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188179\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188178\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188235\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188182\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188164\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188233\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188169\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188197\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188186\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188209\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188187\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323308\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188174\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188177\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188188\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188163\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188181\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9555|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/24/15750?source=related_link\">",
"      Levonorgestrel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_47_25337="Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive";
var content_f24_47_25337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25337/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/47/25337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified (NOS)",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma (ALCL), primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A high fraction of ALCLs are associated with translocations involving ALK, the Anaplastic Lymphoma Kinase gene, located on chromosome 2p23. These ALK+ tumors (sometimes referred to as \"ALKomas\") have a distinctly better clinical outcome than ALK- systemic ALCLs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. As such, the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues classifies &ldquo;ALCL, ALK positive&rdquo; as a distinct clinicopathologic entity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. &ldquo;ALCL, ALK negative&rdquo; is included as a provisional entity to assist the ascertainment of additional data. (See",
"    <a class=\"local\" href=\"#H1575775\">",
"     'ALCL, ALK negative'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ALCL is comprised of two morphologically similar, but clinically distinct subtypes referred to as primary systemic ALCL and primary cutaneous ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Primary cutaneous ALCL is confined to the skin in patients with no pre-existing lymphoproliferative disorder and does not contain translocations involving ALK. In contrast, primary systemic ALCL presents in patients with systemic, extracutaneous disease.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical presentation, diagnosis, and differential diagnosis of ALK+ ALCL will be discussed here. The diagnosis of other",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphomas and the treatment of the PTCLs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALCL is one of the most common forms of a relatively rare group of neoplasms, the peripheral T cell lymphomas (PTCLs). The exact worldwide incidence of ALK+ ALCL is not known, as collection of these types of epidemiologic data is limited in some countries by a lack of resources that are needed for case ascertainment and accurate diagnosis. Epidemiologic data largely come from retrospective analyses of patients treated at major centers in the United States, Europe, and Asia.",
"   </p>",
"   <p>",
"    The largest retrospective study was the International T cell Lymphoma Project, which assessed 1314 cases of peripheral lymphoma of T cell or NK cell origin from 22 centers worldwide diagnosed between 1990 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately 6.6 percent were classified as ALK+ ALCL. The percentage of persons with ALK+ ALCL varied with geographic region. ALK+ ALCL was the most common distinct subtype of PTCL in the United States, accounting for 16 percent of cases. In contrast, ALK+ ALCL accounted for approximately 6 percent and 3 percent of PTCLs in Europe and Asia, respectively.",
"   </p>",
"   <p>",
"    In the United States as a whole, ALCL has an estimated incidence of 0.25 cases per 100,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/1\">",
"     1",
"    </a>",
"    ]. ALCL is less common in Asian Americans than among White Americans, Black Americans, American Indians, or Asian Pacific Islanders. As with most PTCL, there is a male predominance, with a male to female ratio of approximately 2:1. The median age of patients with primary systemic ALK+ ALCL is 34 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. There is a bimodal age distribution, with peaks in",
"    <span class=\"nowrap\">",
"     childhood/young",
"    </span>",
"    adulthood, and again in late adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, ALK+ ALCLs have a rearrangement involving the Anaplastic Lymphoma Kinase gene (ALK), which results in the formation of ALK fusion genes that are implicated in the pathogenesis of ALK+ ALCL. There are multiple chromosomal rearrangements involving the ALK gene that result in the creation of ALK fusion genes that encode chimeric, constitutively active ALK kinases. The best described and most frequent translocation, t(2;5), causes the fusion of the nucleophosmin (NPM) gene (5q35), coding for a nucleolar phosphoprotein, with the portion ALK on chromosome 2p23 that encodes the ALK cytoplasmic domain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Consequently, a hybrid protein is formed in which the amino terminus of NPM is fused with the catalytic domain of ALK [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The translocation product, NPM-ALK, then acts as a constitutively active tyrosine kinase, which can trigger malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/5\">",
"     5",
"    </a>",
"    ] and activate antiapoptotic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/5,7-9\">",
"     5,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro and mouse model studies have demonstrated that expression of human NPM-ALK induces lymphoproliferative disorders of both B and T cell lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. The ability of NPM-ALK to cause both B and T cell tumors in mice is in line with the occurrence of rare human plasmablastic B cell lymphomas with ALK gene rearrangements. Development of mouse models that produce peripheral T cell lymphomas resembling ALCL awaits the development of models in which NPM-ALK expression is restricted to mature T cells.",
"   </p>",
"   <p>",
"    In addition to fusion with NPM, ALK participates in the following variant rearrangements, each of which presumably gives rise to a constitutively active ALK fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      t(1;2), encoding a tropomyosin3",
"      <span class=\"nowrap\">",
"       (TPM3)/ALK",
"      </span>",
"      fusion protein (10 to 20 percent of cases)",
"     </li>",
"     <li>",
"      t(2;3), encoding a TRK fusion gene",
"      <span class=\"nowrap\">",
"       (TFP)/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      inv(2), encoding a ATIC (Pur H",
"      <span class=\"nowrap\">",
"       gene)/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      t(2;17), encoding a clathrin heavy chain",
"      <span class=\"nowrap\">",
"       (CLTC)/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      t(2;17), encoding a",
"      <span class=\"nowrap\">",
"       ALO17/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      t(2;19), encoding a tropomyosin 4",
"      <span class=\"nowrap\">",
"       (TPM4)/ALK",
"      </span>",
"      fusion protein (&lt;1 percent of cases)",
"     </li>",
"     <li>",
"      t(2;22), encoding a non-muscle myosin",
"      <span class=\"nowrap\">",
"       (MYH9)/ALK",
"      </span>",
"      fusion protein (&lt;1 percent of cases)",
"     </li>",
"     <li>",
"      t(2;X), encoding a",
"      <span class=\"nowrap\">",
"       moesin/ALK",
"      </span>",
"      fusion protein (&lt;1 percent of cases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these diverse fusion proteins is believed to have identical functional consequences: fusion of the ALK tyrosine kinase domain to a protein domain with the capacity for self-association, which appears to be the key element that leads to constitutive activation of the ALK tyrosine kinase moiety. It remains to be seen whether ALK+ lymphomas with variant ALK rearrangements (eg, inv20, t(1;2), and t(2;3)) have an identical biology and clinical behavior to the more common tumors associated with the t(2;5) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of adults with ALK+ ALCL present with painless lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Both peripheral and retroperitoneal adenopathy are common. While a majority has systemic symptoms (eg, fever, weight loss), patients may present with isolated lymphadenopathy or with extranodal disease in any site, including the gastrointestinal tract, breast, spleen, liver, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,14-16\">",
"     2,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data regarding the clinical presentation of patients with ALK+ ALCL largely come from retrospective analyses of patients treated at major centers in the United States, Europe, and Asia. The largest retrospective study was the International T cell Lymphoma Project, which assessed 1314 cases of peripheral lymphoma of T cell or NK cell origin, 55 of which were ALK+ ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/4\">",
"     4",
"    </a>",
"    ]. In this series, 65 percent of patients with ALK+ ALCL had advanced (stage III or IV) disease at presentation (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately the same percentage had B symptoms such as fever, drenching night sweats, and unintentional weight loss. The lymph nodes were the only site of disease in 54 percent, while 19 percent had involvement of more than one extranodal site. Bulky lymphadenopathy (&gt;10 cm) was present in 21 percent. The most common sites of extranodal involvement were bone (14 percent), bone marrow (12 percent), subcutaneous tissue and spleen (10 percent each), skin and lung (8 percent each), and liver (3 percent). The majority of patients had an Eastern Oncology Cooperative Group (ECOG) performance status of two or better (65 percent) (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The age of presentation of patients with ALK+ ALCL is much younger than that seen in patients with ALK- ALCL and other T cell lymphomas. In the International T cell Project, the median age difference was 24 years (34 versus 58 years, respectively) and many more patients with ALK+ ALCL were younger than 60 years at presentation (85 versus 58 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon laboratory investigation, a subset of patients had an elevated lactate dehydrogenase (LDH) level (37 percent), anemia (27 percent), or thrombocytopenia (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. Circulating tumor cells are rare at the time of diagnosis, but are not uncommon at the time of relapse (",
"    <a class=\"graphic graphic_picture graphicRef85991 \" href=\"UTD.htm?22/15/22771\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histologic features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5617650\">",
"    <span class=\"h4\">",
"     Classical variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 to 80 percent of ALCL demonstrate classical morphology, in which the tumor is composed of large cells with round or pleomorphic, often horseshoe-shaped or \"embryoid\" nuclei with multiple (or single) prominent nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef85995 \" href=\"UTD.htm?1/16/1281\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. The cells have abundant cytoplasm, which gives them an epithelial or histiocyte-like appearance. The \"hallmark cell,\" which is classically identified with ALCL, has an eccentric nucleus and a prominent, pale Golgi region, or paranuclear hof (",
"    <a class=\"graphic graphic_picture graphicRef85992 \" href=\"UTD.htm?10/44/10951\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/17\">",
"     17",
"    </a>",
"    ]. Normal and atypical appearing mitoses are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5617657\">",
"    <span class=\"h4\">",
"     Atypical variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of ALCL demonstrate atypical morphology. Several morphologic variants exist and are more commonly present in children with ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Studies of cytogenetic and molecular genetic abnormalities as well as clinical features suggest that these cases belong to the same disease entity as the more anaplastic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. The most common morphologic variants are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Small cell variant",
"      </strong>",
"      &mdash; In these cases, the majority of cells are small to medium in size with clear cytoplasm and irregular nuclei (",
"      <a class=\"graphic graphic_picture graphicRef85996 \" href=\"UTD.htm?20/18/20777\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef85991 \" href=\"UTD.htm?22/15/22771\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphohistiocytic variant",
"      </strong>",
"      &mdash; These cases have large numbers of histiocytes mixed with the neoplastic cells (",
"      <a class=\"graphic graphic_picture graphicRef85997 \" href=\"UTD.htm?14/12/14537\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Monomorphic variant",
"      </strong>",
"      &mdash; The tumor cells have a more monomorphous appearance, with round to oval nuclei and no Reed-Sternberg-like cells; these cases have in common with the more anaplastic cases abundant cytoplasm and a cohesive, often sinusoidal growth pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less common variants include a giant-cell-rich variant and a sarcomatoid variant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Growth pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor cells of primary systemic ALCL grow in a sheet-like cohesive pattern and often preferentially involve the lymph node sinuses or paracortex (",
"    <a class=\"graphic graphic_picture graphicRef85998 \" href=\"UTD.htm?6/10/6314\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/23\">",
"     23",
"    </a>",
"    ]. Early lesions can have a perifollicular pattern of growth. Small cell and lymphohistiocytic variants can show perivascular infiltration of large cells (",
"    <a class=\"graphic graphic_picture graphicRef85996 \" href=\"UTD.htm?20/18/20777\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of ALCL is usually confirmed by immunohistochemistry (",
"    <a class=\"graphic graphic_picture graphicRef85993 \" href=\"UTD.htm?12/1/12312\">",
"     picture 7",
"    </a>",
"    ), but may also be demonstrated using flow cytometry.",
"   </p>",
"   <p>",
"    While the immunophenotype is quite heterogeneous, ALK+ ALCL tumor cells are universally positive for both CD30 and ALK expression and negative for B cell surface markers (eg, CD19, CD20, CD22) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Occasional tumors may express transcription factors that are more typical of B cells, such as PAX5 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/24\">",
"     24",
"    </a>",
"    ] and BCL6 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/25\">",
"     25",
"    </a>",
"    ]. Most tumors express the phenotype of mature activated T cells (HLA-DR+, CD25+), but can also be of null cell type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5617979\">",
"    <span class=\"h3\">",
"     Surface receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key factor in the diagnosis of ALCL is the virtually universal expression of CD30 (previously Ki-1), with a majority of the neoplastic cells having strong expression of CD30 in a membrane and Golgi pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Epithelial membrane antigen (EMA) is often positive in systemic ALCL, but negative in cutaneous ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 60 percent of ALCL tumors express one or more T cell associated antigens (CD3, CD43, or CD45RO). In addition, CD45, which is positive on most lymphoid tumors, can be negative in a substantial minority of cases. CD15, a marker of Hodgkin lymphoma, is rarely positive in ALCL.",
"   </p>",
"   <p>",
"    About 40 percent of primary systemic ALCL cases fail to express either B or T cell antigens (null cell type) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Overall, the primary systemic ALCL tumors can be divided into the following immunophenotypic subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell type &mdash; CD3+",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other T cell markers positive, clonal TCR rearrangements present (60 percent)",
"     </li>",
"     <li>",
"      Null cell type &mdash; All lineage markers negative, but clonal TCR rearrangements present (30 percent); all lineage markers negative, no TCR or IgH rearrangements present (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The expression of surface receptors on ALK+ ALCL was described by the International T cell Lymphoma Project, which assessed 1314 cases of peripheral lymphoma of T cell of NK cell origin, 55 of which were ALK+ ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. In this series, ALK+ ALCL demonstrated universal expression of CD30 (100 percent); frequent expression of EMA (83 percent), TIA1, granzyme B, or perforin (80 percent); variable expression of CD43 (44 percent), CD4 (40 percent), and CD2 (23 percent); and low rates of expression of CD3 (12 percent), CD56 (7 percent), and CD8 (5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     ALK expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, all cases of ALK+ ALCL have a rearrangement involving the anaplastic lymphoma kinase (ALK) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Immunohistochemistry demonstrates expression of ALK, with variable subcellular distribution depending on the partner protein that is fused to ALK. Since ALK expression is normally confined to the central nervous system, immunoreactivity of a lymphoma with an ALK- specific antibody is a reliable predictor of the presence of a chromosomal rearrangement involving ALK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular genetic studies can aid in the diagnosis of ALCL by detecting clonal T cell receptor (TCR) gene rearrangements. However, the most important genetic finding in ALCL is the detection of ALK rearrangements, which are present in all cases of ALK+ ALCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     T cell receptor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of ALK+ ALCL have clonally rearranged TCR genes; roughly 10 percent have no rearrangement of TCR or immunoglobulin genes and belong to the null group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The TCR genes in primary cutaneous ALCL are universally rearranged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     ALK gene rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, all cases of ALK+ ALCL have a rearrangement involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2p23 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. There are several recognized translocations and inversions involving ALK [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      t(2;5), encoding a nuclear phosphoprotein",
"      <span class=\"nowrap\">",
"       (NPM)/ALK",
"      </span>",
"      fusion protein (70 to 75 percent of cases)",
"     </li>",
"     <li>",
"      t(1;2), encoding a tropomyosin3",
"      <span class=\"nowrap\">",
"       (TPM3)/ALK",
"      </span>",
"      fusion protein (10 to 20 percent of cases)",
"     </li>",
"     <li>",
"      t(2;3), encoding a TRK fusion gene",
"      <span class=\"nowrap\">",
"       (TFP)/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      inv(2), encoding a ATIC (Pur H",
"      <span class=\"nowrap\">",
"       gene)/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      t(2;17), encoding a clathrin heavy",
"      <span class=\"nowrap\">",
"       (CLTC)/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      t(2;17), encoding a",
"      <span class=\"nowrap\">",
"       ALO17/ALK",
"      </span>",
"      fusion protein (2 to 5 percent of cases)",
"     </li>",
"     <li>",
"      t(2;19), encoding a tropomyosin 4",
"      <span class=\"nowrap\">",
"       (TPM4)/ALK",
"      </span>",
"      fusion protein (&lt;1 percent of cases)",
"     </li>",
"     <li>",
"      t(2;22), encoding a non-muscle myosin",
"      <span class=\"nowrap\">",
"       (MYH9)/ALK",
"      </span>",
"      fusion protein (&lt;1 percent of cases)",
"     </li>",
"     <li>",
"      t(2;X), encoding a",
"      <span class=\"nowrap\">",
"       moesin/ALK",
"      </span>",
"      fusion protein (&lt;1 percent of cases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary systemic ALK+ ALCL is best made by excisional tissue biopsy, most commonly a lymph node. A discussion of lymph node and tissue biopsy, including the selection of a lymph node to biopsy, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Lymph node and tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic diagnosis of ALK+ ALCL is based upon characteristic morphologic features and immunohistochemical patterns found on biopsy specimens in conjunction with the clinical features found on presentation. On histology, the tumor is composed of large cells, often with horseshoe-shaped nuclei, prominent nucleoli, with or without a paranuclear hof, exhibiting in a cohesive growth pattern. On immunohistochemistry, there is a homogeneous and strong expression of CD30 in a membrane and Golgi pattern. There is also expression of T cell antigens or no lineage-specific antigens in the case of the null cell type. ALK gene rearrangement can be inferred by immunostaining for ALK or detected directly using molecular genetics or cytogenetics and by definition must be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ALK+ ALCL includes other lymphoid neoplasms of T or null cell origin and some B cell neoplasms, such as the anaplastic type of diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma, which may have similar morphologic features (",
"    <a class=\"graphic graphic_table graphicRef86090 \" href=\"UTD.htm?32/2/32812\">",
"     table 3",
"    </a>",
"    ). A general approach to adults and children who present with lymphadenopathy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1575775\">",
"    <span class=\"h2\">",
"     ALCL, ALK negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ALK+ ALCL and ALK- ALCL were previously classified as one clinicopathologic entity, termed anaplastic large cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/30\">",
"     30",
"    </a>",
"    ]. These two subtypes of systemic ALCL have similar clinical presentations, histologic features, and pattern of surface receptor expression, but can be distinguished by the presence or absence of ALK rearrangements by immunostains or molecular genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the age of patients presenting with ALK+ ALCL is approximately two decades younger than that of patients with ALK- ALCL. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'ALK expression'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'ALK gene rearrangements'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following the determination that ALK+ ALCL has a distinctly better clinical outcome than ALK- ALCL, the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues classified &ldquo;ALCL, ALK positive&rdquo; as a distinct clinicopathologic entity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. &ldquo;ALCL, ALK negative&rdquo; was created as a provisional entity, included to assist the ascertainment of additional data. Initial reports suggest that patients with ALK- ALCL tumors have a prognosis that is inferior to ALK+ ALCL, but superior to peripheral T cell lymphomas, not otherwise specified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'ALK status'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5619109\">",
"    <span class=\"h2\">",
"     Primary cutaneous ALCL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The broad clinicopathologic entity ALCL is comprised of two morphologically identical, but clinically distinct subtypes referred to as primary systemic ALCL and primary cutaneous ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Primary cutaneous ALCL is confined to the skin in patients with no pre-existing lymphoproliferative disorder and does not contain translocations involving ALK; instead, rearrangements involving the",
"    <span class=\"nowrap\">",
"     IRF4/MUM1",
"    </span>",
"    gene are common in this entity. It is distinguished from other forms of ALCL by the absence of systemic, extracutaneous disease.",
"   </p>",
"   <p>",
"    Most cases of primary cutaneous ALCL present with solitary or localized skin tumors or nodules, usually involving the trunk, face, extremities, or buttocks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. These lesions frequently demonstrate necrosis or ulceration. Tumors can show partial or complete spontaneous regression, but have a tendency to relapse. The diagnosis of primary cutaneous ALCL is made based upon a skin biopsy in a patient who has disease confined to the skin and no pre-existing lymphoproliferative disorder. On histology, large lymphoid cells similar to those in primary systemic ALCL diffusely infiltrate the upper and deep dermis and often the subcutaneous tissue, but lack epidermotropism. On immunohistochemistry there is a homogeneous and strong expression of CD30 in a membrane and Golgi pattern. There is expression of T cell antigens, but ALK is absent. Unlike ALK+ ALCL, 25 to 50 percent of cutaneous ALK- ALCLs have gene rearrangements involving the IRF-4 gene (also known as MUM-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     DLBCL, anaplastic type",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases of diffuse large B cell lymphoma (DLBCL), the cells are morphologically identical to those of anaplastic large cell lymphoma",
"    <span class=\"nowrap\">",
"     T/null",
"    </span>",
"    cell type, and strongly express CD30 as well as B cell antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ]. Although these have been called B cell anaplastic large cell lymphoma (B-ALCL) in the past, they are now considered to be a morphologic variant of DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/32\">",
"     32",
"    </a>",
"    ]. The key diagnostic criterion for such cases is the expression of B cell antigens, which are not expressed in ALCL. DLBCL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1930143\">",
"    <span class=\"h2\">",
"     DLBCL, plasmablastic type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmablastic lymphoma is a heterogeneous category of diffuse large B cell lymphoma (DLBCL), some of which are associated with Epstein Barr virus (EBV) infection, HIV infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunodeficiency states. A small minority of tumors with this morphology expresses ALK and also harbors ALK gene rearrangements. They are easily distinguished from ALCL, ALK+ by the absence of T cell markers and the expression of B cell markers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H1386908#H1386908\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Plasmablastic lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, some patients were diagnosed as having a variant of ALCL resembling Hodgkin lymphoma of nodular sclerosis type (NSHD), originally called ALCL Hodgkin's-related, and then called ALCL Hodgkin's-like (ALCL-HL) in the REAL classification [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This subtype was defined as having architectural features of Hodgkin lymphoma (nodularity and sclerosis) but cytologic features of ALCL (sheets of neoplastic cells and sinusoidal infiltration).",
"   </p>",
"   <p>",
"    The current consensus is that the majority of these cases can be resolved by a combination of morphologic and immunophenotypic features as either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hodgkin lymphoma (CD15+, CD30+,",
"      <span class=\"nowrap\">",
"       PAX/BSAP+,",
"      </span>",
"      T cell antigen -, ALK-)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma (CD15-, CD30+,",
"      <span class=\"nowrap\">",
"       PAX5/BSAP-,",
"      </span>",
"      T cell antigen",
"      <span class=\"nowrap\">",
"       +/-,",
"      </span>",
"      <span class=\"nowrap\">",
"       ALK+/-)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, this separate category has been eliminated from the current WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/30\">",
"     30",
"    </a>",
"    ]. Nonetheless, there are occasional cases in which the combination of morphology, immunophenotype, and even genetic studies may not resolve ALCL and Hodgkin lymphoma with certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/36\">",
"     36",
"    </a>",
"    ]. The diagnosis of Hodgkin lymphoma is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While ALCL has been historically grouped as an aggressive non-Hodgkin lymphoma (NHL), the clinical course varies considerably among subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/30,33,37\">",
"     30,33,37",
"    </a>",
"    ]. The main predictors of survival in patients with primary systemic ALCL are the ALK status of the tumor and the International Prognostic Index (IPI). Other predictors of worse outcome include older age (&ge;40 years) and increased beta-2 microglobulin (&ge;3",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/38\">",
"     38",
"    </a>",
"    ]. In children with ALCL, high numbers of circulating tumor cells in the peripheral blood or bone marrow denotes a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/39\">",
"     39",
"    </a>",
"    ]. ALK is universally expressed in ALK+ ALCL. However, the impact of ALK expression on the prognosis of patients with ALCL is discussed in detail below to provide prognostic guidance for patients with systemic ALCL as a whole and to provide support for the inclusion of ALK+ ALCL as a distinct clinicopathologic entity in the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     ALK status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies have found that patients with ALK+ primary systemic ALCL have better overall survival than those with ALK- disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,38,40,41\">",
"     2,38,40,41",
"    </a>",
"    ]. This prognostic advantage is present in both children and younger adults with ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/42\">",
"     42",
"    </a>",
"    ]. One of the initial retrospective analyses of 57 patients with T",
"    <span class=\"nowrap\">",
"     cell/null",
"    </span>",
"    primary systemic ALCL found that patients with ALK+ tumors had significantly higher rates of five-year overall survival (93 versus 37 percent) when compared with patients with ALK- tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest retrospective analysis of the effect of ALK positivity on outcome was the International Peripheral T cell lymphoma (IPTL) Project [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. This project studied outcomes in 159 systemic ALCLs and 22 primary cutaneous ALCLs. Primary cutaneous ALCL behaved indolently, having a five-year overall survival of 90 percent, but with a high propensity for cutaneous relapse. Systemic ALK+ ALCL pursued an aggressive course but responded well to therapy, having an overall five-year survival of 70 percent. Systemic ALK- ALCL had a five-year survival that was significantly worse than that of ALK+ ALCL (49 versus 70 percent), but significantly better than other peripheral T cell lymphomas (49 versus 32 percent). As a result, the IPTL determined that each of these variants deserved to be maintained in a separate diagnostic group.",
"   </p>",
"   <p>",
"    The distinction of ALK+ ALCL from ALK- ALCL is further supported by gene expression profiling (GEP) studies that have demonstrated different clustering patterns that may distinguish ALK+ ALCL and ALK- ALCL both from each other and from other T cell lymphoma subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     International Prognostic Index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Prognostic Index (IPI) was originally devised as a prognostic tool to predict survival of patients with clinically aggressive non-Hodgkin lymphoma following treatment with doxorubicin-containing chemotherapy regimens (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 4",
"    </a>",
"    ). It incorporates the patient's age, serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group (ECOG) performance status, Ann Arbor clinical stage, and the number of involved extranodal sites. Patients are then divided based on these factors into four risk groups with significantly different outcomes. The details of the IPI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have found the IPI to be an independent predictor of outcome in patients with ALCL, in general, and ALK+ ALCL, in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,40,41,46\">",
"     2,40,41,46",
"    </a>",
"    ]. The independent value of each component of the IPI and other items is not entirely clear. Age at diagnosis has been recognized as a prognostic factor. ALCL that arise during childhood, the vast majority of which are ALK+, are characterized by high-stage but therapy-responsive disease; overall survival is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/14,47-49\">",
"     14,47-49",
"    </a>",
"    ]. In adults, the tumor is clinically aggressive but potentially curable, having an overall survival similar to that of diffuse large B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2,35,50-52\">",
"     2,35,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The International Peripheral T cell Lymphoma Project, described above, reported estimated five-year overall survival rates for patients with ALK+ ALCL of 90, 68, 23, and 33 percent for patients with an IPI of 0 or 1, 2, 3, and 4 or 5, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"     2",
"    </a>",
"    ]. Corresponding estimates of five-year survival in patients with ALK- ALCL were 74, 62, 31, and 13 percent, respectively. Poor performance status, high stage, and elevated LDH were also predictive of lower survival in patients with ALK+ and ALK- ALCL. In addition, increased age, multiple extranodal sites, and anemia were poor prognostic factors in ALK+, but not ALK-, ALCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ALK positive anaplastic large cell lymphoma (ALK+ ALCL) is a lymphoid neoplasm of T or null origin associated with translocations involving ALK, the Anaplastic Lymphoma Kinase gene, located on chromosome 2p23. ALK+ ALCL is one of the most common forms of peripheral T cell lymphoma. It is a lymphoma most commonly seen in children and young adults, and it has a male predominance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The majority of patients with ALK+ ALCL present with painless adenopathy and are found to have widespread disease on staging. B symptoms are not uncommon. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      On lymph node biopsy, the tumor is composed of large cells with horseshoe-shaped nuclei, prominent nucleoli, with or without a paranuclear hof, growing in a cohesive growth pattern. Immunohistochemical analysis demonstrates a strong and homogeneous CD30 expression in a membrane and Golgi pattern. There is also expression of T cell antigens or no lineage-specific antigens as in the case of the null cell type. The presence of an ALK rearrangement can be inferred by immunostaining for ALK (indirectly) or detected directly by molecular genetics or cytogenetics. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The diagnosis of ALK+ ALCL is based on the pathologic features of lymph node or skin biopsy in combination with a clinical evaluation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The differential diagnosis of ALK+ ALCL includes other lymphoid neoplasms of T or null cell origin and some B cell neoplasms, which may have similar morphologic features (",
"      <a class=\"graphic graphic_table graphicRef86090 \" href=\"UTD.htm?32/2/32812\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ALK+ ALCL often pursues a clinically aggressive course, but is usually responsive to therapy. The most important prognostic factor is the patient's International Prognostic Index (IPI). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/1\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/2\">",
"      Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/4\">",
"      Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/5\">",
"      Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/6\">",
"      Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/7\">",
"      Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000; 96:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/8\">",
"      Ciarle R, Voena C, Ambrogio C, et al. The anaplastic lyphoma kinase in the pathogenesis of cancer. Nature Cancer Reviews 2008; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/9\">",
"      Hsu FY, Zhao Y, Anderson WF, Johnston PB. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 2007; 25:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/10\">",
"      Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/11\">",
"      Wlodarska I, De Wolf-Peeters C, Falini B, et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 1998; 92:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/12\">",
"      Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/13\">",
"      Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000; 95:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/14\">",
"      Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/15\">",
"      Tan DS, Eng PC, Lim ST, et al. Primary tracheal lymphoma causing respiratory failure. J Thorac Oncol 2008; 3:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/16\">",
"      de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008; 300:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/17\">",
"      Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/18\">",
"      Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology 1990; 16:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/19\">",
"      Kinney MC, Collins RD, Greer JP, et al. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 1993; 17:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/20\">",
"      Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas (\"ALK lymphomas\") with a wide morphological spectrum. Am J Pathol 1998; 153:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/21\">",
"      Chan JK, Ng CS, Hui PK, et al. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types. Histopathology 1989; 15:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/22\">",
"      Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/23\">",
"      Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/24\">",
"      Feldman AL, Law ME, Inwards DJ, et al. PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. Mod Pathol 2010; 23:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/25\">",
"      Quintanilla-Martinez L, Pittaluga S, Miething C, et al. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood 2006; 108:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/26\">",
"      de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 1993; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/27\">",
"      Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988; 72:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/28\">",
"      Burns BF, Dardick I. Ki-1-positive non-Hodgkin's lymphomas. An immunophenotypic, ultrastructural, and morphometric study. Am J Clin Pathol 1990; 93:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/29\">",
"      Schwarting R, Gerdes J, D&uuml;rkop H, et al. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989; 74:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/30\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/31\">",
"      Benner MF, Jansen PM, Meijer CJ, Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2009; 161:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/32\">",
"      Haralambieva E, Pulford KA, Lamant L, et al. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Haematol 2000; 109:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/33\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/34\">",
"      Pileri S, Bocchia M, Baroni CD, et al. Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol 1994; 86:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/35\">",
"      Zinzani PL, Bendandi M, Martelli M, et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 1996; 14:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/36\">",
"      Nishikori M, Maesako Y, Ueda C, et al. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 2003; 101:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/37\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/38\">",
"      Sibon D, Fournier M, Bri&egrave;re J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 2012; 30:3939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/39\">",
"      Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2007; 110:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/40\">",
"      Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93:3913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/41\">",
"      Schmitz N, Tr&uuml;mper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116:3418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/42\">",
"      Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/43\">",
"      Lamant L, de Reyni&egrave;s A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/44\">",
"      Salaverria I, Be&agrave; S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/45\">",
"      Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010; 28:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/46\">",
"      Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000; 96:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/47\">",
"      Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/48\">",
"      Weisenburger DD, Gordon BG, Vose JM, et al. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. Blood 1996; 87:3860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/49\">",
"      Mori T, Kiyokawa N, Shimada H, et al. Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol 2003; 121:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/50\">",
"      Greer JP, Kinney MC, Collins RD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 1991; 9:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/51\">",
"      Shulman LN, Frisard B, Antin JH, et al. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol 1993; 11:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25337/abstract/52\">",
"      Tilly H, Gaulard P, Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997; 90:3727.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4705 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25337=[""].join("\n");
var outline_f24_47_25337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5617650\">",
"      Classical variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5617657\">",
"      Atypical variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Growth pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5617979\">",
"      - Surface receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - ALK expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - T cell receptor genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - ALK gene rearrangements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1575775\">",
"      ALCL, ALK negative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5619109\">",
"      Primary cutaneous ALCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DLBCL, anaplastic type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1930143\">",
"      DLBCL, plasmablastic type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ALK status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      International Prognostic Index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4705|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/15/22771\" title=\"picture 1\">",
"      ALCL small cell peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/16/1281\" title=\"picture 2\">",
"      ALCL classical variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/44/10951\" title=\"picture 3\">",
"      ALCL hallmark cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/18/20777\" title=\"picture 4\">",
"      ALCL small cell variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/12/14537\" title=\"picture 5\">",
"      ALCL lymphohistiocytic variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/10/6314\" title=\"picture 6\">",
"      ALCL sinusoidal infiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/1/12312\" title=\"picture 7\">",
"      ALCL immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/2/32812\" title=\"table 3\">",
"      DDx ALK positive ALCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 4\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_47_25338="Radiation therapy for Ewing sarcoma family of tumors";
var content_f24_47_25338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiation therapy for Ewing sarcoma family of tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/47/25338/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/47/25338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma (ES) is a rare malignancy that most often presents as an undifferentiated primary bone tumor; less commonly, it arises in soft tissue (extraosseous Ewing sarcoma, EES). Both are part of a spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes the more differentiated peripheral primitive neuroectodermal tumor (PNET, previously called peripheral neuroepithelioma, adult neuroblastoma, and Askin's tumor of the chest wall) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/1\">",
"     1",
"    </a>",
"    ]. PNET can also present either in bone or soft tissue. Because these tumors share similar histological and immunohistochemical characteristics and unique nonrandom chromosomal translocations, they are considered to have a common origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EFT also share important clinical features, including a peak incidence between the age of 10 and 20, a tendency towards rapid spread to lungs, bone, and bone marrow, and responsiveness to the same chemotherapeutic regimens and radiotherapy (RT). Because relapse rates are high in patients undergoing local therapy alone (80 to 90 percent), it is surmised that the majority have subclinical metastatic disease at the time of diagnosis, even in the absence of overt metastases. The routine administration of intensive multiagent chemotherapy, which can eradicate these deposits, has had a dramatic impact on outcomes. Five-year survival rates for patients with Ewing sarcoma in the United States rose from 36 to 56 percent during the periods 1975 to 1984 and 1985 to 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local control at the primary tumor site can be accomplished by surgery, RT, or both. The choice of modality usually represents a tradeoff between functional result and treatment-related morbidity, particularly the risk of a secondary radiation-induced malignancy. Although modern treatment protocols emphasize surgery for optimal local control, patients who lack a function-preserving surgical option because of tumor location or extent, and those who have clearly unresectable primary tumors following induction chemotherapy are appropriate candidates for RT.",
"   </p>",
"   <p>",
"    Since more than 90 percent of patients with EFT have either detectable or subclinical metastases at diagnosis, local therapy, if delivered correctly, is probably not the critical event in determining survival. However, if local therapy is delivered poorly or given in such a way that it compromises the delivery of adequate chemotherapy, survival can be greatly compromised. Moreover, local failure is associated with a very poor survival outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we will discuss the role of radiation therapy in the local management of the EFT. Epidemiology, pathology, molecular genetics, clinical presentation, and diagnosis of these tumors, as well as surgical principles and the use of chemotherapy are presented elsewhere. Central (supratentorial) PNET tumors are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H20#H20\">",
"     \"Uncommon brain tumors\", section on 'Supratentorial primitive neuroectodermal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RT FOR LOCAL CONTROL OF THE PRIMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiosensitivity of Ewing sarcoma was first noted in the original description by James Ewing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/4\">",
"     4",
"    </a>",
"    ]. Historically, RT was preferred over surgery because of less acute morbidity, acceptable rates of local control (50 to 77 percent), and poor long-term prognosis, largely due to distant dissemination in the absence of effective chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The introduction of multiagent chemotherapy into the management of EFT in the 1970s led to an increase in cure rates as well as higher local control rates after RT (72 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. As more children survived their tumors, balancing long-term local disease control with long-term functional results assumed greater importance. The recognition of late effects of RT (eg, fracture, second malignant neoplasms) as well as improvements in surgical techniques resulted in a shift towards the use of surgery rather than RT.",
"   </p>",
"   <p>",
"    Current protocols tailor local treatment to the individual patient with the goal of maximizing local tumor control while minimizing treatment-related morbidity. In general, patients are selected for local therapy in such a way that they are treated with surgery or RT but not both, since the combined use of surgery and RT places patients at risk for morbidity from both modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there is a role for combined therapy in some circumstances, particularly for large tumors (particularly involving the pelvis), and for cases in which resection margins are positive or close. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Adjuvant RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RT versus surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both surgery and RT represent effective local treatment for Ewing sarcoma. There are no randomized trials which directly compare both modalities, and their relative roles continue to be debated. Contemporary treatment guidelines emphasize surgical resection as the local control modality of choice if it is believed that the lesion can be resected with negative margins, without excessively morbidity, and with the expectation of a reasonable functional result. Surgery is preferred for potentially resectable lesions, and for those arising in dispensable bones (eg, fibula, rib, small lesions of the hands or feet) for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It avoids the risk of secondary radiation-induced sarcomas.",
"     </li>",
"     <li>",
"      An analysis of the degree of necrosis in the excised tumor can permit refinements in the estimate of prognosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link&amp;anchor=H27#H27\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the skeletally immature child, resection may be associated with less morbidity than radiation, which can retard bone growth and cause deformity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in most cases, the decision to use RT for treatment of the primary site is made only after review of the potential surgical options for a given lesion. Patients who lack a function-preserving surgical option because of tumor location or extent, and those who have clearly unresectable primary tumors following induction chemotherapy are appropriate candidates for RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Influence of tumor site",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the local control strategy for an individual patient, the need to attain complete tumor eradication must be weighed against the twin goals of maximizing function and minimizing long-term morbidity. Although treatment decisions must be individualized according to the expected deficits from surgical resection at any site, the following generalizations can be made regarding the influence of tumor site on the choice of local treatment (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is generally agreed that surgery is preferred for lesions arising in dispensable bones (eg, fibula or rib).",
"     </li>",
"     <li>",
"      Tumors affecting the long bones of the leg, distal humerus, or ulna can usually be resected and reconstructed using intercalary techniques (allografts, autografts, or metallic prostheses) or joint replacement, depending on tumor location. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link&amp;anchor=H19#H19\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Allografts and endoprostheses'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      On the other hand, primary tumors involving the proximal humerus and upper scapula may be best treated with RT, since limb reconstruction is difficult and shoulder morbidity may be substantial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link&amp;anchor=H10#H10\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Extremity lesions: limb-sparing procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with lesions of the skull, facial bones, or vertebrae are often candidates for nonsurgical treatment because of the difficulty in achieving negative margins without substantial functional deficit [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of series report better results with surgery over RT alone for pelvic bone tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/14-18\">",
"       14-18",
"      </a>",
"      ], but this is a controversial area. Surgical treatment for pelvic sarcomas, which are often bulky, is challenging. Lesions of the iliac wing, ischium, or pubis can usually be resected after a good response to chemotherapy without substantial functional morbidity. For tumors of the periacetabular region and those that cross the sacroiliac joint, there is less enthusiasm for surgical resection given the significant resulting functional deficit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link&amp;anchor=H15#H15\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Pelvic tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because no randomized trial has directly compared both modalities, only a relative comparison can be made from retrospective reports and the prospective trials that have mainly tested different multiagent chemotherapy regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for localized disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many retrospective series, rates of local control and survival are superior after surgery compared to RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/9,10,16,19-30\">",
"     9,10,16,19-30",
"    </a>",
"    ]. However, larger cooperative group studies have failed to reflect this advantage, and selection bias likely accounts for at least some of these results. Smaller, more favorably situated peripheral tumors are more often resected while larger, axial lesions (which have a higher rate of local failure in most series and a poorer prognosis overall [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/9,20,21,31\">",
"     9,20,21,31",
"    </a>",
"    ]) are referred for RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Tumor site and size'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, RT delivery techniques may also have contributed to poorer outcomes in early series. As an example, in the Cooperative Ewing's Sarcoma Study (CESS)-81 trial, relapse-free survival (RFS) for patients undergoing irradiation of the primary site in the initial phase of the trial was only 55 percent, significantly lower than for surgically treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/22\">",
"     22",
"    </a>",
"    ]. On review, the high rate of local failure after RT alone (50 percent) was attributed to geographic \"miss\". After a quality assurance program was initiated, local control rates improved significantly, and RFS increased to 80 percent. In a subsequent study, CESS-86, which included central quality assurance, the five-year RFS rates following chemotherapy plus either RT or surgery were 67 and 65 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/6\">",
"     6",
"    </a>",
"    ]. The importance of RT dose and field planning to local control is discussed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Radiation treatment planning'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several studies support the adequacy of RT alone for local control:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One retrospective report included 39 patients who were treated between 1975 and 1991 at two Boston hospitals with multiagent chemotherapy and varying combinations of surgery and RT [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/32\">",
"       32",
"      </a>",
"      ]. Twenty had RT alone, 16 both surgery plus RT, and 3 surgery alone. Despite the use of combination chemotherapy, five-year disease-free survival (DFS) was only approximately 30 percent, emphasizing the high-risk nature of these mainly axial lesions. However, local control rates were similar among patients treated with RT alone or surgery (85 and 84 percent, respectively).",
"     </li>",
"     <li>",
"      Another case series included 60 patients treated for EFT at Memorial Sloan Kettering between 1990 and 2004; 31 underwent RT as the sole modality for local control, the remainder in conjunction with surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/33\">",
"       33",
"      </a>",
"      ]. The relatively poor prognosis of this group is reflected by the fact that most were centrally located tumors (spine, pelvis, proximal extremities), 52 percent were &ge;8 cm in size, and one-third were metastatic at diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, with a median follow-up of 41 months, DFS and overall survival rates for patients with nonmetastatic disease at presentation were 70 and 86 percent respectively. There were only nine local recurrences, five of which developed in patients who presented with overt metastases. The three-year actuarial local control rates for the entire group and those undergoing definitive RT alone were 77 and 78 percent, respectively. The presence of overt metastases emerged as the only significant adverse prognostic factor for local control, a finding that has been confirmed by others [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/9,34\">",
"     9,34",
"    </a>",
"    ]. Long-term treatment-related complications were minimal, and there were no secondary malignancies. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Late effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relationship between local control modality (surgery, RT, or both) and the subsequent risk for local failure was examined in a subgroup of 75 patients treated for nonmetastatic pelvic EFT in US Intergroup study 0091 (IESS III), a randomized comparison of VACA (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      ) with or without alternating IE (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/35\">",
"       35",
"      </a>",
"      ]. Choice of local control modality was left to the treating clinicians; 12 underwent surgery, 44 received RT, and 19 received both.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rates of five-year, event-free survival (EFS) and cumulative incidence of local failure (as any component of first failure) in the entire group were 49 and 21 percent, respectively. There was no significant difference in either endpoint according to tumor size (&lt;8 versus &ge;8 cm) or choice of local control modality. However, there was a trend toward improved local control in patients receiving",
"    <span class=\"nowrap\">",
"     VACA/IE",
"    </span>",
"    as compared to VACA alone (cumulative incidence of local failure 11 versus 30 percent; p = .06), which was present regardless of the local control modality.",
"   </p>",
"   <p>",
"    Although not a universal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/6,33,36\">",
"     6,33,36",
"    </a>",
"    ], many studies suggest that smaller rather than larger tumors are more likely to be locally controlled after RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/9,15,19,37-41\">",
"     9,15,19,37-41",
"    </a>",
"    ]. As an example, in a report of 100 patients with localized Ewing sarcoma of bone, local control rates were significantly higher after RT for the 14 lesions that were &le;100 cm3 in volume compared to larger lesions (93 versus 60 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is usually not recommended for patients who undergo a complete resection in order to avoid exposing them to the risk of a secondary malignancy. Although indications for postoperative RT are not firmly established, the following are common scenarios in which RT is recommended in conjunction with surgery for EFT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For bulky tumors in difficult sites such as the pelvis, combined surgery and RT might allow for a more limited surgical procedure, better functional outcome, and enhanced local control as compared to single modality therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/9,15,33,43\">",
"       9,15,33,43",
"      </a>",
"      ]. RT can be given either preoperatively or postoperatively, based upon institutional protocols and experience.",
"     </li>",
"     <li>",
"      Patients who are left with macroscopic amounts of viable tumor in the resected specimen following neoadjuvant chemotherapy have worse survival than those with minimal or no residual tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/10,20,37,41,44-47\">",
"       10,20,37,41,44-47",
"      </a>",
"      ]. There are no data evaluating the effectiveness of adjuvant RT in this situation; however, it can be considered if there is concern about the adequacy of the margins.",
"     </li>",
"     <li>",
"      The role of adjuvant thoracic irradiation is unsettled. The United States Intergroup Ewing's Sarcoma Study (IESS)-I trial showed that bilateral whole lung irradiation was an effective adjuvant treatment for patients with localized EFT, but prolonged follow-up favored four-drug multiagent chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/8\">",
"       8",
"      </a>",
"      ]. Prophylactic whole lung irradiation has not been studied in any subsequent trial, and no studies have used it in addition to modern combination chemotherapy regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/48\">",
"       48",
"      </a>",
"      ], except in patients with lung metastases at diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pulmonary metastases'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      On the other hand, adjuvant hemithorax irradiation improves outcomes in patients with high-risk chest wall primary tumors (close or involved margins, initial pleural effusion, pleural infiltration, and intraoperative contamination of the pleural space) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative RT is usually recommended if there is residual microscopic or gross disease after surgery, or inadequate surgical margins. Inadequate resection margins (ie, a marginal or intralesional resection (",
"      <a class=\"graphic graphic_table graphicRef56598 \" href=\"UTD.htm?13/31/13819\">",
"       table 1",
"      </a>",
"      ) are associated with a worse outcome as compared to radical or wide resection) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/27,51\">",
"       27,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of surgical margins on outcome was described in a series of 244 patients who were enrolled in CESS studies for localized EFT and underwent surgery as a component of local therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/27\">",
"     27",
"    </a>",
"    ]. Ninety-four had definitive surgery alone, 131 received postoperative RT, and 19 had preoperative RT. Surgical margins were radical, wide, marginal, and intralesional in 29,148, 39, and 28 patients, respectively. The local and combined (local plus systemic) relapse rate was significantly lower after a complete resection (radical or wide) with or without RT than after an incomplete resection (marginal or intralesional) with or without RT (5 versus 12 percent, p = 0.045). However, the relapse rate was not significantly lower in patients who received RT after incomplete surgery compared to those who did not (12 versus 14 percent). Ten-year survival rates for the cohorts undergoing radical, wide, marginal, and intralesional resection were 58, 65, 61, and 71 percent, respectively; the differences were not statistically significant.",
"   </p>",
"   <p>",
"    However, the data to support the benefit of RT in this setting are surprisingly scant, and conflicting:",
"   </p>",
"   <p>",
"    The efficacy of combined surgery and RT was evaluated in a retrospective series of 39 patients treated for localized EFT at the St Jude Hospital between 1978 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/52\">",
"     52",
"    </a>",
"    ]. With combined local therapy, local control rates were excellent, even for patients with positive surgical margins (eight-year local failure rates for patients with positive and negative surgical margins were 17 and 5 percent, respectively), and the corresponding overall survival rates were 71 and 94 percent, respectively.",
"   </p>",
"   <p>",
"    On the other hand, a lack of benefit for adjuvant RT was suggested in a large single-institutional retrospective series, in which the addition of moderate dose adjuvant RT (45 Gy) to patients with inadequate margins did not seem to improve local control or overall disease-free survival. The authors concluded that patients for whom inadequate margins were anticipated at the time of preoperative evaluation might be better treated by full dose radiotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most clinical protocols for EFT emphasize surgery for treatment of the primary lesion, RT is an effective option for local control in patients who lack a function-preserving surgical option because of tumor location or extent, and those who have clearly unresectable primary tumors despite induction chemotherapy. If a tumor appears to be categorically unresectable following induction therapy, debulking surgery should be avoided and the patient referred for definitive RT.",
"   </p>",
"   <p>",
"    Indications for adjuvant RT in patients who have undergone resection of a EFT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bulky tumors in difficult sites (eg, the pelvis); in this setting, RT can be given either preoperatively or postoperatively, based upon institutional protocols and experience. Our own preference, when positive margins are considered likely, is to use preoperative irradiation.",
"     </li>",
"     <li>",
"      If there is residual microscopic or gross disease after surgery, or inadequate surgical margins",
"     </li>",
"     <li>",
"      Patients who are left with significant amounts of viable tumor in the resected specimen and less than wide margins following neoadjuvant chemotherapy",
"     </li>",
"     <li>",
"      Adjuvant hemithorax irradiation is indicated in patients with high-risk chest wall primary tumors (close or involved margins, initial pleural effusion, pleural infiltration, and intraoperative contamination of the pleural space)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RT FOR METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with overt metastatic disease at presentation have a significantly less favorable outcome than do those with localized disease. However, aggressive multimodality therapy can relieve pain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/54\">",
"     54",
"    </a>",
"    ], prolong the progression-free interval, and provide long-term relapse-free survival (and possible cure) in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Disease extent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of the primary site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local control can pose major issues, even for patients with overt metastatic disease. In such cases, it may be difficult to justify a large resection of the primary site because of the poor long-term prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/15,55\">",
"     15,55",
"    </a>",
"    ]. However, resection may be reconsidered in selected patients if chemotherapy results in significant volume reduction, particularly if areas of small volume metastatic disease are also amenable to surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, RT can provide adequate local control with acceptable morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/6,21,22,56\">",
"     6,21,22,56",
"    </a>",
"    ]. If substantial amounts of bone marrow will need to be included in the field, RT may be delayed until the end of systemic therapy to avoid interfering with chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a limited number of lung metastases do not share the same dismal prognosis of metastatic disease at other sites (ie, bone or bone marrow), because of the ability to accomplish wide resections both easily and repeatedly. Chemotherapy is a necessary component of therapy. In highly selected patients, between 20 and 40 percent five-year survival can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective reports from large cooperative groups suggest that the addition of low-dose bilateral lung irradiation (15 to 20 Gy) benefits patients with EFT presenting with pulmonary metastases, even if all lesions are resected or completely respond to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/8,22,48,57,59-63\">",
"     8,22,48,57,59-63",
"    </a>",
"    ]. In the CESS and EICESS trials, the rate of pulmonary relapse was reduced by 50 percent over that for patients who did not undergo lung RT, and this was accompanied by improvements in event free survival (from 19 to 40 percent in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/60\">",
"     60",
"    </a>",
"    ]) as well [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, most of the available data supporting benefit from RT in this setting are from nonrandomized series, and patient selection factors confound interpretation of the data. There are no randomized trials that confirm the benefit of this approach.",
"   </p>",
"   <p>",
"    Despite the lack of controlled trials, low-dose bilateral lung irradiation (15 to 20 Gy, in daily 1.5 to 2.0 Gy fractions) with a focal boost dose to a total of 40 to 50 Gy to large deposits is commonly recommended for patients with pulmonary metastases who have had a good response to chemotherapy. Long-term toxicity appears to be acceptable. This was shown in a retrospective analysis of data from the prospectively performed European Intergroup Cooperative Ewing's Sarcoma Study, in which pulmonary function tests were available for 37 patients who were treated with whole lung irradiation (with or without a boost) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/64\">",
"     64",
"    </a>",
"    ]. At a median follow-up 25 months, none, mild, moderate or severe pulmonary complications were seen in 43, 29, 21 and 7 percent of patients treated with whole lung irradiation without further boost. Slightly higher complication rates were reported in patients who had an additional radiation boost or surgery to the thorax in addition to RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bone and soft tissue metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with solitary or circumscribed bone or soft tissue lesions fare less well in the long run than those with isolated pulmonary metastases. Nevertheless, with aggressive multimodality therapy, perhaps 10 percent will be long-term survivors. For patients with solitary or limited bone metastases, RT is delivered to metastatic lesions (doses of 40 to 50 Gy) in addition to irradiation of the primary tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Total body irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body irradiation (TBI) or sequential hemibody irradiation as a component of systemic treatment for patients with high-risk features or metastatic disease at presentation has been investigated in a limited fashion at a few institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/36,65-67\">",
"     36,65-67",
"    </a>",
"    ]. Unfortunately, the results of these trials have been disappointing; TBI has not contributed significantly to the control of metastatic disease. This approach should not be considered at present outside of the context of a clinical trial.",
"   </p>",
"   <p>",
"    The use of TBI as a conditioning regimen prior to high-dose chemotherapy and hematopoietic stem cell transplantation for patients with poor-risk disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Dose intense chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIATION TREATMENT PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the relative rarity of EFT, the potential for cure, and the importance of minimizing late side effects from therapy (see below), radiation therapy (RT) must be administered by radiation oncologists who are familiar with the optimal treatment techniques. RT is currently planned using CT simulation to allow for three dimensional (3-D) conformal treatment planning. Biopsy sites and surgical scars should be marked with radioopaque markers to allow inclusion into the target volume when deemed appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, Ewing sarcoma was thought to be a tumor of the bone marrow. Consequently, RT was administered to the entire marrow cavity of the involved bone, and the site of gross disease boosted to a higher dose. However, an analysis of the RT fields for the Intergroup Ewing's Sarcoma Study Group (IESS) trial I suggested that most relapses were at the site of initially bulky tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/7,8,68\">",
"     7,8,68",
"    </a>",
"    ]. Subsequent efforts were geared toward reducing the irradiated field and targeting higher doses to the site of the initial primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/6,19\">",
"     6,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1983, the Pediatric Oncology Group attempted a randomized trial of whole bone versus tailored-field RT after 12 weeks of induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/21\">",
"     21",
"    </a>",
"    ]. After preliminary analysis showed that tailored field was as effective as whole-bone RT, the randomized study was stopped and subsequent patients were treated with limited fields. At three years, the rates of local control and event-free survival were 76 and 54 percent, respectively.",
"   </p>",
"   <p>",
"    IESS trial III, which opened in 1988, was the first cooperative group trial to include tailored RT ports, and the first to be carried out with modern MRI imaging of the primary site and CT-based treatment planning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/69\">",
"     69",
"    </a>",
"    ]. The main randomization was between standard versus more intensive chemotherapy (VAC with or without IE). The addition of IE significantly improved five-year survival (72 versus 61 percent) and event-free survival rates (69 versus 54 percent), particularly for patients with pelvic primary tumors. Moreover, the five-cumulative rate of local recurrence either alone or with systemic relapse was 20 percent in the VAC group compared to only 7 percent in the",
"    <span class=\"nowrap\">",
"     VAC/IE",
"    </span>",
"    group. These data underscore the contribution of intensive chemotherapy to both local control and survival for patients with nonmetastatic EFT at diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for localized disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current recommendations for RT define an initial clinical target volume to include the original bone and soft tissue tumor with a 2.0 cm margin. As noted above, for patients with chest wall tumors and malignant effusions, the field includes the entire ipsilateral hemithorax to a dose of 15 Gy prior to cone down to the chest wall tumor. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Adjuvant RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Attention to potential RT effects on normal tissue is critical in radiation planning to minimize late effects, particularly in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Even partial treatment of uninvolved epiphyseal growth plates is avoided in order to minimize treatment-induced limb shortening [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Circumferential irradiation of a limb is avoided to reduce the risk of limb edema and fibrosis.",
"     </li>",
"     <li>",
"      Gonadal avoidance or additional shielding (for the testes) is important to retain fertility.",
"     </li>",
"     <li>",
"      Excellent results can be achieved from RT of lesions of the hand or foot [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/71\">",
"       71",
"      </a>",
"      ]. However, walking places repetitive stress on the soft tissues of the sole of the feet, and dose sparing for the sole of the foot can improve the functional outcome of treatment.",
"     </li>",
"     <li>",
"      Irradiation of the Achilles tendon is usually avoided. Lesions of the calcaneus can be treated; although some atrophy of the heel pad has been reported, the functional impairment is usually minor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nail beds should be excluded from the radiated field when possible.",
"     </li>",
"     <li>",
"      For pelvic tumors, distention of the bladder prior to each day's treatment can reduce the amount of small bowel in the radiated field, but care must be taken to avoid radiation to significant portions of the bladder in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      to reduce the risk of hemorrhagic cystitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is anticipated that improvements in RT technique over the last 20 years (ie, the adoption of tailored radiation ports as opposed to whole bone ports used in the period 1960 to 1980, three-dimensional (3D) conformal RT, intensity modulated RT (IMRT), and proton therapy (see below) and use of lower and risk-adapted RT doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/56,73\">",
"     56,73",
"    </a>",
"    ]) will reduce the risk of late effects. Nevertheless, the relatively high complication rate seen with earlier treatment approaches and the delayed nature of many of these complications underscore the need for long-term posttreatment follow-up. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Sequelae of treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Proton beam therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One way to reduce the volume of normal tissue irradiated is with charged particle irradiation using protons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantage of protons over conventional photons is in their dose distribution. The physical characteristics of the proton beam result in the majority of the energy being deposited at the end of a linear track, called a Bragg peak, with the dose falling rapidly to zero beyond the Bragg peak. Compared to photon beam irradiation, proton beam therapy permits the delivery of high doses of RT to the target volume while reducing the radiation dose received by normal tissues distal to the target. Depending on the tumor target configuration and the portal selection, this can result in up to 60 percent reduction in the dose received by uninvolved normal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach may be particularly beneficial for Ewing sarcomas arising in the bones of the paranasal sinus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80047 graphicRef80490 \" href=\"UTD.htm?29/7/29817\">",
"     image 1A-B",
"    </a>",
"    ), the pelvis, and the spine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the proximity of the spinal cord, the dose to vertebral body primaries using conventional photon irradiation has been often limited to 45 Gy. Proton beam therapy permits the delivery of higher doses while respecting spinal cord constraints (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61084 \" href=\"UTD.htm?20/9/20629\">",
"       image 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When used for pelvic lesions, proton beam therapy is associated with better sparing of the intestine, rectum, bladder, pelvic bone marrow, and femoral head as compared to photon irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to less acute morbidity, one would also anticipate a reduction in late, RT-induced tumors in patients treated with protons because of the lower volume of normal tissue in the irradiated field (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/77\">",
"     77",
"    </a>",
"    ]. Proton beam irradiation is approved for use in Children's Oncology Group protocols for EFT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our group recently reported experience with proton beam irradiation in 30 children undergoing chemoradiation with or without surgery for Ewing sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/79\">",
"     79",
"    </a>",
"    ]. At a median follow-up of 38.4 months, the three-year actuarial rates of event-free survival, local control, and overall survival were 60, 86, and 89 percent, respectively. RT was acutely well tolerated, with mostly mild-to-moderate skin reactions. The only serious late effects were four hematologic malignancies (three acute myelogenous leukemia [AML] and one myelodysplastic syndrome [MDS]), which are known risks of topoisomerase and anthracycline exposure. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Second malignancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Concern has been raised that neutron scatter radiation associated with passively scattered proton beam lines may also result in secondary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/80\">",
"     80",
"    </a>",
"    ]. The magnitude of this risk is uncertain and may be low in the beam lines in modern facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/81\">",
"     81",
"    </a>",
"    ]; it is expected to be significantly reduced by the use of scanned proton beams [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/82\">",
"     82",
"    </a>",
"    ]. These issues will only be addressed by careful further follow-up of patients treated with protons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intensity modulated radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity modulated RT (IMRT) requires the same careful three dimensional radiation treatment planning used for 3D-CRT. However, IMRT utilizes variable, computer-controlled intensities within each RT beam, in contrast to the uniform doses within each 3D-CRT beam. Compared to most other treatment techniques, IMRT can achieve a higher degree of accuracy in conforming the radiation to the planned target while sparing normal tissue and reducing the incidence of some late complications. The advantages of IMRT are particularly evident when the target volumes have complex shapes or concave regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial experience with IMRT for Ewing sarcoma has been promising [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/33\">",
"     33",
"    </a>",
"    ]. However, critics argue that the risk of a second malignancy might be higher because the multiple portals used with IMRT to achieve conformality of the high-dose region around the target result in delivery of low-moderate doses of radiation to a larger volume of surrounding tissue than with 3D conformal RT techniques. In addition, for IMRT delivery, the linear accelerator is delivering more monitor units and, therefore, a larger total-body dose because of leakage of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/80\">",
"     80",
"    </a>",
"    ]. IMRT supporters point out that since the risk of radiation-induced tumors is dose dependent, this risk may not in fact be increased. These questions will only be answered by careful further follow-up of patients treated with IMRT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT dose is an important factor in local control, particularly for large tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/34,56\">",
"     34,56",
"    </a>",
"    ]. For patients treated with chemotherapy and RT, recent cooperative studies in the United States have employed 45 Gy in 25 fractions to the initial clinical target volume as defined above, followed by a 10.8 Gy boost in six fractions to the site of original bony disease and any residual soft tissue disease that remains following chemotherapy. Because of the proximity of the spinal cord, the dose to vertebral body primaries has been often limited to 45 Gy, although techniques such as protons and IMRT can permit the safe delivery of higher doses. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Proton beam therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Intensity modulated radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients undergoing adjuvant postoperative RT, doses of 45 to 50.4 Gy are recommended for microscopic, and 55.8 Gy for gross residual disease. If preoperative RT is given for bulky tumors, doses in the range of 45 Gy are used.",
"   </p>",
"   <p>",
"    Lower doses (eg, 30 to 36 Gy) have been studied at St Jude and Sloan Kettering [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/56,83\">",
"     56,83",
"    </a>",
"    ]. In one early report of patients undergoing definitive RT, local control rates were 90 percent using RT doses of 35 Gy for smaller lesions (&le;8 cm) with a favorable response to chemotherapy, but they were inferior (52 percent) for larger lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/56\">",
"     56",
"    </a>",
"    ]. Others suggest that doses as low as 30 Gy may be sufficient in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/83\">",
"     83",
"    </a>",
"    ]. However, further studies are needed before lower doses of RT can be accepted as standard practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiation schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional RT schedules usually consist of once daily RT doses of 1.8 to 2.0 Gy per fraction. Accelerated fractionation RT does not seem to improve rates of local control or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/6,19,22,33,84\">",
"     6,19,22,33,84",
"    </a>",
"    ]. However, data from the University of Florida suggest that hyperfractionated RT (1.2 Gy twice daily with a six hour interfraction interval) may be associated with less long-term toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The series consisted of 75 patients with localized Ewing tumor of the extremity or pelvis (lower extremity, 30; upper extremity, 19; pelvis, 26) who were treated with definitive RT at the University of Florida between 1970 and 2006 . RT was performed on a once-daily (40 percent, median dose was 55.2 Gy in 1.8-Gy daily fractions) or twice-daily (60 percent, median dose 55.0 Gy in 1.2 Gy twice-daily fractions) basis. Functional outcome was assessed using the Toronto Extremity Salvage Score [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger tumors had significantly worse cause-specific survival (81 versus 39 percent for tumors &lt;8 cm versus &ge;8 cm), but there were no patient characteristics or treatment variables that were predictive of local failure. No fractures occurred in patients treated with hyperfractionation or with tumors of the distal extremities. Severe late complications were more frequently associated with use of &lt;8 MV photons and fields encompassing the entire bone or hemipelvis. A significantly better Toronto Extremity Salvage Score was associated with a late-effect biologically effective dose of &lt;91.7 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/68\">",
"     68",
"    </a>",
"    ]. The authors concluded that limited field sizes with hyperfractionated high-energy RT could minimize long-term complications and provide superior functional outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     IORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit for intraoperative RT (IORT) has been suggested in retrospective series involving a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. However, peripheral nerves are dose-limiting tissue structures for IORT, so the risk of severe neuropathy and soft tissue necrosis must be considered if this approach is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SEQUELAE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially curative treatment of EFT is necessarily aggressive. The toxicity of RT given in conjunction with intensive chemotherapy can be separated into short-term and long-term complications. The severity of both can be limited by careful attention to technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Acute effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute reactions are those that occur during or shortly after the completion of RT. The most prominent affect tissues within the radiated field that contain rapidly dividing cells, and include desquamation of the skin, myelosuppression, mucositis, diarrhea, nausea, and cystitis. All except myelosuppression are site-specific. Severity depends upon the amount of normal tissue in the radiated field, the radiation fraction size, and the timing of chemotherapy in relation to the RT.",
"   </p>",
"   <p>",
"    Many acute effects, particularly myelosuppression, are exacerbated or potentiated by the use of intensive systemic chemotherapy. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      can cause hemorrhagic cystitis; the amount of bladder in the treatment field should be limited to avoid compounding this problem. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link\">",
"       \"Cystitis in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"       Dactinomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      act as radiation sensitizers and can enhance acute radiation toxicity. If these drugs are used as a component of systemic chemotherapy, breaks should be instituted during the RT or administration of these agents should be delayed until acute RT reactions subside. Current practice in the Children's Oncology Group (COG) studies is to administer RT concurrently with the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"        ifosfamide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"        etoposide",
"       </a>",
"      </span>",
"      cycles of chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"       \"Treatment of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute reactions are usually self-limited and subside within 10 to 14 days of RT completion. Dry desquamation can be managed topically with emollient creams. The development of wet desquamation may require a temporary break in therapy in addition to thrice daily cleansing with warm water and mild soap, petrolatum-based ointments, nonadherent dressings, and, if patients are neutropenic, a topical antibiotic ointment or systemic antibiotics depending on the clinical scenario.",
"   </p>",
"   <p>",
"    Mucositis and diarrhea are managed with supportive measures; if severe, a treatment break may be required. Patients receiving proton beam irradiation for treatment of vertebral lesions tend to have less nausea and diarrhea than those undergoing photon beam irradiation because of the lack of an exit dose to bowel anterior to the spine. Patients receiving whole lung irradiation are at risk for radiation pneumonitis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Proton beam therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Late effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late reactions occur months to years after completing a course of RT. Severity is not always predicted by the severity of acute effects. Late changes in normal tissues caused by RT are related to field size, the volume of normal tissues in the field, and the dose received by normal tissue. Other important factors include patient age at the time of treatment, skeletal maturity, adherence to a rehabilitation program, and whether a pathologic fracture is present at diagnosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Younger, prepubertal children are at greatest risk for radiation-induced arrest of bone growth [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/88\">",
"       88",
"      </a>",
"      ]. Sparing of uninvolved epiphyseal plates minimizes limb shortening after RT of extremity lesions.",
"     </li>",
"     <li>",
"      RT doses above 60 Gy are associated with markedly increased rates of soft tissue induration and fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/89,90\">",
"       89,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-dose circumferential irradiation of an extremity is associated with edema, fibrosis, and compromised limb function [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/91\">",
"       91",
"      </a>",
"      ]. This can be avoided by sparing of an adequate strip of tissue.",
"     </li>",
"     <li>",
"      Weight-bearing bones are at risk for pathologic fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/90\">",
"       90",
"      </a>",
"      ]. The highest risk is within the first 18 months of RT completion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Refinements in diagnostic imaging, RT planning, and techniques over time (tailored field size, hyperfractionated treatment schedules, IMRT, proton beam irradiation) have resulted in better limb function among long-term survivors, and more recent series suggest that excellent functional results can be obtained in the majority of patients following RT for EFT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/19,72,89\">",
"     19,72,89",
"    </a>",
"    ]. A posttreatment rehabilitation program, including active range of motion of affected joints, is also important in improving and maintaining limb function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of secondary neoplasia after treatment for EFT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/73,92-95\">",
"     73,92-95",
"    </a>",
"    ]. RT-induced osteosarcomas and therapy-related (alkylating agents, epidophyllotoxins) leukemias predominate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link&amp;anchor=H6#H6\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Complications in long-term survivors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the radiation-related bone tumors are osteosarcomas, although other tumors are reported. The magnitude of risk is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/46,73,92-94,96-98\">",
"     46,73,92-94,96-98",
"    </a>",
"    ]. Early data suggested that the cumulative risk of a secondary sarcoma after treatment for EFT was approximately 35 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/97\">",
"     97",
"    </a>",
"    ]. The Late Effects Study Group, examining the late effects of treatment for childhood cancer, reported an estimated cumulative incidence of secondary sarcomas after treatment of EFT that approached 22 percent at 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/93\">",
"     93",
"    </a>",
"    ]. These and other investigators identified RT dose as the major predisposing factor for development of a radiation-induced sarcoma, particularly above 60 Gy.",
"   </p>",
"   <p>",
"    Subsequent experience with protocols utilizing lower doses of RT and tailored RT fields suggest that the magnitude of the risk is somewhat lower [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/46,73,94,98\">",
"     46,73,94,98",
"    </a>",
"    ]. The two largest series are described in detail:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series with longest follow-up includes 266 survivors of EFT treated at St Jude, the National Cancer Institute, and the University of Florida, and followed for a median 9.5 years (range 3 to 30) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/73\">",
"       73",
"      </a>",
"      ]. The cumulative RT doses were none, 21 to 48, 48 to 60, and &gt;60 Gy in 8, 23, 45, and 24 percent, respectively. Overall, 16 children developed second malignancies, which included 10 sarcomas. The estimated cumulative risk at 20 years was 9.2 percent for any malignancy, and 6.5 percent for a secondary sarcoma. The median time to the diagnosis of the second malignancy after completion of therapy was 7.6 years. All the secondary sarcomas occurred near or at the primary site of the Ewing sarcoma and within the primary irradiated field.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As has been noted by others, the cumulative incidence rate of secondary sarcoma was radiation dose-dependent. No secondary sarcomas developed among patients who had received less than 48 Gy, while the absolute risk of secondary sarcoma was 130 cases per 10,000 person-years of observation among patients who had received &ge;60 Gy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dunst et al reported on second malignancies among 674 patients enrolled in the Cooperative Ewing's Sarcoma Study Group (CESS)-81 and 86 studies, and followed for an average of 5.1 years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/94\">",
"       94",
"      </a>",
"      ]. Only eight developed a second malignancy, four were treatment-related",
"      <span class=\"nowrap\">",
"       leukemias/myelodysplastic",
"      </span>",
"      syndrome, and there were three sarcomas. The cumulative risk of a second malignancy at 10 and 15 years was 2.9 and 4.7 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term follow-up guidelines after treatment of childhood malignancy have been published by the Children's Oncology Group and are available online [",
"    <a class=\"abstract\" href=\"UTD.htm?24/47/25338/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT and other risk factors for secondary sarcomas after treatment of childhood cancer are discussed further elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H27#H27\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'RT and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31794?source=see_link\">",
"       \"Patient information: Ewing sarcoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma is a rare malignancy that most often presents as an undifferentiated primary bone tumor; less commonly, it arises in soft tissue. Both are part of a spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes the more differentiated peripheral primitive neuroectodermal tumor (PNET). These entities share important clinical features, including a tendency towards rapid spread to lungs, bone, and bone marrow, and responsiveness to the same chemotherapeutic regimens and radiotherapy (RT). Because relapse rates are high in patients undergoing local therapy alone (80 to 90 percent), it is surmised that the majority have subclinical metastatic disease at the time of diagnosis, even in the absence of overt metastases. Intensive multiagent chemotherapy can eradicate these deposits, and is a critical component of therapy for both localized and advanced disease. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized EFT, local and systemic therapy are both necessary to achieve cure. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'General principles'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for localized disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either surgery or RT can provide effective local control. Contemporary treatment guidelines emphasize surgical resection as the modality of choice if it is believed that the lesion can be resected with negative margins, without excessively morbidity, and with the expectation of a reasonable functional result. A major advantage of surgery is the lack of association with treatment-related sarcomas. For patients who lack a function-preserving surgical option because of tumor location or extent, and those who have clearly unresectable primary tumors following induction chemotherapy, we recommend RT (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'RT versus surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the indications for adjuvant RT are not firmly established in patients undergoing surgery for localized EFT, we suggest adjuvant RT in the following circumstances (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Adjuvant RT'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bulky tumors in difficult sites (eg, the pelvis); in this setting, RT can be given either preoperatively or postoperatively, based upon institutional protocols and experience",
"     </li>",
"     <li>",
"      If there is residual microscopic or gross disease after surgery, or inadequate surgical margins (ie, a marginal or intralesional resection as compared to a wide or radical excision)",
"     </li>",
"     <li>",
"      Patients who are left with significant amounts of viable tumor in the resected specimen following neoadjuvant chemotherapy who have less than wide surgical margins",
"     </li>",
"     <li>",
"      Adjuvant hemithorax irradiation is indicated in patients with high-risk chest wall primary tumors (close or involved margins, initial pleural effusion, pleural infiltration, and intraoperative contamination of the pleural space)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although prognosis is clearly worse than for localized disease, a subset of patients who present with overt metastatic disease can be cured, particularly if they have limited pulmonary metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with metastatic EFT, we suggest RT rather than surgery for treatment of the primary site in most patients (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). Surgery could be reconsidered in selected patients if chemotherapy results in significant volume reduction, particularly if areas of small volume metastatic disease are also amenable to surgical resection. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'RT for metastatic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of whole lung irradiation after resection of pulmonary metastases is unclear. Nevertheless, because of the potential for reduced pulmonary relapse and improved event-free survival, and the low rate of pulmonary toxicity, we suggest bilateral low-dose lung irradiation (15 to 18 Gy) even if all lesions are resected or completely respond to chemotherapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pulmonary metastases'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/1\">",
"      Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997; 44:991.",
"     </a>",
"    </li>",
"    <li>",
"     Smith MA, Gurney JG, Ries LA. Cancer in adolescents 15 to 19 years old. In: Cancer incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Ries, LA, Smith, MAS, Gurney, JG, et al (Eds). SEER program, National Cancer Institute, Bethesda MD, 1999. (Pub #99-4649).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/3\">",
"      Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003; 14:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/4\">",
"      Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc 1921; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/5\">",
"      WANG CC, SCHULZ MD. Ewing's sarcoma; a study of fifty cases treated at the Massachusetts General Hospital, 1930-1952 inclusive. N Engl J Med 1953; 248:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/6\">",
"      Dunst J, J&uuml;rgens H, Sauer R, et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995; 32:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/7\">",
"      Perez CA, Tefft M, Nesbit M, et al. The role of radiation therapy in the management of non-metastatic Ewing's sarcoma of bone. Report of the Intergroup Ewing's Sarcoma Study. Int J Radiat Oncol Biol Phys 1981; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/8\">",
"      Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/9\">",
"      Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003; 55:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/10\">",
"      Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 1999; 86:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/11\">",
"      Evans R, Nesbit M, Askin F, et al. Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones. Int J Radiat Oncol Biol Phys 1985; 11:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/12\">",
"      Jenkin RD. Ewing's sarcoma: radiation treatment at the primary site--regarding Dunst et al., IJROBP 32:919-930; 1995. Int J Radiat Oncol Biol Phys 1995; 32:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/13\">",
"      Schuck A, Ahrens S, von Schorlemer I, et al. Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2005; 63:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/14\">",
"      Donati D, Yin J, Di Bella C, et al. Local and distant control in non-metastatic pelvic Ewing's sarcoma patients. J Surg Oncol 2007; 96:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/15\">",
"      Hoffmann C, Ahrens S, Dunst J, et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer 1999; 85:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/16\">",
"      Carrie C, Mascard E, Gomez F, et al. Nonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology. Med Pediatr Oncol 1999; 33:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/17\">",
"      Sucato DJ, Rougraff B, McGrath BE, et al. Ewing's sarcoma of the pelvis. Long-term survival and functional outcome. Clin Orthop Relat Res 2000; :193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/18\">",
"      Indelicato DJ, Keole SR, Shahlaee AH, et al. Impact of local management on long-term outcomes in Ewing tumors of the pelvis and sacral bones: the University of Florida experience. Int J Radiat Oncol Biol Phys 2008; 72:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/19\">",
"      Indelicato DJ, Keole SR, Shahlaee AH, et al. Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys 2008; 72:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/20\">",
"      Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/21\">",
"      Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/22\">",
"      Dunst J, Sauer R, Burgers JM, et al. Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer 1991; 67:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/23\">",
"      Ahmad R, Mayol BR, Davis M, Rougraff BT. Extraskeletal Ewing's sarcoma. Cancer 1999; 85:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/24\">",
"      Wilkins RM, Pritchard DJ, Burgert EO Jr, Unni KK. Ewing's sarcoma of bone. Experience with 140 patients. Cancer 1986; 58:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/25\">",
"      Givens SS, Woo SY, Huang LY, et al. Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor for successful multimodality therapy. Int J Oncol 1999; 14:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/26\">",
"      Indelicato DJ, Keole SR, Shahlaee AH, et al. Long-term clinical and functional outcomes after treatment for localized Ewing's tumor of the lower extremity. Int J Radiat Oncol Biol Phys 2008; 70:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/27\">",
"      Ozaki T, Hillmann A, Hoffmann C, et al. Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study. Cancer 1996; 78:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/28\">",
"      Marcove RC, Rosen G. Radical en bloc excision of Ewing's sarcoma. Clin Orthop Relat Res 1980; :86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/29\">",
"      Sailer SL, Harmon DC, Mankin HJ, et al. Ewing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys 1988; 15:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/30\">",
"      Aparicio J, Mun&aacute;rriz B, Pastor M, et al. Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution. Oncology 1998; 55:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/31\">",
"      Bacci G, Ferrari S, Mercuri M, et al. Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. J Pediatr Hematol Oncol 2003; 25:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/32\">",
"      Sailer SL. The Role of Radiation Therapy in Localized Ewing' Sarcoma. Semin Radiat Oncol 1997; 7:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/33\">",
"      La TH, Meyers PA, Wexler LH, et al. Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era. Int J Radiat Oncol Biol Phys 2006; 64:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/34\">",
"      Krasin MJ, Rodriguez-Galindo C, Billups CA, et al. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2004; 60:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/35\">",
"      Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. J Clin Oncol 2006; 24:3838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/36\">",
"      Marcus RB Jr, Cantor A, Heare TC, et al. Local control and function after twice-a-day radiotherapy for Ewing's sarcoma of bone. Int J Radiat Oncol Biol Phys 1991; 21:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/37\">",
"      Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/38\">",
"      Barbieri E, Emiliani E, Zini G, et al. Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 1990; 19:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/39\">",
"      J&uuml;rgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/40\">",
"      Venkateswaran L, Rodriguez-Galindo C, Merchant TE, et al. Primary Ewing tumor of the vertebrae: clinical characteristics, prognostic factors, and outcome. Med Pediatr Oncol 2001; 37:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/41\">",
"      Ahrens S, Hoffmann C, Jabar S, et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999; 32:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/42\">",
"      Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer 2004; 42:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/43\">",
"      R&ouml;dl RW, Hoffmann C, Gosheger G, et al. Ewing's sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol 2003; 83:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/44\">",
"      Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/45\">",
"      Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001; 85:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/46\">",
"      Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/47\">",
"      Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/48\">",
"      Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/49\">",
"      Schuck A, Ahrens S, Konarzewska A, et al. Hemithorax irradiation for Ewing tumors of the chest wall. Int J Radiat Oncol Biol Phys 2002; 54:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/50\">",
"      Shamberger RC, LaQuaglia MP, Gebhardt MC, et al. Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 2003; 238:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/51\">",
"      Sluga M, Windhager R, Lang S, et al. The role of surgery and resection margins in the treatment of Ewing's sarcoma. Clin Orthop Relat Res 2001; :394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/52\">",
"      Krasin MJ, Rodriguez-Galindo C, Davidoff AM, et al. Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. Pediatr Blood Cancer 2004; 43:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/53\">",
"      Bacci G, Longhi A, Briccoli A, et al. The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2006; 65:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/54\">",
"      Koontz BF, Clough RW, Halperin EC. Palliative radiation therapy for metastatic Ewing sarcoma. Cancer 2006; 106:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/55\">",
"      Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001; 37:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/56\">",
"      Arai Y, Kun LE, Brooks MT, et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/57\">",
"      Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/58\">",
"      Bacci G, Briccoli A, Picci P, Ferrari S. Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy. Eur J Cancer 1995; 31A:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/59\">",
"      Dunst J, Paulussen M, J&uuml;rgens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlenther Onkol 1993; 169:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/60\">",
"      Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/61\">",
"      Pilepich MV, Vietti TJ, Nesbit ME, et al. Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma-Intergroup study. Cancer 1981; 47:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/62\">",
"      Spunt SL, McCarville MB, Kun LE, et al. Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis. J Pediatr Hematol Oncol 2001; 23:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/63\">",
"      Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/64\">",
"      B&ouml;lling T, Schuck A, Paulussen M, et al. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol 2008; 184:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/65\">",
"      Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21:3072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/66\">",
"      Berry MP, Jenkin RD, Harwood AR, et al. Ewing's sarcoma: a trial of adjuvant chemotherapy and sequential half-body irradiation. Int J Radiat Oncol Biol Phys 1986; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/67\">",
"      Kinsella TJ, Glaubiger D, Diesseroth A, et al. Intensive combined modality therapy including low-dose TBI in high-risk Ewing's Sarcoma Patients. Int J Radiat Oncol Biol Phys 1983; 9:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/68\">",
"      Razek A, Perez CA, Tefft M, et al. Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma. Cancer 1980; 46:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/69\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/70\">",
"      Gonzalez DG, Breur K. Clinical data from irradiated growing long bones in children. Int J Radiat Oncol Biol Phys 1983; 9:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/71\">",
"      Johnstone PA, Wexler LH, Venzon DJ, et al. Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys 1994; 29:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/72\">",
"      Kinsella TJ, Loeffler JS, Fraass BA, Tepper J. Extremity preservation by combined modality therapy in sarcomas of the hand and foot: an analysis of local control, disease free survival and functional result. Int J Radiat Oncol Biol Phys 1983; 9:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/73\">",
"      Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/74\">",
"      Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005; 63:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/75\">",
"      Isacsson U, Hagberg H, Johansson KA, et al. Potential advantages of protons over conventional radiation beams for paraspinal tumours. Radiother Oncol 1997; 45:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/76\">",
"      Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002; 54:824.",
"     </a>",
"    </li>",
"    <li>",
"     Chung CS, Keating N, Yock T, Tarbell N. Comparative Analysis of Second Malignancy Risk in Patients Treated with Proton Therapy versus Conventional Photon Therapy, Int J Radiat Oncol Biol Phys 2008; 72:S8.",
"    </li>",
"    <li>",
"     Tarbell N, 2002, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/79\">",
"      Rombi B, DeLaney TF, MacDonald SM, et al. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 2012; 82:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/80\">",
"      Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/81\">",
"      Polf JC, Newhauser WD, Titt U. Patient neutron dose equivalent exposures outside of the proton therapy treatment field. Radiat Prot Dosimetry 2005; 115:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/82\">",
"      Schneider U, Agosteo S, Pedroni E, Besserer J. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys 2002; 53:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/83\">",
"      Merchant TE, Kushner BH, Sheldon JM, et al. Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma. Med Pediatr Oncol 1999; 33:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/84\">",
"      Bolek TW, Marcus RB Jr, Mendenhall NP, et al. Local control and functional results after twice-daily radiotherapy for Ewing's sarcoma of the extremities. Int J Radiat Oncol Biol Phys 1996; 35:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/85\">",
"      Davis AM, Wright JG, Williams JI, et al. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res 1996; 5:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/86\">",
"      Stea B, Kinsella TJ, Triche TJ, et al. Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy. Int J Radiat Oncol Biol Phys 1987; 13:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/87\">",
"      Calvo FA, Ortiz de Urbina D, Sierrases&uacute;maga L, et al. Intraoperative radiotherapy in the multidisciplinary treatment of bone sarcomas in children and adolescents. Med Pediatr Oncol 1991; 19:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/88\">",
"      Thomas PR, Perez CA, Neff JR, et al. The management of Ewing's sarcoma: role of radiotherapy in local tumor control. Cancer Treat Rep 1984; 68:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/89\">",
"      Jentzsch K, Binder H, Cramer H, et al. Leg function after radiotherapy for Ewing's sarcoma. Cancer 1981; 47:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/90\">",
"      Fuchs B, Valenzuela RG, Inwards C, et al. Complications in long-term survivors of Ewing sarcoma. Cancer 2003; 98:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/91\">",
"      Tefft M, Lattin PB, Jereb B, et al. Acute and late effects on normal tissues following combined chemo- and radiotherapy for childhood rhabdomyosarcoma and Ewing's sarcoma. Cancer 1976; 37:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/92\">",
"      McLean TW, Hertel C, Young ML, et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol 1999; 21:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/93\">",
"      Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/94\">",
"      Dunst J, Ahrens S, Paulussen M, et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998; 42:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/95\">",
"      Smith LM, Donaldson SS. Incidence and management of secondary malignancies in patients with retinoblastoma and Ewing's sarcoma. Oncology (Williston Park) 1991; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/96\">",
"      Paulussen M, Ahrens S, Lehnert M, et al. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001; 12:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/97\">",
"      Strong LC, Herson J, Osborne BM, Sutow WW. Risk of radiation-related subsequent malignant tumors in survivors of Ewing's sarcoma. J Natl Cancer Inst 1979; 62:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/47/25338/abstract/98\">",
"      Gasparini M, Lombardi F, Ballerini E, et al. Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Med Pediatr Oncol 1994; 23:406.",
"     </a>",
"    </li>",
"    <li>",
"     Long-term follow-up guidelines after treatment for chioldhood malignancy by the Children's Oncology Group. www.survivorshipguidelines.org (Accessed on September 07, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7748 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25338=[""].join("\n");
var outline_f24_47_25338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RT FOR LOCAL CONTROL OF THE PRIMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RT versus surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Influence of tumor site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RT FOR METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of the primary site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bone and soft tissue metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Total body irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIATION TREATMENT PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Proton beam therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intensity modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiation schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - IORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SEQUELAE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Acute effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Late effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7748|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/10/21669\" title=\"diagnostic image 1A\">",
"      Proton plan EFT paranas sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/56/2949\" title=\"diagnostic image 1B\">",
"      Photon plan EFT paranas sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/9/20629\" title=\"diagnostic image 2\">",
"      Proton plan lumbar vert EFT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/31/13819\" title=\"table 1\">",
"      Resection types sarcoma MSTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31794?source=related_link\">",
"      Patient information: Ewing sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_47_25339="Classification PH function";
var content_f24_47_25339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization (WHO) functional classification for pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        WHO functional classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Patients with pulmonary hypertension but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue or dyspnea, chest pain, or heart syncope.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in undue fatigue or dyspnea, chest pain, or heart syncope.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes undue fatigue or dyspnea, chest pain, or heart syncope.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Patients with pulmonary hypertension resulting in inability to carry on any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by physical activity.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rich, S. Primary pulmonary hypertension: executive summary. Evian, France. World Health Organization, 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25339=[""].join("\n");
var outline_f24_47_25339=null;
var title_f24_47_25340="Characteristics suture material";
var content_f24_47_25340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of sutures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Knot security",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tensile strength",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tissue reaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wound security, days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain gut",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromic gut",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglycolic acid",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglactin",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polydioxanone",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglyconate",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poliglecaprone",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyamide",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyester",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        300+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polybutester",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        300+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polypropylene",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        300+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stainless steel",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        300+",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25340=[""].join("\n");
var outline_f24_47_25340=null;
var title_f24_47_25341="AVR survival and CAD";
var content_f24_47_25341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after aortic valve replacement in aortic stenosis with left ventricular dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves show that patients with aortic stenosis and left ventricular dysfunction who undergo aortic valve replacement have a survival which is similar to that expected in the overall population in the absence of significant coronary artery disease (CAD, defined as &ge;2 vessel disease or left main disease). In contrast, survival is reduced when significant CAD is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Connolly HM, Oh JK, Orszulak TA, et al. Circulation 1997; 95:2395.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25341=[""].join("\n");
var outline_f24_47_25341=null;
var title_f24_47_25342="Ileocolic anastomosis - anvil and spike of circular stapler";
var content_f24_47_25342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ileocolic anastomosis - anvil and spike of circular stapler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25342=[""].join("\n");
var outline_f24_47_25342=null;
var title_f24_47_25343="Deep veins of the leg PI";
var content_f24_47_25343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deep veins of the leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In people with deep vein thrombosis, blood clots can form in the deep veins of the legs (shown in blue).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_47_25343=[""].join("\n");
var outline_f24_47_25343=null;
